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Analysis of Variation in Clubfoot Candidate Genes 
Audrey Ester 
Advisor: Jacqueline T. Hecht, PhD 
Isolated clubfoot, a common birth defect occurring in more than 135,000 livebirths 
worldwide each year, is associated with significant health care and financial burdens.  
Clubfoot is defined by forefoot adduction, hindfoot varus, midfoot cavus and hindfoot 
equinus.  Isolated clubfoot, which is the focus of these studies, is distinct from syndromic 
clubfoot because there are no other associated malformations.  Population, family, twin and 
segregation analysis studies provide evidence that genetic and environmental factors play an 
etiologic role in isolated clubfoot.  The studies described in this thesis were performed to 
define the role of genetic variation in isolated clubfoot.  Interrogation of a deletion region 
associated with syndromic clubfoot, suggested that CASP8 and CASP10, two apoptotic 
genes, play a role in isolated clubfoot.  To explore the role of apoptotic genes in clubfoot, 
SNPs spanning genes involved in the apoptotic pathway in the six chromosomal deletion 
regions, and limb patterning genes, HOXD and HOXA, were interrogated.  SNPs in 
mitochondrial mediated apoptotic genes and several SNPs in HOXA and HOXD genes were 
modestly associated with clubfoot with the most significant SNP, rs3801776, located in the 
basal promoter of HOXA9.  Several significant associations were found with SNPs in NFAT2 
and TNIP2.  Significant gene interactions were detected between SNPs in HOX and apoptotic 
genes.  These findings suggest a model for clubfoot in which variation in one gene is not 
sufficient to cause the malformation but requires variation several genes to perturb protein 
expression sufficiently to alter muscle and foot development.  These results significantly 
impact our knowledge base by delineating underlying mechanisms causing clubfoot. 
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Introduction to Clubfoot 
Foot deformities are common.  One group results from flexible positional abnormalities 
and are easily treated with minor manipulations and is likely due to intrauterine constraint1.  
The second group is rigid malformations referred to as talipes equinovarus, and is the only 
true clubfoot.  This malformation involves the foot held in equinus (rigid downward position) 
and adducted (turned towards the midline of the body)2.  Clubfeet often have misshapen 
bones such as a flattened talus, the navicular is often vertical instead of horizontal, and 
cuneiforms are often stacked behind each other2.  The position of the clubfoot resembles an 
embryonic foot at the beginning of the second month, although during no stage of normal 
development is the navicular vertical2.  While the bones may be misshaped and aligned 
differently in clubfoot, it is unknown if this is the primary cause of clubfoot, or if it is 
secondary to abnormal musculature or tendon placement.   
Musculature and tendons of clubfeet 
Clubfeet are also characterized by hypoplasia of the calf muscles, which often persists 
throughout life; however there are conflicting studies about muscle placement, fiber density, 
and even muscle size3.  Irani and Sherman examined eleven fetal clubfeet from 22 to 36 
gestational weeks of age3.  In one case, the cross-section of the calf muscle from the affected 
limb was larger than the unaffected limb, but the muscles appeared to be the same size 
bilaterally even though the limb appeared larger3.  However, another affected foot showed 
muscle masses that corresponded to the unaffected foot, but each mass was much smaller 
than that of the control limb3.  In general, Irani and Sherman concluded that muscles of 
clubfeet are underdeveloped and smaller when compared to unaffected limbs3.  Because the 
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calf muscles have found to be hypoplastic, they have been the focus of several histological 
studies in clubfeet. 
In 1977, Isaacs et al. investigated the types, number, size, and direction of muscle fibers 
in individuals with clubfeet.  This study concluded that clubfoot calf muscles are “grossly 
abnormal”, with higher numbers of Type I fibers, and both types of muscle fibers were larger 
than controls4.  Type I muscle fibers are also known as slow twitch muscle fibers and are 
redder in color because they have a higher myoglobin and oxygen content5,6.  These fibers 
are used in long-term activity because they resist fatigue, as opposed to fast twitch (Type II) 
muscle fibers, which are used during short bursts of activities, are more fatigable and can 
only receive energy from glycolysis5,6.  In addition to higher numbers of Type I muscle 
fibers, Isaacs et al. found evidence of denervation in calf muscles of clubfoot4.  The larger 
muscle fibers imply that atrophy is not the reason for smaller muscles, but might be caused 
by a neuropathy4.  The patients in this study were referred for study due to the presence of a 
rigid talipes equinovarus, but does not mention any other associated abnormalities4.  
Fukuhara et al. performed histomorphometric and immunohistochemical studies on 16 
fetal clubfeet and 27 normal feet (seven normal feet from unilateral patients and 20 feet from 
spontaneously aborted fetuses of the same age range as those affected)7.  This study found 
that the bone malformations were secondary to ligament and collagen changes7.  The tibialis 
posterior ligament was found to be enlarged, and the orientation of the collagen fibers was 
disrupted7.  A syndromic clubfoot animal model was created in the 1960s by Drachman et al. 
through the paralysis of chick embryos8.  These animals exhibit “jaw deformities, scoliosis, 
characteristic flexion contractures of the knee, ankle, and toe joints, with severe deformity of 
the articulating surfaces”8.  Germiller et al. used this model to determine the muscle and 
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tendon sizes in this model compared to control chicks8.  The total volume of muscles and soft 
tissue of the paralyzed chicks decreased as the dose of paralyzing drug increased8.  In 
addition the tendons were significantly smaller with increasing paralysis and merged at the 
bottom of the calf8.  This is in contrast to the size of the cross-sectional area of the tibial 
muscle, which was not correlated with the drug dose8.  This suggests that in the drug-induced 
clubfoot model, muscle and tendon cross-sectional area were smaller than those of controls8.  
This supports data from previous studies that suggest that calf muscles in nonsyndromic 
clubfeet are abnormally small. 
In 1998, a prospective study was performed by Loren et al. in which muscles of children 
with clubfoot were examined histologically, and further investigated if surgical intervention 
impacted these histopathological findings1.  About half of the patients with clubfeet showed 
abnormal muscle morphology1.  Twenty percent had fiber type disproportion, and 30% had 
fiber size variation (>3:1 ratio)1.  The clubfeet with abnormal muscle morphologies had an 
increased risk for clubfoot recurrence and a second operation (5.6 fold increase)1.   
Omeroglu et al. studied ten fetuses with clubfoot who also had spina bifida9.  Spina bifida 
is often associated with deformities of the foot and ankle, which usually result from muscle 
imbalance or denervation.  Of these foot deformities, clubfoot is the most common in spina 
bifida patients with “L3 and higher neurosegmental lesions”9.  The muscle size of the control 
group was larger than that of the affected limbs, and there was a higher proportion of fibrosis 
in clubfoot limbs than those of control muscles9.  This study concluded that the fibrosis was 
secondary to atrophy in the skeletal muscle tissue, and the clubfoot is most the result of 
muscle inactivity9.  This is possibly due to the atrophy or the atrophy may occur because of 
the lack of muscle movement9.  
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A histological study of clubfoot in 2006 reported on 431 muscle specimens obtained from 
68 patient surgeries.  This study gave very different results with 86.3% having “no 
discernible pathology”10.  Atrophy and an over-abundance of type I muscle fibers was found 
in 12.8% of the specimens10.  This study was much larger than the Omeroglu study and was a 
better representation of the average clubfoot compared to normal musculature.  Other case 
studies have reported an additional muscle coming out of the soleus muscle.11-13  There have 
also been reports of a flexor digitorum accessorius longus muscle that is aberrant in children 
with clubfoot14-16.  These case studies involve small numbers of clubfeet and from individual 
collection sites.  In addition, many of these evaluated the “clubfoot deformity” but do not 
discriminate between idiopathic clubfoot and syndromic clubfoot, and so these clubfeet 
might have different musculature due to syndromes (such as a neuropathy).  A large-scale 
comprehensive study in idiopathic clubfoot patients is needed to validate these findings.   
Treatment of clubfoot 
There are several methods of clubfoot treatment, including aggressive operative 
intervention, conservative manipulations of the feet, and a combination of the two methods17.  
Historically, operative treatments were the first choice among doctors, often performing a 
comprehensive treatment that uses surgery to correct all aspects of the deformity.  However, 
a more conservative approach has been taken consisting of manipulation, casting, and 
bracing of the foot, followed by surgery if necessary17. 
Conservative Treatment 
The two most common conservative treatments are the Ponseti and Montpellier (French) 
methods, which both promote the progressive stretching of the muscles and tendons in an 
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attempt to forgo surgical soft tissue release18.  The Ponseti method consists or serial castings 
that hold the foot in an overcorrected position, a tendonectomy if needed, and then braces 
that again hold the foot in an overcorrected position18.  The Montpellier method requires 
much more intensive participation on the part of the physician and requires the patient to 
have long inpatient manipulations and “continuous passive motion”18.  The Montpellier 
method is more expensive and not widely used outside of France18.   
Operative Treatment 
Operative treatments consist of individual surgeries to address each component of the 
clubfoot deformity, or can repair multiple components or the entire deformity.  Many doctors 
who prefer to use an operative treatment accept that the end result is not a normal foot17.  
Posterior release is the most common surgery after conservative treatment, although more 
aggressive surgery may be necessary.  This soft tissue release consists of releasing the 
Achilles tendon, as well as tendons restraining the ankle and subtalar joints18.  If the clubfoot 
deformity is more extensive, it may require medial and lateral tendon releases as well18.   
Complications of Treatment 
The Ponseti method has a high rate of correction, but almost always requires an Achilles 
tenotomy18.  Usually the only complications of the Ponseti method are related to slippage of 
the casts or failure to comply with bracing18.  Undercorrection following surgery can be 
difficult because the scar tissue is less flexible and hinders further surgeries18.  
Overcorrection is harder to treat, and can even cause a “rocker bottom” foot18.  The most 
common complication for all methods of treatment is recurrence of the clubfoot18.  The 
Ponseti method treats recurrent clubfeet by recasting or rebracing until the deformity is 
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corrected and possible surgery if necessary18.  Recurrence can also occur because of scar 
tissue following surgery preventing the stretching of muscles and tendons during bracing18.  
The Ilizarov technique is used almost exclusively for recurrent clubfeet, although long term 
success has not been reported17.  The Ilizarov method uses an external, circular frame, and 
this method is often supplemented with other types of surgery as well. 
Treatment Innovations 
Botulinum toxin-A (Botox) has been used as a substitute for an Achilles tenotomy17.  The 
results of one study are a disappointment as the injected infants showed no difference than 
those injected with a placebo with regard to further treatment17.  However, additional studies 
have shown that Botox is an effective treatment and reduces the need for tendon releases19,20.  
Surgery is still required in few cases, but Botox can still be used as a conservative treatment 
before resorting to tendon release20.   
In order to improve treatments for children with clubfoot, the extent of the tissues 
affected and the cause of the deformity need to be determined.  In addition, correct 
classification and identification of the causes of clubfoot are needed. 
Normal foot development 
Limb formation is a complex process involving cell proliferation, patterning, and 
programmed cell death21,22.  The hind limb begins to develop as a small swelling during the 
fourth week of gestation, with morphogenesis being completed by the end of the eighth 
week23.  The legs, which develop in the midline in equinus should move to plantar grade by 
the twelfth week24.  Perturbations in any of the developmental processes may affect the final 
positioning, particularly those causing hypoplastic muscles or shortened tendons that are 
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universally associated with clubfoot1,7,11,14.  The hind limbs are composed of three basic 
segments: the stylopod (upper limb), the zeugopod (lower limb), and the autopod (foot).  The 
expansion and differentiation of cells in the limb bud is regulated by many secreted signaling 
factors. 
Signaling factors of normal foot development  
Limb development involves both dorsal ventral patterning and proximal distal outgrowth, 
which requires an intricate expression and diffusion pattern of growth factor signaling25.  
There are three major signaling centers that control these axes of development, the AER, the 
zone of polarizing activity (ZPA), and the ectoderm26.  The AER maintains the proximal 
distal outgrowth, the ZPA migrates behind the AER regulating the anterior-posterior axis, 
and the ectoderm controls the dorsal-ventral axis26.   
The emerging limb bud forms with the leading most edge of the outgrowth, known as the 
apical ectodermal ridge (AER)26.  The AER maintains proliferating cells and secretes factors 
that prevent cells from differentiating into cartilage25.  The AER is characterized by both 
proliferating cells and cells undergoing programmed cell death, and these have been shown 
to be in the same regions26.  One model theorizes that the longer cells remain in the AER, the 
more distal the cells are located when they differentiate27.  Another theory suggests that the 
fate of cells comprising the limb is predetermined and therefore time does not dictate the 
differentiation of cells27. Outside of the AER, somites begins to proliferate and differentiate 
into muscle precursors26.   
These signaling centers secrete growth factors and other signals that diffuse through the 
limb bud, interacting and forming overlapping and diverging gradients26.  These signaling 
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regions are conserved throughout vertebrate development including fish28.  This interplay of 
secreted signaling factors is what leads to the distinct and normal limb26. 
FGF signaling 
Limb development first begins with the expression of fibroblast growth factor (FGF) 8, 
which is expressed by the intermediate mesoderm in the trunk of the embryo27.  This first 
wave of FGF8 induces expression of WNT-2B and -8C, which in turn stimulates expression 
of FGF1027.  FGF10 signals a second wave of FGF8 expression in the AER27, and in turn 
maintains expression of FGF1027.  The AER is controlled primarily by FGFs, including 
FGF2, 8, 9 and FGF receptor (FGFR) 2b, which are expressed constitutively throughout the 
AER, and FGF4 and 17 are expressed in the posterior AER27.  Because of the expression 
pattern of FGF4 and 17, it is thought that these growth factors stimulate and maintain the 
ZPA27.   
Sonic Hedgehog and GLI3 signaling 
Sonic hedgehog (SHH) is a secreted signaling molecule that is interpreted through 
another molecule, GLI329.  In limb development, SHH regulates the distribution of GLI3, and 
GLI3 is in turn regulated by SHH through processing29.  SHH expression is restricted to the 
ZPA, and is thought to act as a morphogen by regulation other signaling factors depending on 
its concentration in specific tissues and regions29.  However, a double knockout of SHH and 
GLI3 showed a restoration of ventral cell types that were missing in SHH-/- mice, indicating 
that the extent of their functions is unknown29.   
Within the ZPA, SHH is responsible for the pattering of the digits29.  Ectopic expression 
of SHH causes polydactyly29.  However knockout of GLI3 can produce synpolydactyly, 
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which suggests that GLI3 may be involved in apoptosis and separation of digits29.  However, 
the knockouts of SHH or GLI3 do not affect the distal portions of the limb, suggesting that 
the ZPA is involved only in the initial development of the autopod29. 
SHH also stimulates the expression of other genes involved in limb development 
including HOXD genes30.  SHH is a homolog of hedgehog (HH) in drosophila, and it  has 
been shown to regulate gene expression of members of the bone morphogenic protein (BMP) 
family, which can stimulate apoptosis30.   
Homeobox (HOX) Genes 
The HOX genes are transcription factors which regulate differentiation and patterning of 
cells31,32.  In vertebrates there are 39 HOX genes in four clusters, and each cluster is on a 
separate chromosome.  The HOX clusters are regulated temporally and spatially by global 
promoters, noncoding RNAs, transcription factors, and other regulatory elements during 
embryogenesis31,33.  5’ genes of the HOXA and HOXD clusters (9-13) are expressed in the 
mesoderm and muscles of the developing limbs34.  The 5’ genes are expressed later and more 
distally with HOXA13 and HOXD13 being expressed latest and in the distal autopod35.  HOX 
mutations lead abnormal limb development, and each of the 5’ genes correlates with a 
missing limb segment35.  A deletion of HOXA11 and HOXD11 results in elimination of the 
zeugopod, but the deletion of HOXA13 and HOXD13 causes absence of the autopod35.   
Retinoic Acid 
Retinoic acid (RA) is derived from vitamin A, which is necessary for normal embryo 
development28.  RA acts as a transcription factor binding to retinoic acid response elements 
(RAREs) that either activate or repress genes28.  High levels of retinoic acid can lead to birth 
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defects, but a deficiency of retinoic acid can prevent normal embryonic development28.  RA 
is postulated to be a morphogen, a molecule to which cells respond differently depending on 
its concentration28.  RA can stimulate SHH production and can also mimic a ZPA graft, 
leading to digit duplications30.  While the implantation of a RA bead in the limb causes 
polydactyly, there is no evidence that it plays a direct role in normal limb development28.  
However, RA expression is required in the trunk of the embryo where the limb buds will 
form36.  This early expression is needed even though other factors will be expressed in the 
region such as SHH which also confer limb bud placement36.  Retinoic acid deficiency can 
lead to a wide array of malformations including cleft palate, unfused nasal passages, and 
syndactyly36.  These malformations reported result from a lack of apoptosis, suggesting that 
RA can induce/regulate apoptosis during embryonic development36. 
Apoptosis 
Apoptosis or programmed cell death (PCD) is the process that a cell undergoes when it 
receives signal(s) indicating that the cell is no longer needed37.  Typically this is associated 
with the shaping of the limb including digits and other skeletal elements37.  Apoptosis occurs 
in many different regions of the developing limb, although some major regions of apoptosis 
have been named necrotic regions because their naming occurred before the discovery of 
PCD37.  A large region of apoptosis in the mesenchyme is known as the opaque patch, which 
regulates PCD in the skeleton of the zeugopod37.  Failure of apoptosis to occur in the opaque 
patch leads to fusion of the tibia and fibula37. 
There is also apoptosis in the interdigital mesoderm which results in the formation of 
separate fingers, and its absence can lead to a fusion of the fingers37.  During the outgrowth 
of the limb bud, apoptosis occurs in the AER, and if that apoptosis is inhibited, the AER 
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overgrows and results in polydactyly37.  Studies have also shown a role for apoptosis in joint 
formation and possibly guiding nerves through the developing limb22.  In addition to these 
large regions of apoptosis, there is also PCD within the developing muscles and tendons22.   
Muscle and Tendon Development 
Muscles cells originate from the somatic mesoderm, produced through signaling factors 
PAX3 and MYOD, and then migrate to the appropriate location under control of Homeobox 
gene, LBX122.  These muscles migrate to regions that correspond to the major delineation of 
the limb (stylopod, zeugopod, and autopod)22.  These regions further separate into the cell 
clusters that will become the individual muscles of each joint region22.  The formation of 
these muscle cell clusters requires rapid replication, and cell are often produced in surplus, 
requiring regulation through PCD22.  These large areas of muscle mass are termed muscle 
bellies, which is the bulge in the middle of the muscle between the regions that attach to 
tendons22. 
In addition, muscles require attachment to tendons to inhibit loss of muscle mass and 
increased apoptosis22.  Muscles show an increase in apoptosis when a tendon is severed 
through surgery22.  This suggests that tendon lengthening during treatment of clubfoot may 
contribute to muscle wasting and atrophy of the calf muscles.  The connective tissues of the 
tendons develop first, regulated by β-catenin and WNT signaling, and provide a scaffold 
where the muscle cells migrate22. 
The apoptosis that regulates muscle cell growth is dependent on RA signaling, and 
inhibition of RA causes a disorganization of the tendon tissues22.  The retinoic acid receptor 
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(RARβ) and CYP26A1 are expressed in the tissues that undergo apoptosis and expression is 
inversely proportional to the amount of retinoic acid in the tissues22. 
Causes of Clubfoot 
Clubfoot is a common birth defect although the birth prevalence varies from a low of 
1/2500 in African Americans to a high of 1/150 in Polynesians, with a worldwide average 
rate of approximately 1/100038-41.  Half of all cases have unilateral involvement, and of those 
the right side is affected more frequently than the left38.  Males are affected twice as often as 
females42.  Segregation analyses suggest that clubfoot is likely caused by a single gene with 
reduced penetrance or several other genes with minor effects and environmental influences42-
46.  Because males are affected more frequently than males, it is hypothesized that clubfoot 
follows the Carter (multifactorial) effect, in which females require more susceptibility loci 
than males47.  This is supported by family studies that show male children of affected 
mothers have the highest affection rates, and females of affected fathers have the lowest 
affection rates47.   In addition to genetic contribution to the clubfoot model, several 
environmental factors have been suggested to play a role in clubfoot development48-51. 
Intrauterine constraint has been suggested as an environmental etiologic factor, but no 
conclusive data supports this theory.52  Seasonal variation has also been suggested to 
contribute to clubfoot but this has not been supported53-56.  Maternal smoking is associated 
with clubfoot and increases the odds of having a child with clubfoot (OR 1.3-2.2)57-59.  In 
addition, a family history of clubfoot in a woman who smokes while pregnant increases her 
risk of having a child with clubfoot by twenty fold58.  Maternal smoking is not only strongly 
associated with clubfoot, but it is the only environmental factor shown to contribute to 
clubfoot with results that are readily reproducible52-59. 
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Evidence supporting a genetic etiology underlying clubfoot comes from (1) aggregation 
of clubfoot in families, (2) twin studies and (3) segregation analyses.  Clubfoot can be found 
throughout multiple generations in families, which suggests a that clubfoot is in part 
genetic60.  A Danish twin study analyzed 52 twin pairs and found that 17% of monozygotic 
twins were concordant compared to only 5% of dizygotic twins, suggesting genetics plays a 
role in clubfoot61.  A second twin study found that monozygotic twins had a higher 
concordance of 32.5% than that of dizygotic twins (2.9%)62,63.  The twin studies vary in 
percentages due to differences in populations studied, but that is to be expected due to 
differences in clubfoot etiology between ethnicities and populations.  These twin studies 
suggest genetic liability for clubfoot because monozygotic twins share more genes than 
dizygotic twins.   
Several segregation analyses have been performed with many different conclusions for 
the populations studied including, a dominant gene, a recessive gene, incomplete penetrance, 
X-linked, and polygenic inheritance43,44,63-65.  One segregation analysis concluded that 
clubfoot is caused by a major gene that is affected by modifier genes and environmental 
factors for Caucasians44.  A study by Palmer supports this finding66.  However, another study 
that assessed Hawaiians, Caucasians and Asians found a major gene affect with 
multifactorial contribution for Hawaiians and Caucasians while no major gene was involved 
in the Asian etiology43.  The segregation analysis on nonHispanic whites and US born 
Hispanics found similar rates of occurrence under a recessive model with reduced 
penetrance67.  Altogether these segregation analyses demonstrate different modes of 
inheritance for different populations, and most likely there will be an interaction of several 
genes and environmental factors.  These studies clearly suggest a genetic etiology, and 
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genetic studies are needed to understand the development of clubfoot and improve genetic 
counseling and risk determination. 
Genetic Mapping 
Genetic mapping identifies loci that are either linked or associated with a disease or 
disease susceptibility, and there are several different methods for genetic mapping68.  
Linkage mapping uses the number of meiotic crossover events that take place to identify 
chromosome regions that harbor susceptibility genes, measured in linkage disequilibrium 
(LD)68.  Linkage disequilibrium  occurs when two loci are passed together during meiosis 
more often than by chance due to lack of meiotic crossover between the two loci68.  Because 
these events are traced through meiotic events, linkage studies can only be performed in 
families and large pedigrees with many affected individuals68.  The best markers to identify 
linkage are microsatellite polymorphisms, which are short repeats that have varying numbers 
of repeats in different alleles68.  These markers are highly polymorphic and provide the most 
information for linkage analyses68.  In addition, multipoint analysis can be used to 
extrapolate information between markers. 
Association studies are closely related to linkage studies and are based on populations 
being derived from founders, and limited meiotic crossovers produce inherited haplotypes 
over many generations68.   Association studies work well with case control studies, however 
association tests can also be performed in samples composed of families and trios68.  
Association studies typically use single nucleotide polymorphisms (SNPs) as markers 
because they are bi-allelic and are available in high-throughput formats.  SNPs are much 
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more common than microsatellite markers and therefore can be used for fine mapping 
because several markers within a gene can be selected68.  
Genome-wide genotyping methods are expensive, and so several methods can be used to 
retain power of the study and reduce the cost68.  Tagged SNPs represent a particular 
haplotype, and genotype information for the other SNPs in that haplotype can be inferred 
from the genotype of the tagged SNP68.  In addition, regions of the genome can be targeted 
through analysis of candidate genes.  These may be genes that are in linked regions that need 
to be fine mapped, genes involved in processes that may lead to the disease if perturbed, or 
genes that cause a syndrome that has the disease phenotype.  These mapping techniques can 
be used to identify variation that contributes to the disease process. 
Previous Genetic Studies 
One of the first studies to narrow the search for genetic variation leading to clubfoot was 
performed by Brewer et al69.  This study included children who had a variety of syndromes 
caused by large chromosomal deletion regions.  The children were then grouped by 
phenotypic features, such as clubfoot and then the chromosomal deletion regions were 
compared69.  Even though the affected individuals have different syndromes, the overlapping 
deletion regions between individuals with a shared trait might contain genes that contribute 
to the idiopathic condition69.  The study found six large chromosomal deletion regions shared 
among individuals with syndromic clubfoot: 2q31-33, 3q23-24, 4p16-14, 7p22, 13q33-34 
and 18q22-2369.  Brewer performed a follow up to this study by performing a similar analysis 
of children with large duplication regions, which found two more regions associated with 
clubfoot: 6q21–27, 10p15–1170.  
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There have been few genetic mapping studies of idiopathic clubfoot.  Deitz et al. 
performed a segregation analysis on a clubfoot family with four generations available for 
genotyping, with 13 affected individuals and 41 unaffected individuals71.  This study found 
two chromosomal regions of interest with LOD scores above 2.0.  The authors identified two 
possible candidate genes, WNT7A and LMX-1, although further study was needed to assess 
variations in these genes71.  Shyy et al. followed up this study with the sequencing of two 
genes in these candidate regions, WNT7A and CAND272.  The sequencing of exons and 
promoters identified a variant in each gene, although the variants occurred in equal numbers 
of cases and controls72.  The authors concluded that these two genes did not contribute to 
idiopathic clubfoot. 
Because smoking has been strongly associated with clubfoot, genes involved in toxin 
metabolism, if perturbed, could increase susceptibility to clubfoot.  N-acetyltransferase 
(NAT2) acetylates toxins including free radicals found in cigarette smoke, and slow 
acetylation of these molecules can lead to the formation of adducts, which can impair normal 
development73,74.  Specific SNPs within NAT2 have been shown to lead to slower acetylation 
of target molecules.  Five variants in NAT2 were genotyped in our clubfoot population, and 
one of these sites had fewer than expected normal homozygotes in the affected individuals75.  
Additionally, in a small case-control study, there were more slow acetylators than expected 
in the cases, suggesting that slow acetylators may have a higher risk for clubfoot75. 
Distal arthrogryposis is a contracture syndrome that includes clubfoot in the phenotype as 
well as contractures of the hand, which has been shown to be cause by mutations in several 
different genes involved in the muscle contracture complex76.  Gurnett et al. conducted a 
small study, interrogating MYH3, TNNT3, and TPM2 (muscle contraction genes) for 
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association with clubfoot76.  All exons and 5’ and 3’ regions were sequenced in 20 idiopathic 
clubfoot patients76.  Rare variants were found, but did not segregate with the disease and 
therefore are not thought to contribute to clubfoot76. 
  A linkage analysis was performed on a five generation family stated to have idiopathic 
clubfoot, although the proband had bilateral polydactyly and missing the tibia of his right leg 
and other individuals had bilateral hypoplastic patella77.  This implies that the family does 
not have idiopathic clubfoot.  The linkage analysis yielded a LOD score of 3.31 on 
chromosome 5, and PITX1 was a candidate gene found in the linkage region77.  PITX1 is a 
transcription factor that is required for hindlimb expression, and loss of its expression causes 
mouse hindlimbs to resemble forelimbs77.  PITX1 also has higher expression in the right side 
of the body, and contributes to differences in development between the two sides such as the 
ventricles of the heart77.  A mutation in PITX1 was found in five affected family members 
but not in 500 normal controls.  The researchers concluded that the findings suggest PITX1 or 
the pathway it is involved in plays a role in idiopathic clubfoot, although the family did not 
have idiopathic clubfoot77.  They further concluded that PITX1 might contribute to the right 
foot being affected more often in unilateral clubfoot due to the higher expression levels in the 
right limb77.  
The Hecht lab began systematically analyzing the regions identified by Brewer et al. and 
interrogating them for genes associated with isolated clubfoot69,78.  Beginning with the 2q31-
33 region, nine short tandem repeat (STR) markers were selected spanning the region and 
tested for association in our clubfoot population consisting of nonHispanic white and 
Hispanic families with or without history of clubfoot78.  Two STRs segregated with affected 
individuals, and three genes (Caspase 8, Caspase 10, and CFLAR) were located near one of 
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the STRs.  SNPs were selected in these genes and tested for association in the same clubfoot 
population because these genes are involved in the apoptotic pathway and participate in limb 
development78.  One SNP from Caspase (CASP) 10 had an altered transmission in the 
clubfoot population (p=0.002)78. 
Several labs have used retinoic acid, a known teratogen, to induce syndromic clubfoot-like 
deformities in mice and rats79-81.  Only one study evaluated protein levels in the exposed 
offspring who had facial clefts and neural tube defects 79.  Several proteins were down regulated 
including X-linked inhibitor of apoptosis protein (XIAP), troponin T1 (TNNT1) and collagen type 
2 (COL2α1)79.  Increased apoptosis was also observed in these rats79.  This study suggests that 
these genes might be involved in clubfoot, but have not yet been evaluated. 
Significance 
Clubfoot is a common birth defect that affects about 130,000 newborns throughout the 
world every year.  Treatment modalities such as casting and surgery have improved the long 
term outcome but residual foot and leg abnormalities often persist42,82,83.  Little is known the 
etiology of clubfoot. Genes are known to play a role in clubfoot, but the challenge is to 
identify these.  If the genetic pathways contributing to clubfoot can be determined, then 
preconceptual treatments may be developed, or a new method of diagnosis may be 
developed.  The goal of this project is to define genes that contribute to clubfoot.  In addition, 
the identification of high risk haplotypes could improve genetic counseling.  This work is 
significant because it aims to determine the underlying mechanism causing a common 
birth defect that involves abnormal limb development.   
Brewer et al. identified six large deletion regions that overlapped in individuals with 
syndromic clubfoot and hypothesized that these regions may contain genes that contribute to 
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idiopathic clubfoot69. Each of the six regions contained genes which are involved in the 
apoptotic pathway as well as genes that interact with the apoptotic pathway 
(www.stanford.source.edu).  To determine whether variation in these genes plays a role in 
clubfoot, the SNPs within these apoptotic genes were genotyped and tested for association or 
linkage to clubfoot.  These results are discussed in Chapters 3 and 4. 
The 2q31-33 syndromic deletion region from the Brewer study contains the HOXD gene 
cluster which directs axial and limb patterning during development (www.genome.ucsc.edu)31,33.  
HOXA is located on chromosome 7p15-14 and has a redundant function with HOXD33.  
Mutations in HOXA and HOXD genes have been associated with six syndromes that involve limb 
abnormalities, which include synpolydactyly and brachydactyly 
(http://www.ncbi.nlm.nih.gov/sites/entrez?db=omim).  The association of HOX mutations with 
limb anomalies led us to interrogate the HOXA and HOXD gene clusters in our clubfoot samples.  
The results of these studies are found in Chapter 5. 
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Chapter 2: Materials and Methods 
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Study Population 
Probands with clubfoot were identified through Shriners Hospitals for Children of 
Houston and Los Angeles and the Scottish Rite Hospital of Dallas and are designated as the 
“discovery population”.  Affected individuals were diagnosed with clubfoot through clinical 
and radiographic diagnosis.  Individuals with chromosomal abnormalities, syndromes or 
postnatal events associated with clubfoot were excluded.  Ethnicity was self-reported and 
informed consent was obtained. Two generation pedigrees were obtained for all probands, 
and these pedigrees were classified into those with affected relatives (multiplex family 
history) or those without affected relatives (simplex trios).  Pedigrees were extended for 
multiplex families to include all individuals affected.   
A validation clubfoot population of 144 nonHispanic white trios was obtained from 
Washington University to test positive results found in the discovery population.  For the 
HoxD10 M319K mutation analysis, two positive controls with congenital vertical talus 
(CVT) with this mutation were obtained from Dr. Dobbs at Washington University.   595 
unrelated, unaffected negative controls were ascertained through the cleft lip and palate 
clinics at Children's Hospital, Boston, Texas Children's Hospital, Houston, and the University 
of Texas Craniofacial Clinic, Houston. 
Samples 
DNA was extracted from blood or saliva samples collected from participating 
individuals.  DNA was extracted from blood using the DNA Isolation Kit for Mammalian 
Blood (Roche, Palo Alto, CA) or saliva with Oragene Purifier (DNA Genotek Inc., Ottawa, 
Ontario, Canada).  Each of these kits was used according to the manufacturer’s instructions.  
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DNA samples were quantified using the Nanodrop spectrophotometer (Thermo Fisher 
Scientific, Waltham, MA) and checked for degradation by running on a 2% agarose gel.  
DNA was then stored at -20°C. 
Gene Selection 
Brewer et al. studied children with large deletion regions clubfoot to try and narrow 
down genomic regions associated with idiopathic clubfoot69.  They aligned chromosomal 
deletion regions in these children and identified the smallest overlapping regions69.  These 
regions might contain genes that contribute to idiopathic clubfoot.  Candidate genes within 
these regions, including HOX and apoptotic genes, were interrogated for association with 
clubfoot.  These studies are described in Chapters 3, 4 and 5. 
Genotyping 
Genotyping was performed using single nucleotide polymorphisms (SNPs) as genetic 
markers.  SNPs were selected using the National Center for BioInformatics (NCBI, 
http://www.ncbi.nlm.nih.gov) and Ensembl (http://www.ensembl.org) websites.  SNPs 
selected were based on heterozygosity (>0.3), placement in gene, tagging ability and 
coverage of gene.  Software programs Haploview84 and SNPBrowser were also used for SNP 
selection.  Genotyping was performed using TaqMan® SNP Genotyping Assays and 
SNPlexTM Genotyping System (Applied Biosystems, Foster City, CA).  TaqMan® results 
were analyzed on the 7900HT using SDS 2.1 (Applied Biosystems, Foster City, CA).  
SNPlexTM results were analyzed on a 3730 using GeneMapper® 4.0 (Applied Biosystems, 
Foster City, CA).  Both TaqMan® and SNPlexTM reactions were performed according to 
standard protocols.  The HoxD10 M319K mutation was detected using a custom TaqMan® 
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assay.  The primers were designed using File Builder 3.0 (Applied Biosystems, Foster City, 
CA).  
Statistical Analyses 
The data was originally analyzed as a whole and then probands were stratified by 
ethnicity alone and ethnicity and family history.  Allele frequencies and Hardy-Weinberg 
Equilibrium (HWE) were calculated using SAS (v9.1).  Pairwise linkage disequilibrium 
values (D′ and r2) were calculated using GOLD85.   
Different methods for assessing linkage and/or association were performed in order to 
obtain the greatest amount of information from this dataset.  Parametric and non-parametric 
linkage analyses were conducted using Merlin86.  Graphical Overview of Linkage 
Disequilibrium (GOLD) was used to calculate the disequilibrium coefficient (D′) between 
pairs of SNPs87.  The pedigree disequilibrium test (PDT) and the family based association 
test (FBAT) were used to determine  association in clubfoot families88,89.  The PDT tests for 
altered transmission of alleles within pedigrees. The Geno-PDT is a function within the PDT, 
and tests specific genotypes is more accurate when looking at dominant and recessive 
models75.  Family based associated test (FBAT) was used to test for association and the 
HBAT function within FBAT was used to test haplotypes90.  HBAT and FBAT were run 
under a recessive model.   
Association in the Presence of Linkage (APL) was used because the program 
incorporates data even when a parental genotype is missing91.  Altered transmission of 
pairwise haplotypes within a gene was analyzed using APL.  Positive associated SNPs 
(p<0.05) were then analyzed for gene-gene interaction using Generalized Estimating 
Equations (GEE)92 
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Sequencing 
The region surrounding mir196-b was amplified using polymerase chain reaction 
(PCR) with primers: Fwd- 5’-GCTCGCTGGGCTGCAAGATTTGG-3’ and Rvs- 5’-
CTGCGGAGAAAGACACGAGGCTC-3’.  The PCR was performed using the following 
program: 94oC for 2:00 [98oC for 0:10, 55oC ± 1oC for 0:30, 72oC for 1:00] for 35 cycles and 
72oC for 10:00.  Five percent DMSO was added to the reaction because of the high G-C 
content of the DNA.  The 552bp product was sequenced by Lone Star Labs, Inc. (Houston, 
TX).  Sequence was analyzed using Sequencher (Gene Codes, Ann Arbor, Michigan).   
Transcription Factor Binding Prediction 
Both the (-2) miR196-b and SNP16 variants are in potential promoter regions and 
could affect putative binding sites.  Three in silico prediction programs, Alibaba2, Patch and 
Transcription Element Search Software (TESS), were used to assess whether ancestral or 
alternate sequences changed or generated a transcription factor binding site93-95.  The 
ancestral allele is defined by NCBI as the allele that is found in chimpanzee and is thought to 
be shared by the common ancestor (http://www.ncbi.nlm.nih.gov.ezproxyhost. 
library.tmc.edu/bookshelf/br.fcgi?book=helpsnpfaq&part=Content#Content.Ancestral_Allele
_Dat).  The in silico testing provides theoretical data which needs to be confirmed with 
functional testing. 
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Chapter 3: Mitochondrial Mediated Apoptotic 
Pathway and Clubfoot 
 
This chapter is a presentation of work from a previously published paper.  For more 
information please refer to:  Ester, AR, et al.  Apoptotic gene analysis in idiopathic talipes 
equinovarus (clubfoot).  Current Orthopedic Related Research.  2007 Sep; 462: 32-7. 
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Background of Apoptosis and clubfoot 
Deletion Regions Associated with Clubfoot 
 Cytogenetic deletion mapping has been used in mapping many diseases, although a 
comprehensive study of these deletions had not been performed in birth defects.  Therefore, 
Brewer et al. decided to study children with different birth defects caused by chromosome 
deletions69.  The study consisted of 1,753 children with 47 different phenotypes, although 
some children had multiple malformations69.  Similar malformations were grouped together 
and assessed for common deletion regions69.   For clubfoot, six chromosomal deletion 
regions were found: 2q31-33, 3q23-24, 4p16-14, 7p22, 13q33-34, and 18q22-23, and are 
candidate regions for harboring genes involved in isolated clubfoot69.  However, there are 
294 known genes in these regions, so further mapping is required to identify the genes 
associated with clubfoot. 
Fine Mapping of Chromosome 2 Deletion Region 
Interrogation of the chromosome 2 deletion region associated with clubfoot was 
performed to narrow the clubfoot candidate region78.  Nine microsatellite markers spanning 
the 2q31-33 region were genotyped in 83 trios and 57 families with clubfoot.    
GATA149B10 and D2S1371 were significantly associated with clubfoot78.  However, these 
markers only narrowed the region to 6cM, and further fine mapping was needed.  Three 
candidate genes were identified near one of the satellite markers: Casp8, Casp10, and 
CFLAR, which are all involved in apoptosis78.  Eleven SNPs across these three genes were 
analyzed, and rs3769825 in Casp8 and rs3900115 and rs3731714 in Casp10 were associated 
with clubfoot78.  These results suggest a role of apoptosis in clubfoot. 
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Apoptosis 
  Apoptosis or programmed cell death (PCD) is the process by which cells die in response 
to cell signals96.  This process includes chromosome condensation, cell shrinkage, membrane 
blebbing, formation of apoptotic bodies and degradation of these bodies by surrounding 
cells96.  These apoptotic bodies are then taken up and digested by neighboring phagocytes97.  
This process is different from necrosis which does not follow this defined progression of cell 
death98.  Apoptosis regulates cell proliferation during development and plays an active role in 
the homeostasis of cells after embryogenesis.  Loss of apoptosis can lead to cancer98. 
Mitochondrial Mediated Apoptosis 
There are six protein motifs that are associated with apoptosis: caspase (CASP), caspase 
recruitment domain, death domain (DD), death effecter domain (DED), BIR domain and 
BCL-2 homology domain98.  DDs are required for coupling of death receptors and inter-
protein binding of the death-signaling complex, and without them the apoptotic signal could 
not be transmitted99.  The extrinsic mitochondrial mediated apoptotic pathway begins with 
the coupling and self-activation of death receptors in response to their ligands which are 
released in response to cellular signals98.  The activated receptors then recruit death domain 
containing proteins, which activate the extrinsic mitochondria mediated apoptotic pathway 
(Fig. 3.1)98.   
Activator Caspases 
Caspases (CASP) 2, 8, 9, and 10 are known as activator caspases and respond to external 
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Fig. 3.1.  Mitochondrial mediated apoptotic pathway 
     30
signals to initiate apoptosis97.  Caspases cleave after aspartic acid residues and target RNA 
splicing, DNA repair proteins and other caspases100.  Caspases are synthesized as inert 
proteins, procaspases, and activation of caspases lead to the cellular changes seen during 
PCD 97,100.  Activator caspases have long prodomains that recruit adaptor proteins, and Casp8 
and 10 contain death effector domains (DEDs), and the adaptor domains are responsible for 
activating the caspases97.  The activated death receptor binds CASP8 and 10 through the 
DED, activating the proteins and cleaving BID (BH3-interacting domain death agonist), a 
BCL2 family protein97. 
BID 
BID participates in a mitotic checkpoint and maintains genomic stability, but its main 
role is in the extrinsic mitochondrial mediated apoptotic pathway101.  Full length BID has 
been shown to have minor apoptotic activity, but once BID is cleaved by CASP8, the 
transmembrane domain is able to incorporate into the outer mitochondrial membrane101.  
This insertion stimulates a cascade, leading to permeabilization of the mitochondrial 
membrane101.  Once the membrane becomes permeable, cytochrome c is released from the 
mitochondria101.  This allows the apoptotic cascade to continue, leading to the eventual 
degradation of the cell101. 
BCL-2 
BCL-2 is an anti-apoptotic member of the BCL-2 family, and is localized to surfaces of 
membranes, including the mitochondria, nucleus and endoplasmic reticulum102.  BCL-2 
functions to keep the mitochondrial membrane intact, thus preventing the release of 
cytochrome c during normal cell functions103.  BCL-2 is targeted by activated BID, and once 
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BID enters the mitochondria membrane, Bcl-2 can no longer contain cytochrome c within the 
mitochondria103.  Once cytochrome c is released, CASP9 and APAF-1 are activated103. 
CASP9 and APAF-1 
CASP9 is the most studied and best characterized of the caspases, and activation requires 
incorporation into the apoptosome104.  The apoptosome consists of CASP9, cytochrome c, 
APAF-1, and cofactor dATP/ATP104.  APAF-1 binds to procaspase 9 in the presence of 
cytochrome c.  The apoptosome can only form when the mitochondrial mediated apoptotic 
pathway has been activated and cytochrome c has been released from the mitochondria104.  
Once a homodimer of procaspase 9 assembles into the apoptosome, the procaspase has a low 
level basal activity that is three times higher than that of unbound procaspase 9104.  This 
allows auto-activation of CASP9, creating an active apoptosome104. The apoptosome then 
activates CASP3104. 
CASP3 
CASP3 has a key role in apoptosis, and is known as an effector caspase105.  CASP3 
cleaves many substrates including poly ADP ribose polymerase (PARP), which is cleaved 
during apoptosis105.  Once these substrates are cleaved, the cell undergoes many changes 
including membrane blebbing96.  The cell breaks into many different apoptotic bodies, which 
are then degraded by phagocytes96. 
Study Design 
To assess mitochondrial mediated apoptotic genes for association with clubfoot, SNPs 
were selected spanning seven apoptotic genes, CASP8, CASP10, BID, BCL-2, APAF-1, 
CASP9 and CASP3.  Because CASP8 and CASP10 were already tested in a smaller sample 
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set, only the significant SNPs were rerun in the expanded sample.  The data set consisted of 
82 nonHispanic white (NHW) simplex trios, 88 NHW multiplex families, 128 Hispanic 
simplex trios and 51 Hispanic multiplex families.  Forty SNPs in seven genes were 
genotyped in these families (Table 3.1).   
Results 
Allele frequencies in NHW and Hispanics were compared, and because of the large 
number of comparisons, a conservative threshold of p<0.00125 was used to assess 
significance106. No differences in allele frequencies were detected between NHW and 
Hispanics for the SNPs in CASP8, 9 and 10106.  However, allele frequencies differed for five 
out of eight SNPs in CASP3, five out of seven in APAF-1, two out of five in BCL-2 and two 
out of eight in BID (data not shown)106.  The two populations were analyzed separately 
because of these allele differences.  Pairwise linkage disequilibrium (LD) was calculated 
using unaffected individuals, and the patterns of LD were similar between NHW and 
Hispanics106.  A representative LD plot for CASP9 is shown in Table 3.2, which shows that 
the LD patterns are similar between NHW and Hispanics (all LD plots are found in Appendix 
A).   
Parametric linkage analysis, which assumes a specific mode of inheritance, did not detect 
linkage for any of the SNPs tested106.  Non-parametric linkage analysis found suggestive 
evidence for association for rs1049253 and rs1049216 (p=0.07 and 0.06, respectively) in 
CASP3 in the Hispanic sample (complete data not shown)106.  
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Table 3.1.  Location of SNPs analyzed, predicted protein changes and differences in 
allele frequencies between NHW and Hispanics. 
 
Gene/Chr
Region SNP Allele 
BP 
Position Location 
AA 
Change NHW Hisp. P-Value 
rs35718454 T/G 15725876 Upstream - 0.534 0.575 0.092 
rs1052571 G/A 15723200 Exon 2 A28V 0.584 0.622 0.307 
rs4646008 G/A 15717314 Exon 2 S99L 0.996 0.999 0.254 
rs2308941 G/A 15717305 Exon 2 T102I 0.977 0.981 0.651 
rs2020897 C/G 15717268 Exon 2 E114D 0.993 0.994 0.475 
rs1820204 A/G 15717202 Exon 2 F136L 0.522 0.587 0.047 
rs2042370 G/A 15714329 Intron 2 - 0.564 0.612 0.135 
rs2308950 C/T 15706093 Exon 4 R173H 0.970 0.988 0.161 
CASP9 
1p36.21 
rs4233533 G/A 15701774 Intron 6 - 0.711 0.738 0.723 
rs3900115 A/G 201758922 Exon 3 Synon. 0.541 0.612 0.051 CASP10 
2q33.1 rs3731714 A/G 201769065 Intron 5 - 0.772 0.769 0.916 
CASP8 
2q33.1 rs3769825 C/T 201819625 Intron 9 - 0.503 0.538 0.346 
rs1049253 C/T 185785945 3’ UTR - 0.796 0.851 0.092 
rs1049216 T/C 185787083 3’ UTR - 0.716 0.439 < 0.00001 
rs1049210 C/A 185789219 Exon 7 E190D 0.995 0.998 0.820 
rs1405944 T/A 185790347 Intron 5 - 0.512 0.249 < 0.00001 
rs2696057 G/C 185792828 Intron 4 - 0.834 0.809 0.130 
rs2720378 C/G 185805107 Intron 2 - 0.714 0.434 < 0.00001 
rs4647602 A/C 185806795 Intron 1 - 0.921 0.651 < 0.00001 
CASP3 
4q35.1 
rs1405937 G/C 185808932 Upstream - 0.837 0.562 < 0.00001 
rs7310804 A/G 97543189 3’ UTR - 0.514 0.458 0.108 
rs2278361 A/G 97567338 Intron 2 - 0.789 0.712 < 0.00001 
rs2288729 T/C 97591721 Intron 10 - 0.652 0.618 0.00008 
rs6538879 A/G 97612225 Intron 14 - 0.750 0.732 0.00072 
rs3782558 G/C 97629924 Intron 17 - 0.541 0.561 0.061 
rs1866477 G/T 97643964 Intron 22 - 0.885 0.929 0.00076 
APAF-1 
12q23.1 
rs7968661 A/G 97661515 Downstream - 0.680 0.628 0.00003 
rs1564483 A/G 58945634 3’ UTR - 0.742 0.884 0.00003 
rs8083946 G/A 59056901 Intron 1 - 0.606 0.548 0.936 
rs1801018 T/C 59136859 Exon 3 Synon. 0.579 0.575 0.274 
rs2551402 C/A 59141002 Downstream - 0.515 0.631 0.00004 
BCL-2 
18q21.33 
rs1809319 C/T 59173614 Downstream - 0.663 0.600 0.005 
rs8919 G/A 16593057 Upstream - 0.532 0.432 0.007 
rs181399 T/C 16605318 Intron 3 - 0.821 0.858 0.941 
rs2072392 A/G 16606612 Exon 3 Synon. 0.973 0.963 0.509 
rs8190315 T/C 16606764 Exon 3 S56G 0.976 0.982 0.322 
rs181405 G/A 16613000 Intron 1 - 0.535 0.439 0.075 
rs181410 A/T 16617436 Intron 1 - 0.655 0.804 0.007 
rs5747351 A/G 16626375 Intron 1 - 0.601 0.436 < 0.00001 
BID 
22q11.21 
rs3788284 G/C 16632103 Intron 1 - 0.555 0.433 0.00023 
AA = amino acid, Synon.=synonymous, NHW= nonHispanic white, Hisp.=Hispanic; Chromosome position noted under gene
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All single SNPs with a p<0.1 are shown in Table 3.3.  rs3769825 (CASP3) and 
rs2551402 (BCL-2) gave p-values of 0.05 and 0.07, respectively in the Hispanic simplex 
cases (Table 3.3)106.  No SNPs had an altered transmission in the Hispanic multiplex 
families.  In the nonHispanic white simplex trios, rs2278361 and rs2288729 in APAF-1 and 
rs2551402 in BCL-2 yielded p-values of 0.03, 0.06 and 0.06, respectively106.  SNPs 
rs2278361 and rs2288729 in APAF-1 were in strong LD (Appendix A).  In the nonHispanic 
white multiplex families, rs4233533 in CASP9 and rs2696057 in CASP3 gave nonsignificant 
p-values of 0.09 and 0.08, respectively106.  Results from the PDT analysis were similar to the 
FBAT results (Table 3.3)106.  However, two SNPs with suggestive p-values were identified in 
the Hispanic multiplex families; one in CASP10 (rs3731714) and the other in BID 
(rs2072392), which were not detected by FBAT106. 
Haplotypes were generated using HBAT and are shown in Table 3.4.  The haplotypes are 
not true haplotypes because the SNPs do not reside in same gene or on the same 
chromosome.  However, in complex diseases, the underlying etiology is assumed to involve 
variants in multiple genes which are not necessarily on the same chromosome.  By 
identifying these haplotypes, we can begin to determine gene-gene interactions106.  SNPs 
with p<0.1 in one population were evaluated in all populations.  In the Hispanic simplex 
trios, an overall altered transmission of both haplotypes of rs3739825 and rs2551402 in the 
CASP3 and BCL-2  haplotype was found (p=0.017)106.  In the NHW simplex trios, altered 
transmission of haplotypes for rs2278361 (APAF-1) and rs2551402 (BCL-2) and rs2288729 
(APAF-1) and rs2551402 (BCL-2) were found (p=0.03, p=0.02 respectively)106.  Because 
rs2278361 and rs2288729 are in strong LD, only one was considered in each of the  
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Table 3.2. LD plot for CASP9. 
 
 
  hc
v2
84
59
56
 
rs
42
33
53
3 
rs
23
08
95
0 
rs
20
42
37
0 
rs
18
20
20
4 
rs
20
20
89
7 
rs
23
08
94
1 
rs
46
46
00
8 
rs
10
52
57
1 
hcv2845956   0.96 1.00 0.98 0.95 0.95 1.00 0.85 0.98 
rs4233533 0.92   1.00 0.82 1.00 1.00 1.00 1.00 0.82 
rs2308950 0.18 0.10   0.92 1.00 0.48 1.00 1.00 1.00 
rs2042370 0.97 0.91 1.00   1.00 1.00 1.00 1.00 0.93 
rs1820204 0.97 0.98 0.22 0.99   0.00 1.00 1.00 0.98 
rs2020897 0.99 1.00 1.00 1.00 1.00   1.00 1.00 1.00 
rs2308941 1.00 0.31 0.23 0.29 1.00 1.00   1.00 1.00 
rs4646008 0.00 0.00 0.00 0.00 0.00 0.00 0.00   1.00 
rs1052571 0.93 0.87 1.00 0.95 0.96 1.00 0.36 0.00   
NonHispanic whites shown above the diagonal, Hispanics shown below the diagonal.  
p<0.05 shown in yellow. 
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Table 3.3.  Apoptotic single SNP results by population. 
 
 
PDT Group 
 
SNP 
 
FBAT
 Global Summed 
rs3769825 (CASP8) 0.05 0.09 0.03 Hispanic-
Simplex rs2551402 (BCL-2) 0.07 0.08 0.06 
rs3731714 (CASP10) - 0.06 > 0.1 Hispanic-
FH rs2072392 (BID) - 0.07 0.05 
rs2278361* (APAF-1) 0.03 0.04 0.06 
rs2288729* (APAF-1) 0.06 0.08 0.1 NHW-Simplex 
rs2551402 (BCL-2) 0.06 0.07 0.04 
rs4233533 (CASP9) 0.09 > 0.1 > 0.1 NHW-FH rs2696057 (CASP3) 0.08 0.08 0.05 
*SNPs in LD, NHW=nonHispanic white 
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Table 3.4.  Apoptotic haplotype analysis. 
 
Transmitted Group SNPs Haplotype p Value 
Obs. Exp. 
Overall 
p-Value 
1-2 0.0019 42 52 Hispanic-
Trios 
rs3739825/rs2551402 
CASP8/BCL-2 2-1 0.059 30 25 
0.017 
rs2278361/rs2551402 
APAF-1/BCL-2 1-2 0.03 33 36 ns NHW-Trios 
rs2288729/rs2551402 
APAF-1/BCL-2 1-1 0.02 17 12 ns 
NHW-FHx rs4233533/rs2696057 CASP9/CASP3 2-2 0.02 83 74 ns 
Obs.=observed, Exp.=expected, NHW= nonHispanic white, FHx=multiplex families, ns=not significant 
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haplotypes.  Lastly, in the NHW multiplex families, altered transmission of a CASP9 and 
CASP3 haplotype (rs4233533/rs2696057) was detected (p=0.02)106. 
EMDR analysis was utilized to generate 1-, 2-, 3- and 4-locus models that discriminate 
between affecteds and unaffecteds for simplex trios.  This method identifies which SNPs 
depending on the number of loci considered are best at segregating the affected from the 
nonaffected individuals106.  This analysis can identify high risk haplotypes by categorizing 
which SNPs are most likely to confer risk.  As shown in Table 3.5, none of the SNPs 
represented under different models produced significant results.  Based on our results, 
rs3769825 in CASP8 was identified as a SNP of interest106. 
Discussion 
In this study, we interrogated seven apoptotic genes, CASP3, CASP8, CASP9, CASP10, 
BID, BCL-2 and APAF-1, using 40 SNPs and tested for linkage and association with 
clubfoot106.  Suggestive evidence for association was found for a SNP in each of the seven 
genes, CASP3, CASP8, CASP9, CASP10, BID, BCL-2 and APAF-1106.  Gene-gene 
interactions were identified with altered transmission of multi-gene haplotypes in both NHW 
and Hispanics106.  Lastly, one SNP, rs3769825 in CASP8 was also found to be the best 
discriminator between affecteds and unaffecteds in the Hispanic simplex trios106.  All 
together these results suggest that the interaction of several genes within the mitochondrial 
mediated apoptotic pathway influences the development of clubfoot106.   
Of interest, a previous analyses identified altered transmission of rs3900115 in CASP10 
in three of the four sample groups tested in clubfoot families.107  While only the Hispanic 
multiplex families gave suggestive results, this study identified a different CASP10 SNP 
(rs3731714) as the best single locus model (although this result was not significant)106.  This 
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Table. 3.5.  High risk haplotypes*. 
 
Model NHW 
1 locus rs3731714 (CASP10)    
2 locus rs7968661 (APAF-1) 
rs1809319 
(BCL-2)   
3 locus rs3782558 (APAF-1) 
rs7968661 
(APAF-1) 
rs1809319 
(BCL-2)  
4 locus rs4233533 (CASP9) 
rs1405937 
(CASP3) 
rs8083946 
(BCL-2) 
rs181405 
(BID) 
Model Hispanic 
1 locus rs3769825 (CASP8)    
2 locus rs1052571 (CASP9) 
rs3769825 
(CASP8)   
3 locus rs2720378 (CASP3) 
rs8919 
(BID) 
rs5747351 
(BID)  
4 locus rs1049216 (CASP3) 
rs2720378 
(CASP3) rs8919 (BID) 
rs5747351 
(BID) 
NHW=nonHispanic white, *EMDR analysis
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lack of consistent findings may reflect a difference in the clubfoot data sets that have 
expanded as more samples were collected.  Since other SNPs within genes in this pathway 
have yielded suggestive results, we are encouraged that this pathway contributes to the 
clubfoot106. 
In complex diseases, it is expected that perturbation of multiple interacting genes are 
necessary for the birth defect and may reflect a high risk haplotype106.  The haplotype based 
function of FBAT (HBAT) can be used to identify altered transmission of haplotypes in both 
families and trios.  “Multifactor dimensionality reduction (MDR) analysis can also detect at-
risk haplotypes constructed from multiple genes, but the haplotypes are created by using a 
case-control based algorithm instead of family based algorithms such as used in HBAT”106.   
The findings of this study and the known role of apoptosis in limb and muscle 
development strongly suggest that further interrogation studies of additional apoptotic genes 
and upstream signaling factors that activate apoptosis are necessary and are the focus of 
studies described in Chapter 4.   
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Chapter 4: Analysis of Candidate Genes in Clubfoot 
Deletion Regions 
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Introduction 
Isolated clubfoot is a common birth defect, occurring in 1/700-1000 live births affecting 
135,000 newborns each year38,40,65,108.  Talipes equinovarus (TEV) is identified by three 
clinical foot characteristics: forefoot adduction, hindfoot varus and hindfoot equinus109.  The 
tarsal joint is also misaligned and the arch is often more concave110.  Calf muscles are frequently 
hypoplastic and remain smaller throughout life110.  Isolated clubfoot is distinct from syndromic 
clubfoot in that it occurs without any other anomalies. Males are affected twice as often as 
females and the frequency varies across ethnicities65.  Treatment consists of serial castings for six 
weeks with casts being changed every week110.  Soft tissue releases, bony procedures and/or 
tendon transfers are sometimes needed following serial casting and bracing110.  
Clubfoot is a complex birth defect caused by both genetic and environmental factors65. 
Several environmental factors have been suggested to contribute to clubfoot, but only maternal 
smoking has been consistently associated57-59.  Evidence supporting a genetic etiology for 
clubfoot comes from (1) aggregation of clubfoot in families, (2) twin studies which demonstrate a 
32.5% concordance in monozygotic twins compared to 2.9% in dizygotic twins and (3) 
segregation analyses, which have suggested that clubfoot is most likely caused by a single gene 
with major effects as well as other genes with minor effects and environmental factors44,45,58,67. 
A previous study interrogated minimal overlapping chromosomal deletion regions in 
individuals with large deletions that had clubfoot as a phenotype.  That study found six large 
chromosomal deletion regions, 2q31-33, 3q23-24, 4p16-14, 7p22, 13q33-34 and 18q22-23, 
shared among individuals with syndromic clubfoot69.   Investigation of those regions using 
Ensembl database (www.ensembl.org) identified 194 known genes69.  Of these genes, there 
were 52 candidate genes involved in apoptosis, muscle development, morphogenesis and cell 
 43
Table 4.1. Apoptotic genes in chromosomal deletion regions 
 
2q31-33 3q23-34 4p14-16 7p22 13q33-34 18q22-23 
ZAK RNF7 TLR10 RBAK ING1 SOCS6 
CERKL ATR TLR1 TRIAD3 TFDP1 NFAT2 
GULP1 SSB4 TLR6 CARMA1 TNFSF13B TNFRSF11A 
SUMO1 TFDP2 WDR19 
ATF HIP2 
CREB1 EMP 
STAT1 HTT 
STAT4 
 
TNIP2 
   
proliferation (www.source.stanford.edu).  Interestingly, apoptotic pathway genes were 
identified in each of the six deletion regions which was remarkable because apoptotic genes 
have been previously associated with clubfoot (Table 4.1 and Fig. 4.1) 106. 
The 29 candidate 
apoptotic genes can 
be broken down into 
several groups: 
immune response 
genes that stimulate apoptosis, transcription factors, genes involved in engulfment of 
apoptotic bodies, and other apoptotic genes.  A summary about each of these genes are 
presented below. 
Immunity Related Genes 
ZAK 
Leucine-zipper sterile α-motif (ZAK) is a serine/threonine kinase, which activates the 
c-Jun N-terminal kinase (JNK) pathway and the transcription factor NFκB through the MAP 
kinase kinase (MKK) pathway111.  Activation of ZAK can lead to cell arrest in the G2/M 
stage of the cell cycle, and prolonged expression of ZAK induces apoptosis through the JNK 
pathway by activating MAPKK 7 (MKK7)111. 
SUMO1 
Small ubiquitin related modifier 1 (SUMO1) can be conjugated to proteins, leading to a 
regulation of these proteins112.  This attachment is processed through several enzymes similar 
to ubiquitination, although “SUMOylation does not lead to degradation”112.  SUMO1 has 
been shown to interact with DAXX, which is a transcriptional repressor involved in the 
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apoptotic pathway (www.source.standford.edu)113.  In addition, SUMO1 sumoylates NFκB, 
which is a transcription factor that regulates apoptosis and inflammation114. 
RNF7 
Ring finger protein 7 (RNF7) is also known as sensitive to apoptosis gene (SAG), and is 
an E3 ubiquitin ligase115.  Ubiquitin is a protein that is ligated to other proteins through a 
series of three ligases and marks the protein for degradation115.  RNF7 ubiquitinates c-Jun 
and inhibits AP-1 and cell proliferation115.  In addition, RNF7 conjugates ubiquitin to the 
inhibitor of NFκB, increasing the levels of NFκB and inhibiting apoptosis115.   
TLR Family 
The canonical pathway for toll-like receptors (TLRs) involves the anti-microbial immune 
response, however recent studies have shown that TLRs can activate apoptosis116.  Apoptosis 
it thought to be activated during an immune response to limit the pathologic effects of the 
immune system116.  TLRs activate adapter proteins that bind and activate IRAK kinases, 
which then activate TRAF6, a ubiquitin ligase 116.  This leads to the canonical activation of 
NFκB, which activates MAPKKs and then finally apoptosis116.  So far, only TLRs 2, 3, 4, 7, 
8 and 9 have been identified as activators of this pathway116.  TLR 1, 6 and 10 are in the 
clubfoot deletion regions, but the role of these TLR family members in apoptosis is not 
known. 
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Fig. 4.1.  Apoptotic gene pathway in clubfoot chromosomal deletion regions.  
Interactions between apoptotic, anti-apoptotic and immunity genes found in each of the 
clubfoot deletion regions.  Arch at the top of the page denotes the cell membrane.  Color 
codes for genes are: red = ubiquitin ligase, orange = protein, yellow = transcription factor, 
green = transcription factor target, blue = receptor, dark blue = ligand 
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UBE2K 
Ubiquitin ligase Kinase 2 (UBE2K) was initially discovered to interact with HTT, but 
its targets also include the precursor of NFΚB117.  Once the ubiquitin is ligated to NFΚB 
it is rapidly degraded into a smaller, active form117.  However, activated NFΚB is 
sequestered in the cytoplasm by IΚB as a second mechanism of control117.  UBE2K is 
critical for NFΚB activation, and NFΚB acts as an anti-apoptotic factor by increasing 
expression of BCL-2. 
TNIP2 
TNIP2 or A-20 binding inhibitor of NFΚB (ABIN2) promotes apoptosis through the 
inhibition of NFΚB118.  TNIP family members are involved in the negative feedback loop 
of NFΚB that prevents overexpression that leads to immunological disorders118.  
However, TNIP2 is not activated by NFΚB, although still activates apoptosis through 
NFΚB inhibition118. 
TRIAD3 
TRIAD3 (zinc finger protein inhibiting NFκB) is an E3 ubiquitin protein ligase119.  
The main role for TRIAD3 is regulating TLRs activity through degradation of TLRs119.  
In addition, TRIAD3 prevents the cell from undergoing apoptosis by downregulating 
signaling molecules involved in the TLR activation of NFΚB120. 
CARMA1 
CARMA1 is also known as caspase recruitment domain 11 (CARD11), and 
complexes with BCL10 and MALT1 (paracaspase)121.  This complex activates IKK, 
which releases repression of NFΚB and leads to the immune response121.  “The 
stimulation of surface receptors on immune cells triggers not only changes gene 
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expression but also morphological changes through the reorganization of the actin 
cytoskeleton, thereby contributing to efficient cellular activation121.”  This suggests that 
the genes involved in the immune response may have a secondary function in the 
development of muscles and the muscle contraction apparatus. 
TNFSF 
Tumor necrosis factor superfamily (TNFSF) is a large family of receptors and ligands 
that stimulate the immune response, apoptosis and cell survival122.  TNFRSF11A is also 
known as receptor activator of NFΚB ligand (RANK) and is essential to osteoclast 
formation and activation123.  However, RANK is also expressed in lungs, kidneys and 
skeletal muscle123.  RANK induces downstream expression of AKT and NFκB, and 
therefore is anti-apoptotic123. 
HTT 
Huntington disease is caused by a CAG repeat expansion in the huntingtin protein 
(HTT). The HTT protein plays a role in suppressing apoptosis124.   Functional HTT is 
essential for embryonic development, and overexpression of HTT prevents cleavage of 
PAKs by CASP3124.  PAKs are kinases that regulate cell survival, and HTT protects cells 
that are exposed to apoptotic inducing signals by preventing cleavage of PAKs124. 
Transcription Factor Genes 
STAT1 and STAT4 
Signal transducers and activators of transcription (STAT) proteins are transcription 
factors that regulate several cellular processes including cell proliferation, apoptosis, 
differentiation and angiogenesis125.  STATs are activated by the Janus tyrosine kinase 
(JAK) pathway, but can also be activated by an inherent tyrosine kinase activity of 
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growth factors125.  STAT1 “is considered a tumor suppressor since it inhibits growth and 
acts as a proapoptotic factor”, and can stimulate caspase expression125.   
ATF2/CREB2 
ATF2 is a member of the leucine zipper activator protein 1 (AP-1) transcription factor 
family126.  These proteins can form homo- or heterodimers between family members to 
stimulate gene expression126.  ATF2 is activated by the JNK pathway and is upregulated 
as is c-Jun, of which a majority heterodimerize126.  The c-Jun/ATF2 heterodimer leads to 
apoptosis in response to cellular stress, and when this complex is blocked, apoptosis is 
inhibited126.  Homodimers of ATF2 can not lead to apoptosis, nor can an overexpression 
of c-Jun cause cell death, suggesting that ATF can only induce apoptosis when bound to 
c-Jun126. 
NFAT2 
Nuclear factor of activated T-cells (NFAT) is a family of calcium dependent 
transcription factors127.  NFAT2 is expressed in most cells involved in the immune 
response, but is also expressed in other cells, although not ubiquitously expressed127. 
NFAT2 has been shown to regulate skeletal muscle through control of myocyte 
differentiation127.  In addition, NFAT2 stimulates apoptosis through several pathways 
including the FAS ligand and glucocorticoid induced apoptosis127. 
CREB1 
CREB (c-AMP dependent response element binding protein) is activated along with 
AP-1 genes and the JNK pathway in response to oxidative stress and regulates genes 
involved in cellular proliferation and apoptosis128.  CREB recruits c-AMP and other 
cofactors to CRE binding sites, which are necessary for activation of target genes 
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including c-FOS and BCL-2128.  CREB has been shown to downregulate production of 
BCL-2, and inhibition of CREB results in an increase in BCL-2 transcription and cell 
survival128.  Therefore, CREB1 is a pro-apoptotic protein. 
TFDP1/2 
Transcription factor DP2 (TFDP2) dimerizes with E2F family members and increases 
transcription of target genes including those involved in apoptosis and the cell cycle129.  
Targets of DP2 include ARF, ATM, CASP8, CASP3/7, CASP9 and BAK/BAD (pro-
apoptotic members of the BCL-2 family)130.  The p53 mediated apoptotic pathway is 
activated by DP proteins, and this cascade stimulates the mitochondrial mediated 
apoptotic pathway130. 
RBAK 
Retinoblastoma-associated Kruppel-associated box protein (RBAK) is a transcription 
factor that is widely expressed in embryonic and adult tissues131.  RBAK and acts as a 
transcriptional repressor by dimerizing with E2F proteins.  It can also stop the cell from 
progressing to the synthesis stage of the cell cycle131.  Many of the E2F targets are 
proapoptotic genes (see TFDP1/2) which can be repressed by RBAK131. 
Engulfment of Apoptotic Body Genes 
EMP 
Erythroblast macrophage protein (EMP) is expressed in both erythroblasts and 
macrophages and helps adhesion between these two cell types during blood production 
and in the fetal liver132.  EMP is required for normal differentiation of erythroblasts, and 
targeted disruption of this protein leads to an embryonic lethal mouse132.  When 
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erythroblasts are cultured in the presence of an anti-EMP antibody a six-fold increase in 
apoptosis was seen132. 
GULP1 
Rapid processing of apoptotic bodies is important during embryogenesis133. GULP1 
acts in the engulfment of apoptotic bodies133.  GULP1 is highly conserved, and in fact 
can rescue c. elegans deficient in the GULP1 homolog CED-6133.  GULP1 also interacts 
directly with low density lipoprotein-related protein 1 (LRP-1) and multiple epidermal 
growth factor domains 10 (MEGF10), which are also involved in engulfing apoptotic 
bodies133.   
Other Apoptosis Related Genes 
ING1 
Inhibitor of growth (ING) proteins are a family of highly conserved apoptotic 
proteins134.  ING1 and ING3 both stimulate apoptosis, but through separate arms of the 
apoptotic pathway.  ING1 inhibits PCNA, which inhibits apoptosis and activates p53134.  
ING1 mice knockouts show increased apoptosis in response to radiation, which suggests 
that ING1 has an anti-apoptotic role in response to DNA damage134.  However, during 
embryogenesis in Xenopus laevus ING1 has a proapoptotic expression pattern134. 
ATR 
Ataxia-Telangiectasia Mutated and Rad-3 related (ATR) is in the DNA damage 
pathway, and has an anti-apoptotic effect in response to this damage135.  ATR activates 
Chk1, which prolongs activity at the replication forks and restarts replication forks where 
activity has been aborted135.  The ATR pathway leads to inhibition of apoptosis, and cells 
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depleted of Chk1 activate CASP3135.  ATR also phosphorylates and activates p53, 
leading to apoptosis136. 
SOCS6 
Suppressors of cytokine signaling (SOCS) block signaling of cytokines, “a large 
family of secreted glycoproteins that regulate fundamental biological processes, including 
embryonic development, immunity, and haematopoiesis”137.  Little is known about the 
function of SOCS6, but family members SOCS1-3 have been well characterized.  SOCS1 
deficient mice develop normally but have a low lymphocyte count due to an inhibition of 
anti-apoptotic BCL-2 family member BAX137.  In addition, SOCS1  acts in a feedback 
loop by inhibiting cytokine signaling137. 
CERKL 
Ceramide-kinase like (CERKL) is involved in the metabolism of ceramide, a 
sphingolipid138.  Sphingolipids are lipid messengers that act as cell sensors produced in 
response to cell stress, cytokines, and cytotoxins and initiate apoptosis138.  However, anti-
apoptotic signals can inhibit apoptosis by removing ceramide from the cell through 
phosphorylation by a ceramide kinase such as CERKL.  
WDR19 
Little is known about WDR19, but expression has been found in several expression 
arrays.  One expression profile found that WDR19 is expressed in the quadriceps, 
although at lower levels than in extraocular muscle139.  Apoptosis induced by 
overexpression of E2-F1 and treatment with doxyrubicin, increased expression of 
WDR19 in melanoma cells 140. 
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Apoptotic genes play an important role in limb and muscle morphogenesis.  All of the 
genes that encode proteins discussed above are involved in some part of the apoptotic 
pathway, and all are located in the clubfoot deletion regions.   Interestingly, many of the 
genes involved in this pathway interact through NFκB, which has been show to be 
involved in muscle development and critical to the immune response (Fig 4.1)141.  
Because these genes could potentially perturb muscle development during 
embryogenesis, this study was undertaken to determine whether genetic variation in these 
candidate genes is associated with isolated clubfoot. 
 
Methods 
Sample Collection 
This study was approved by the University of Texas Committee for Protection of 
Human Subjects (HSC-MS-04-239) and the IRBs of all participating centers.  Probands 
with clubfoot were identified through Shriners Hospitals for Children of Houston and Los 
Angeles, University of Vancouver, British Columbia and the Scottish Rite Hospital of 
Dallas.   Individuals with chromosomal abnormalities, syndromes or postnatal events 
associated with clubfoot were excluded.  Only cases of isolated clubfoot and their family 
members were included in the study.  Ethnicity was self-reported.  The sample was 
composed of 304 simplex trios, of which 124 were non-Hispanic white and 180 were 
Hispanic, and 179 multiplex families, of which 105 were non-Hispanic white and 74 
Hispanic. 
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DNA Extraction and Genotyping 
DNA was extracted from blood and/or saliva samples collected from all individuals.  
DNA was extracted from blood using the DNA Isolation Kit for Mammalian Blood 
(Roche, Palo Alto, CA) or saliva with Oragene Purifier (DNA Genotek Inc., Ottawa, 
Ontario, Canada).  Samples were genotyped using SNPlexTM Genotyping System 
following the manufacturer’s protocol (Applied Biosystems, Foster City, CA) and 
analyzed on a 3730 DNA Analyzer using GeneMapper® 4.0 (Applied Biosystems, Foster 
City, CA).  
Data Analysis 
Several software programs were used to test for association including Pedigree 
Disequilibrium test (PDT) and Association in the Presence of Linkage (APL)91,142.  The 
Geno-PDT, a modified version of the PDT, was employed to test for specific genotypes 
when considering dominant or recessive models75.  Altered transmission of pairwise 
haplotypes within a gene was determined using APL.  SNPs were then evaluated for 
gene-gene interactions using Generalized Estimating Equations (GEE)92. 
Results 
One hundred ninety-two SNPs in 29 apoptotic genes were genotyped in 304 simplex 
simplex (124 NHW and 180 Hispanic) and 179 multiplex families (105 NHW and 74 
Hispanic).  All SNPs and locations are shown in Appendix B, Table B1.  Call rates were 
lower than those found in previous genotyping studies using Taqman assays.  Genotyping 
was performed using ABI SNPlex, which often produces varying results.  For some of the 
SNPs, some data plots required manual calls and for others genotypes could not be 
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determined.  Fifty-six of the SNPs were out of HWE, which is most likely related to the 
low call rates.  These SNPs were excluded from further analysis resulting in 165 SNPs 
analyzed in the NHW group and 157 SNPs in the Hispanic group. 
Significant associations were found in the single SNP analysis with little overlap 
between Hispanics and NHW groups (Table 4.2).  For the NHW group, the most 
significant finding was found by all three tests for rs4690055 in TNIP2 in the simplex 
families (Table 4.2A).  TNIP2 functions as an inhibitor of NFκB as does TLR10.  
rs11096957, in TLR10, is a nonsynonymous coding SNP (N241H) that was significant in 
simplex (p=0.003) and in the aggregate (p=0.004) groups.   TNFSF13B stimulates 
apoptosis through CASP3, although it can also activate NFΚB (Fig 4.1).  Interestingly, 
rs9520835 in TNFSF13B was significant in the aggregate NHW group (APL p=0.004 and 
PDT p=0.009) and in the multiplex families (p=0.005).   Altered transmission was also 
found for a SNP in CREB1, TRIAD3, GULP1 and EMP/MAEA genes. 
In the Hispanic group, four SNPs in the NFATC1 (rs8097537, rs3894049, rs12608349 
and rs370989) showed altered transmission (Table 4.2B).  NFATC1 is responsible for 
activating the apoptotic pathway through the FAS receptor (Fig 4.1).   Two of the four 
significant NFATC1 SNPs, rs8097537 (p=0.0004) and rs3894049 (p=0.0002) were 
identified by all three analytic programs.  Altered transmission in the aggregate and 
simplex groups was found for all four NFATC1 SNPs.  However, rs370989 was also 
significant in the multiplex families (p=0.001).  FAS can also activate NFκB through 
Casp10 and the MAP kinase pathway (Fig 4.1).  ZAK also activates NFκB through the 
MAP kinase pathway.  Altered transmission of rs11686011 in the ZAK gene was found 
for the aggregate group (p=0.007), but not when stratified by family history.  Altered  
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Table 4.2. Apoptosis genes: Single SNP results  
A. NHW 
Families SNP Gene Gene Loc. APL PDT GenoPDT 
rs11096957 TLR10 E4 N241H 0.004 0.041 0.148 Combined  
rs9520835 TNFSF13B I3 0.004 0.009 0.023 
rs10932201 CREB1 I4 0.005 0.137 0.081 
rs9520835 TNFSF13B I3 0.005 0.113 0.166 Multiplex 
rs11771172 TRIAD3 I2 0.006 0.336 0.361 
rs6724428 GULP1 I4 0.006 0.025 0.112 
rs1316393 EMP/MAEA I3 0.010 0.063 0.114 
rs11096957 TLR10 E4 N241H 0.003 0.090 0.203 
Simplex 
 
rs4690055 TNIP2 I2 0.004 0.001 0.007 
 
B. Hispanic  
Families SNP Gene Gene Loc. APL PDT GenoPDT
rs10930693 CREB2 I3 0.038 0.005 0.013 
rs12608349 NFATC1/NFAT2 I4 0.102 0.061 0.001 
rs370989 NFATC1/NFAT2 I10 0.003 0.003 0.003 
rs3894049 NFATC1/NFAT2 I10 0.0002 0.001 0.004 
rs8097537 NFATC1/NFAT2 I3 0.025 0.0004 0.002 
rs2280233 STAT1 I14 0.155 0.007 0.040 
rs6751855 STAT1 U 0.144 0.491 0.010 
rs7239261 TNFRSF11A I1 0.007 0.075 0.179 
rs8094884 TNFRSF11A I6 0.071 0.010 0.111 
rs852374 TRIAD3 D 0.005 0.003 0.020 
Combined 
rs11686011 ZAK I14 0.007 0.182 0.299 
rs6446723 HTT I10 0.0004 0.330 0.587 
rs370989 NFATC1/NFAT2 I10 0.001 0.274 0.164 
rs4941125 TNFRSF11A I1 0.0004 0.608 0.810 Multiplex 
rs852522 TRIAD3 I13 0.006 0.017 0.116 
rs10930693 CREB2 I3 0.024 0.004 0.006 
rs12608349 NFATC1/NFAT2 I4 0.021 0.016 0.005 
rs370989 NFATC1/NFAT2 I10 0.077 0.003 0.009 
rs3894049 NFATC1/NFAT2 I10 0.007 0.0001 0.0003 
rs8097537 NFATC1/NFAT2 I3 0.053 0.0003 0.001 
Simplex  
rs13065446 TFDP2 U 0.369 0.194 0.009 
Gene Loc = gene location: I = intron, D = downstream, U = upstream,  
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transmission was also found for one or two SNPs in CREB2, STAT1, TNFRSF11A, 
TRIAD3, HTT and TFDP2 genes. 
While overall there was little overlap between SNP variants detected in the NHW 
and Hispanic groups, there were some interesting similarities.  For example, two different 
SNPs in TRIAD3 showed altered transmission in both groups (Table 4.2).   rs11771172 in 
TRIAD3 (p = 0.006) was significant in the multiplex NHW families only, whereas 
rs852374 was significant in the aggregate and multiplex Hispanic families.  This suggests 
that TIRAD3 is important in both ethnic groups.  TRIAD3 inhibits NFκB activity by 
inhibiting TLR.  rs10932201 in CREB1 was significantly associated in the multiplex 
NHW families (p=0.005), while rs10930693 in CREB2 was significant in the aggregate 
(p=0.005) and simplex (p=0.004) Hispanic families.  CREB1 and CREB2 are members of 
a gene family that function in different branches of the apoptotic pathway.  It is 
interesting that different genes in the same pathway were significantly associated in the 
different ethnic groups.  Similarly, two SNPs, rs7239261 and rs8094884, in TNFRSF11A 
receptor demonstrated altered transmission in the aggregate (p=0.007 and 0.01, 
respectively) Hispanics families, whereas rs9520835, in TNFSF13B, a ligand family 
member, showed altered transmission in the aggregate (p = 0.004/0.009) and multiplex (p 
= 0.005) NHW families.  This suggests that the same genetic pathway is being perturbed 
in different ethnic groups but by variation in different members of the same gene family.  
Seven two-SNP haplotypes in five genes in the NHW group and 28 two-SNP 
haplotypes in five different genes in the Hispanic group found (Table 4.3).  The most 
significant haplotype in the NHW group involved rs1451821 and rs3733280 in WDR19 
(p=0.002).  Interestingly, most haplotypes in the NHW group do not include significant 
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variants from the single-SNP analysis.  For example, only one significant haplotype, 
contained a SNP, rs6724428 (GULP1), that showed altered transmission in the single-
SNP analysis (Table 4.3A, p=0.005).  However, three significant haplotypes were 
identified for GULP1.  rs10931359 (GULP1) was involved in two haplotypes with 
rs7593946 (p=0.009) and rs12624002 (p=0.004). 
In contrast, for the Hispanic group, 25 of the 28 significant two-SNP haplotypes 
contained SNPs that showed significantly altered transmission in the single-SNP analysis 
(Tables 4.3B).  However, the most significant haplotypes were found for SNPS in 
TRIAD3 and NFAT2.  rs852374 showed altered transmission with seven other TRIAD3 
SNPs and rs3894049 with nine SNPs in NFAT2. This may be due to linkage 
disequilibrium between the variants, and this analysis is ongoing.  Interestingly, the 
overtransmitted allele for rs3894049 in most of the haplotypes is allele 2, but in the 
rs4799055/rs3894049 haplotype the overtransmitted allele for rs3894049 is allele 1, 
which is the opposite of all the other haplotypes (p=0.001).  The significant SNP 
haplotypes for WDR19 and CARD11 did not include the SNPs identified in the single 
SNP analysis. 
Twenty-two gene-gene interactions were identified and there was no overlap when 
comparing by ethnicity (Table 4.4).  For the NHW group, the most significant gene 
interactions were between rs6769676 in RNF7 and rs4273389 in ATR (p=0.0001) and 
rs1517352 in STAT4 and rs11096957 in TLR10 (p=0.0001). The most significant 
interactions in the Hispanic group were between rs4675272 in SUMO1 and rs9520835 in 
TNFSF13B (p=0.0002), rs925847 in STAT4 and rs8094884 in TNFRSF11A (p=0.0003), 
and rs4972533 in ZAK and rs3779092 in TRIAD3 (p=0.0003).  Interestingly, TNFSF13B  
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                 Table 4.3.  Two-SNP Haplotypes Results 
                 A. NHW 
Gene SNP 1 SNP 2 p-value OT UT 
ATR rs6440085 rs6792259 0.003 22 - 
rs7593546 rs10931359 0.009 21 - 
rs12624002 rs10931359 0.004 11 12 GULP1 
rs6724428 rs1354905 0.005 12 11 
ING1 rs1441043 rs6492308 0.005 21 - 
WDR19 rs1451821 rs3733280 0.002 21 12 
ZAK rs4344898 rs1837470 0.005 11 22 
 
             B. Hispanics 
 
Gene SNP 1 SNP 2 p-value OT UT 
rs4941125 rs7239261 0.008 - 11 
rs7239261 rs8094884 0.003 22 11 TNFRSF11A 
rs7239261 rs2290154 0.007 22 12 
rs852374 rs1468996 0.008 11, 12 21,22 
rs852374 rs2302907 0.007 11,12 21,22 
rs852374 rs13239194 0.009 11 21 
rs852374 rs11771172 0.003 11 21 
rs852374 rs6971918 0.005 11 21 
rs852374 rs10257204 0.003 12 - 
TRIAD3 
rs852374 rs6967635 0.009 11 21 
rs1451821 rs9997015 0.006 21 11 WDR19 rs3733280 rs1057807 0.009 11,12 21 
CARD11 rs1713911 rs7778444 0.007 11,21 22 
rs8097537 rs12608349 0.007 21 11 
rs9962479 rs12608349 0.002 22 - 
rs12608349 rs370989 0.004 11 12 
rs4799055 rs370989 0.005 21,11 22,12 
rs7227107 rs370989 0.002 11 12 
rs12608349 rs3894049 0.001 12 11 
rs1660139 rs3894049 0.002 12 11 
rs1667673 rs3894049 0.006 22,12 21 
rs177820 rs3894049 0.004 22,12 11,21 
rs2036892 rs3894049 0.004 22 21 
rs370989 rs3894049 0.002 12 21 
rs4799055 rs3894049 0.001 11,21 22,12 
rs7227107 rs3894049 0.0004 12 11 
rs8090692 rs3894049 0.002 22 11 
NFAT2 
rs8097537 rs7227107 0.007 11 - 
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Table 4.4.  Gene interactions 
A.  NHW 
Gene 1 SNP 1 
Gene 
Loc. Gene 2 SNP 2 
Gene 
Loc. 
p-
value 
CREB1 rs2551640 I1 HTT rs2285086 I2 0.0002 
GULP1 rs1354905 I8 TNFSF13B rs10508198 I2 0.0004 
RNF7 rs1980191 U TLR10 rs11096957
E1 
N241H 0.0008 
RNF7 rs6769676 I1 ATR rs4273389 I31 0.0001 
RNF7 rs6769676 I1 ATR rs13085998 I16 0.0004 
STAT4 rs1517352 I6 TLR10 rs11096957
E1 
N241H 0.0001 
WDR19 rs1057807 D UBE2K rs302947 I2 0.0008 
ZAK rs13032010 I2 CREB1 rs10932201 I4 0.0007 
 
B.  Hispanics 
 
Gene 1 SNP 1 
Gene 
Loc. Gene 2 SNP 2 
Gene 
Loc. 
p-
value 
RBAK rs7778444 3’ TNFRSF11A rs8089829 I7 0.0009 
RBAK rs7778444 3’ TNFSF13B rs9514828 U 0.0008 
CERKL rs1047307 3’ NFAT2 rs177820 I10 0.0009 
CERKL rs1866888 U HTT rs362331 I41 0.0007 
GULP1 rs12474692 I2 RBAK rs7778444 3’ 0.0003 
GULP1 rs7586390 I1 RBAK rs7778444 3’ 0.0006 
RNF7 rs6776205 D TRIAD3 rs13247447 I13 0.0005 
STAT1 rs12468579 D STAT4 rs925847 I21 0.0008 
STAT4 rs925847 I21 TNFRSF11A rs8094884 I6 0.0003 
SUMO1 rs4675272 I1 TNFSF13B rs9520835 I3 0.0002 
TFDP1 rs7325214 U NFAT2 rs7227107 
E9 
Syn 0.0007 
TRL6 rs3821985 
E1 
Syn UBE2K rs305827 I4 0.0005 
ZAK rs11686011 I14 STAT4 rs4341967 I3 0.0006 
ZAK rs4972533 I8 TRIAD3 rs3779092 I13 0.0003 
Gene Loc.=gene location, 3’=3’UTR, U=upstream, I=intron, D=downstream, 
E=exon, Syn=synonymous 
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and TNFRSR11A are both TNF family members suggesting that perturbation of this 
branch of the apoptotic pathway may play role in clubfoot in Hispanics.  
Many of the variants identified in single SNP analysis and in the gene-gene 
interactions were located in potential transcription factor binding sites (Table 4.5).  Three 
prediction programs were used to determine if there were differences in transcription 
factor binding sites between ancestral and alternate alleles for the variants.  Each of the 
programs predicted that most of the SNPs create or ablate transcription factor binding 
sites, although the programs did not agree on which sites.  Interestingly, two prediction 
programs agreed on the creation of an H4TF-2 site for rs4941125 in TNFRSF11A.  Also 
of note, a retinoic acid receptor binding site is predicted to be lost for rs4675272 in 
SUMO1.  This is important because of the role retinoic acid plays in the development and 
patterning of them limbs (Chapter 1).  A STAT5b binding site is predicted to be lost for 
rs1047307 in CERKL, and this transcription factor is a family member of STAT1 and 
STAT4, which have altered transmission in the clubfoot population of this study. Also, for 
rs9514828 in TNFSF13B, an NFκB binding site, which plays an integral role in the 
immune response and apoptotic pathway (Fig. 4.1). However, changes are predicted to 
occur, and further testing will be required to determine if the alleles are functional.   
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Table 4.5.  Predicted transcription factor binding sites.  Comparison of 
ancestral and alternative alleles of significant SNPs in putative regulatory 
regions. Ancestral allele defined by the allele present in chimpanzee.  Gene 
Loc.=gene location, 3’=3’UTR, U=upstream, I=intron, D=downstream, E=exon, 
Syn=synonymous 
 
AFP1=alpha fetoprotein enhancer binding protein 1, AKNA=AT hook 
transcription factor, AP1/2α=activator protein 2, C/EBP=CCAAT enhancer 
binding protein, CDC2=Cell division cycle 2, c-myc=myc oncoprotein, 
CTCF=CCCTC binding factor, E1A-F=E1A enhancer binding protein, 
EG=epsilon globin, EGFR=epidermal growth factor, GATA1=GATA binding 
protein 1, GH=growth hormone, GM-CSF=granulocyte/macrophage colony 
stimulating factor, GR=glucocorticoid receptor, H4TF-2=Histone 4 pHu4A 
gene, HNF3=hepatocyte nuclear factor 3, HSTF=heat shock transcription factor, 
ICSBP=interferon consensus sequence binding protein, IGH=immunoglobulan 
heavy chain, IL4/6=interleukin 4/6, LUN1=Lung, LyF1 =lymphoid transcription 
factor, MBP=Myelin basic protein, NMP-1=nuclear matrix protein, Oct-1=POU 
class 2 homeobox 1, Pit 1a=pituitary-specific factor 1, RARα1=retinoic acid 
receptor alpha, SP1=stimulating protein 1, TBP=TATA binding protein, 
TCF2α=T cell factor 2 alpha, TFIID=transcription initiation factor D 
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     Alibaba Patch TESS 
SNP Gene Gene Loc. 
Anc 
Allele 
Alt 
Allele 
Anc 
Allele Alt Allele Anc Allele Alt Allele 
Anc 
Allele Alt Allele 
rs1047307 CERKL 3’ G A HSTF None STAT5b None None C/EBP 
rs1866888 CERKL U T C None None Pit 1a 
AKNA, IL6, 
C/EBP, MBP, 
EG, TFIID, TBP 
CDC2, 
GH AP1 
rs2551640 CREB1 I1 G* A* None None None CDC2 None None 
rs7586390 GULP1 I1 A G None None AFP1 None None CDC2 
rs7778444 RBAK 3’ G A None Oct-1 None None None None 
rs1980191 RNF7 U A T None Pit 1a GM-CSF 
NMP-1, MBP, 
AKNA, EG, 
TFIID, TBP 
None GH 
rs6769676 RNF7 I1 G T TBP None None None None TCF2α,  E1A-F, CDC2 
rs6751855 STAT1 U G A None 
ICSBP, 
GATA1, 
C/EBP 
GM-CSF c-myc, HNF3, EG, TFIID, TBP None None 
rs4675272 SUMO1 I1 G C None None GR, RARα1 None None None 
rs7325214 TFDP1 U C* T* Oct-1 None None LyF1, AP2α, LUN1 None SP1, c-myc 
rs13065446 TFDP2 U C T None None CTCF, EGFR, IGH Pit 1a C/EBP GH 
rs4941125 TNFRSF11A I1 A G None C/EBP, SP1 IL4 H4TF-2 None HINFP 
rs7239261 TNFRSF11A I1 C A None None None None None C/EBP 
rs9514828 TNFSF13B U C T None NFkB None None None None 
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Discussion 
In previous studies, we found an association between mitochondrial mediated 
apoptotic genes and isolated clubfoot78,106.  For this reason and because clubfoot 
chromosomal deletion regions contained many apoptotic genes, 192 flanking and 
intragenic SNPs in 29 apoptotic genes were interrogated.   For the NHW group, the most 
significant association was found for SNP rs11096957 in TLR10, which creates an amino 
acid substitution.  The H241N is on the surface of the protein, and is not predicted to be 
deleterious to the function of the protein (www.snp3d.org).  However, this variant may 
still be functional if it disrupts splicing enhancers or silencing sites. This SNP may also 
be in linkage disequilibrium with other variants that may be functional.   
In the Hispanic group, the most significant SNP associations were found for NFAT2 
and TNFRSF11A in the single SNP analysis.  Although these NFAT2 SNPs were in 
introns, they were not located in the first or second introns that can harbor transcription 
factor binding sites.  There are multiple transcripts of NFAT2, and isoform D has its start 
site in exon 3, and all SNPs are located downstream of this start site.  Therefore, these 
particular variants are not likely to be involved in promoter regulation.  However, these 
SNPs could affect splice site regulatory elements or be in LD with other functional 
variants.  rs4941125 in TNFRSF11A is in the first intron and could potentially be located 
in a transcription factor binding site.  Both Patch and TESS prediction programs expect a 
HINFP (Histone 4 transcription factor) binding site to be created in the individuals who 
have the alternate allele compared to the ancestral allele (Table 4.5).  H4TF-2 is a 
transcription factor only expressed during DNA synthesis143.  The creation of this binding 
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site in TNFRSF11A may lead to abnormal production and activation of the TNF receptor.  
This finding may be particularly important for the Hispanic group. 
Interestingly, the two-SNP haplotypes in the NHW did not include any of the SNPs 
identified in the single SNP analysis.  The opposite was found for the Hispanic group, 
where many significant haplotypes contained SNPs identified in the single analysis such 
rs3894049 in NFAT2.  Together these results suggest that there are distinct genetic 
etiologies for NHW and Hispanics, and different genes are involved in clubfoot for each 
population. The Hispanic haplotypes confirm the results of the single SNP analysis, 
suggesting that NFAT2 and TRIAD3 are important in clubfoot development within the 
Hispanic population.  Both of these genes act at the cell membrane level of the apoptotic 
cascade and perturbation of gene expression may have a global effect on the apoptotic 
pathway and downstream proteins. 
  Many of the associated SNPs may perturb gene expression, and functional testing is 
required to determine if the predicted transcription factor binding sites change expression.  
Interestingly, although there was no overlap of SNPs involved in gene-gene interactions 
between NHW and Hispanic groups, many of the same genes were involved in the 
interactions.  This suggests that while there is allelic heterogeneity between families, a 
small portion of the same genes consistently contribute to clubfoot.  However, even 
though the same genes are involved in gene-gene interactions, there were significant 
differences between the variants involved in the interactions in NHW and Hispanics.  
This supports the complex model for clubfoot in which perturbation of many genes and 
environment factors contribute to clubfoot. 
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Limb formation is a complex process involving cell proliferation and patterning, 
programmed cell death, and correct positioning of the limb21,22.  The hind limb begins as 
a small swelling during the fourth week of gestation and morphogenesis is complete by 
the end of the eighth week23.  However, the legs, which develop in the midline in 
equinus, should move to plantar grade by the twelfth week24.  Failure of this final 
movement results in clubfoot.  Perturbations in any of the developmental processes may 
affect the final foot positioning, as would abnormal muscle or tendon development that is 
universally associated with clubfoot1,7,11,14.  It is unclear whether the abnormal 
musculature in clubfoot is a primary or secondary abnormality.  It has recently been 
shown that apoptosis is required for development of the muscle bellies and correct 
attachment to tendons22.  Disruption of the apoptotic pathway, whether by increased or 
decreased activity, could alter morphogenesis and prevent the fetal limb movement 
required for normal foot development. 
Based on our model shown in Fig 4.2, individual genetic variants associated with 
clubfoot may be necessary but not sufficient to cause the disorder.  For the individual, the 
combination of many variations within different causative genes, e.g. a high risk genetic 
haplotype (but not necessarily within one gene), could contribute to clubfoot.  In addition, 
those individuals with specific high-risk haplotypes may be more susceptible to 
environmental exposures.  For example, maternal smoking in the general population 
increases the risk of clubfoot four fold, however maternal smoking in women with a 
family history of clubfoot have a twenty fold increased risk of clubfoot58.  When this 
information is incorporated into the working model of clubfoot in Fig. 4.2, maternal 
smoking is more likely to contribute to clubfoot if the babies and/or mothers also have 
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the high-risk haplotype.  This model of clubfoot etiology incorporates genetic variants in 
different pathways including xenobiotic and toxin metabolism, limb and muscle 
development, and apoptosis which have all recently been associated with clubfoot (Fig. 
4.2)78,106,144 .  There may be a threshold of genetic variants needed to cause clubfoot, with 
greater number of high-risk variants increasing the severity of clubfoot.  Our findings fit 
this model, which is based on the multifactorial model first proposed by Carter et al. in 
1965145.   Determining all of these high-risk haplotypes is the continuing challenge but 
will improve genetic counseling and provide more precise risk assessments. 
This study had a limitation in that the call rates of many of the variants that were 
interrogated were lower than expected.  This is most likely due to the chemistry of the 
genotyping assay, SNPlex.  The significant results reported here should be replicated with 
a higher fidelity assay, such as TaqMan in the primary data set and then validated in a 
secondary population such as the recently collected case-control (N=750) clubfoot 
population.   
In summary, this study interrogated apoptotic genes identified in clubfoot deletion 
regions.  We found significantly associated SNPS in genes that are different between 
ethnic groups yet function in many similar apoptotic pathways.  This provides a degree of 
confidence in our results, which nevertheless require validation.   These results add to our 
growing body of knowledge about etiologic causes of clubfoot.    
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Fig 4.2. Clubfoot Model 
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Chapter 5: HOX Transcription Factors and Clubfoot 
 
 
This chapter is a presentation of work from a previously published paper.  For more 
information please refer to:  Ester, AR, Weymouth, K, et al.  Altered transmission of HOX 
and apoptotic SNPs identify a potential common pathway for clubfoot.  American Journal of 
Medical Genetics. December, 2009. 149A (12): 2745-52.  
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HOX Genes 
The HOXD family of genes is a group of candidate genes, as they map to chromosome 
2q31-33, a deletion region identified by Brewer et al. to be associated with clubfoot69,144.  
The HOX proteins are transcription factors that direct patterning of the axial skeleton and 
muscle and limb development31,32.  The HOX gene family consists of 39 genes in four 
paralogous clusters (A, B, C and D) on different chromosomes (7p15.3, 17q21.3, 12q13.3 
and 2q31.1, respectively).  The HOX clusters share common genomic structure (Fig. 1) and 
are temporally and spatially regulated and expressed during embryogenesis31,33.  “Expression 
of the 3’ genes of the clusters begins in the superior regions of the embryo and progresses 
more inferiorly as the more 5’ genes in the cluster are expressed in the developing 
embryo”146.  For example, HOXD9, located towards the 5’ end of the cluster, is expressed 
proximally as the limb bud develops.  The further 5’ genes are, the later and more distal they 
are expressed as the limb extends and differentiates (Fig. 5.1)31. 
The 5’ HOXA genes are expressed in fore- and hind limb muscles of, and are involved in 
patterning and differentiation of muscles in both embryonic limbs and adult limbs during 
muscle repair34.  These 5’ genes have also been detected in myoblast and myotube cell 
lines34.  HOXA11 and HOXA13 have been shown to contribute to cartilage development, and 
HOXA13 regulates cell adhesion during the condensation step of skeletogenesis147.  The 
synchronized development of muscles, tendons and cartilage is crucial for proper formation 
of the limb 21, and 5’ HOXA  genes regulate each of these functions34,147. 
Since the HOXA and HOXD genes play important roles in normal limb development, it 
would be expected that mutations in these genes might disrupt normal limb development 
(OMIM). In fact, there are several known mutations in HOX genes that cause limb 
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malformations.  The HOXD10 T956A/M319K mutation causes autosomal dominant 
congenital vertical talus (CVT)148,149.  Interestingly, a family with CVT and the 
T956A/M319K mutation had one affected individual with CVT in one foot and clubfoot in 
the other foot148. Further evidence of HOXD10 in limb malformations comes from mice in 
which a deletion of the gene results in stiff hind limbs with occasional abnormal rotation of 
the hind leg150,151.  Mutations in several other HOX genes also cause mammalian limb 
abnormalities.  Mutations in HOXD13 cause human synpolydactyly148,152,153.  Mutations in 
HOXA13 in the mouse lead to hypodactyly and the homozygous knock out of this gene is an 
embryonic lethal154. 
HOXA and HOXD genes are important in limb morphogenesis, and disruption of these 
genes individually gives rise to syndromes associated with limb abnormalities.  “While few 
of these syndromes include clubfoot, it is unknown whether different types of genetic 
variation may produce a related phenotype such as isolated clubfoot”.  This phenomenon has 
been documented in nonsyndromic cleft lip and palate, where an IRF6 promoter variant may 
be etiologic in 18% of cases, whereas coding mutations cause van der Woude syndrome155.   
Given the role of HOX genes in limb development, they are candidates for playing an 
etiologic role in isolated clubfoot.  This study was undertaken to determine whether genetic 
variation in the HOXA or HOXD genes is associated with isolated clubfoot, to further 
evaluate whether the T956A/M319K HOXD10 mutation causes clubfoot and to determine if 
variation associated with clubfoot affects the amount of HOX protein produced. 
Study Design 
Nine HOXA and 11 HOXD SNPs (Fig. 5.1, Table 5.1) were genotyped in a primary 
discovery population composed of 304 simplex trios (124 Non-Hispanic white and 180 
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Hispanic) and 179 multiplex families (105 Non-Hispanic white and 74 Hispanic).  An 
independent validation population consisted of 144 nonHispanic white clubfoot simplex 
trios. 
To determine whether the T956A/M319K HOXD10 mutation causes ITEV, 
494 ITEV probands (267 nonHispanic white and 227 Hispanic) were 
genotyped using the TaqMan Genotyping Assay.  Unrelated parents of 
children with sporadic nonsyndromic cleft lip and palate (NSCLP) with no 
known abnormalities were used for the control population consisting of 595 
individuals (380 nonHispanic white and 215 Hispanic) with no anomalies.  
For positive controls, DNA of two affected individuals from a CVT family 
with the HOXD10 T956A/M319K was used.  (Ester, 2009) 
Results 
No T956A/M319K HOXD10 variants were detected among either the unrelated controls.  
We next genotyped SNPs in the HOXA and HOXD gene clusters.  All 20 examined SNPs 
were in HWE in both ethnic groups (data not shown).  Comparisons of SNP allele 
frequencies between nonHispanic whites and Hispanics detected significant differences even 
after Bonferroni correction (p<0.001) in the majority of SNPs (Table 5.1).  Therefore, the 
data were stratified by ethnicity and examined separately.  For SNPs showing no frequency 
differences, the data was combined across ethnicities for APL analysis. Parametric and 
nonparametric multipoint linkage analysis did not detect linkage in HOXA or HOXD genes 
(data not shown).   
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Figure 5.1. Genetic layout of HoxA and HoxD gene clusters 
 
 
 
Genes denoted by rectangles, arrows indicate SNP placement
 73
Table 5.1. HoxA and HoxD SNPs 
  
Gene dbSNP Pos. Alleles MAFa HCFb,c Location 
rs6749771 SNP1 A/G 0.391 0.685 3' of HOXD cluster 
rs1446575 SNP2 C/A 0.385 0.697 HOXD3-HOXD1 
rs1318778 SNP3 G/C 0.289 0.145 3' of HOXD3 
rs1542180 SNP4 G/A 0.378 0.692 5' of HOXD3 
rs1867863 SNP5 C/A 0.341 0.606 5' of HOXD4 
rs2113563 SNP6 T/C 0.306 0.257 HOXD8-HOXD4 
rs2592394 SNP7 C/T 0.305 0.182 HOXD9-HOXD8 
rs847146 SNP8 G/T 0.354 0.361 HOXD11 (intronic) 
rs741610 SNP9 G/A 0.316 0.443 HOXD12-HOXD11 
rs711812 SNP10 T/G 0.325 0.438 5' of HOXD12 
H
ox
D
 
rs6758117 SNP11 T/C 0.302 0.594 5' of HOXD cluster 
rs2462907 SNP12 C/T 0.491 0.461 3' of HOXA cluster 
rs6668 SNP13 C/T 0.375 0.413 3' of HOXA2 
rs2428431 SNP14 C/G 0.367 0.409 HOXA2 (intronic) 
rs3757640 SNP15 C/T 0.267 0.415 HOXA5 (intronic) 
rs3801776 SNP16 G/A 0.226 0.315 5' of HOXA9 
rs3779456 SNP17 T/C 0.442 0.540 HOXA10 (intronic) 
rs1859164 SNP18 T/C 0.479 0.386 HOXA10 (intronic) 
rs6968828 SNP19 G/T 0.462 0.445 HOXA11 (intronic) 
H
ox
A 
rs3807598 SNP20 C/G 0.451 0.305 5' of HOXA cluster 
a MAF = Minor allele frequency in nonHispanic white population 
b HCF = Corresponding frequency in Hispanic of nonHispanic white minor allele 
c HCF signficiantly different from MAF (p<0.001) in bold 
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APL analysis found significant evidence for association with SNPs in both HOXA and 
HOXD in the discovery sample (Table 5.2).  The strongest associations in the NHW sample 
was seen for SNP16, located 5′ to HOXA9, in the combined multiplex and simplex group 
(p=0.004) and when stratified by family history (Table 5.2).  Additionally, a strong 
association for SNP1 in HOXD was found in the NHW simplex families (p=0.009).  In the 
Hispanic sample, the strongest association was with SNP14 (p=0.008) in the HOXA gene 
cluster, with no evidence for association found with SNPs in HOXD.  Interestingly, the 
combined ethnicity data for SNP14 was still significant (Table 5.2). 
Significantly overtransmitted haplotypes for 
HOXA and HOXD were seen in NHW and HOXA in 
Hispanics (Table 5.3 and Appendix C Tables C5 - 
C7).  “These haplotypes primarily involve the SNPs 
identified in the single SNP association analyses”.  
Among NHW the most significant haplotype for 
HOXA involves SNP16 and SNP18, which are in 
the 5’ region of the HOXA cluster (Table 5.3).   
Table 5.2.  Results of APL analysis of HoxA and HoxD in discovery populationa,b 
 
   All Multiplex Simplex 
 dbSNP Pos. All Ethn.  NHW Hisp. NHW  Hisp.  NHW  Hisp. 
rs6749771 SNP1 —
d 0.015 0.899 0.505 0.699 0.009 0.754
H
O
X
D
 
rs1446575 SNP2 — 0.021 0.334 0.026 0.440 0.224 0.134
rs6668 SNP13 0.101 0.802 0.025 0.968 0.119 0.872 0.073
rs2428431 SNP14 0.006 0.345 0.008 0.158 0.081 0.876 0.043
rs3801776 SNP16 — 0.004 0.143 0.032 0.114 0.046 0.449H
O
X
A 
rs3779456 SNP17 — 0.179 0.845 0.042 0.459 0.980 0.702
aSNPs with p<0.05 shown in bold 
Table 5.3.  Overtransmitted 
HoxA and HoxD haplotypes in 
discovery samplea,b 
 
 Haplotype p-value 
NonHispanic White 
SNP1/SNP2 0.007 
SNP1/SNP6 0.007 HOXD SNP1/SNP7 0.006 
HOXxA SNP16/SNP18 0.004 
Hispanic 
SNP14/SNP15 0.009 
SNP14/SNP19 0.006 HOXA 
SNP16/SNP12 0.006 
   aHaplotypes with p<0.01 shown 
bp-values uncorrected for multiple testing 
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Both of these genes are expressed during limb development.  In Hispanics, haplotypes 
involving SNP14 or SNP16 (HOXA) were also overtransmitted (0.006≤p≤0.009; Table 5.3 
and Appendix C, Table C5).  
There was no evidence for gene-gene interactions between HOXA and HOXD in the 
NHW discovery population.  However for the Hispanic population, there were interactions 
between HOXA and HOXD for SNPs 11/14 and 5/16 (p=0.006 and p=0.007) (data not 
shown).   
The validation sample provided moderate evidence for association with SNP16 in HOXA 
(p=0.028).  Analysis of 2-SNP haplotypes in the validation population identified seven 
HOXA haplotypes with altered transmission, although these haplotypes were not identified in 
the discovery sample (Table 5.3 and Appendix C, Table C8).  “The most significant 
haplotypes in the validation population were SNP17/20 (p=0.007) and SNP18/20 
(p=0.0003)”. 
There were no interactions between SNPs in HOXA and HOXD in the validation sample 
(data not shown).  However, multiple interactions between HOXA and HOXD SNPs were 
identified in the validation sample.  
Previously variants in mitochondrial mediated apoptotic genes were found to be 
associated with clubfoot (Chapter 3), and we evaluated our data from both studies to look for 
potential gene-gene interactions in the discovery sample106.  The results are presented in 
Table 5.4 and Appendix C, Tables C12 and C13.  While multiple interactions between HOX 
genes and mitochondrial mediated genes in both ethnicities, none of these interactions with 
p<0.01 were the same in both ethnicities.  There was, however, strong evidence for 
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Table 5.4. Gene-gene interactions for Hox, IGFBP3 and 
mitochondrial-mediated apoptotic variantsa,b 
 
A. nonHispanic White 
Gene 1 SNP 1 Gene 2 SNP 2 p-value 
CASP3 rs1049216 rs6749771 (SNP1) 0.002 
CASP3 rs1405937 rs6749771 (SNP1) 0.005 
CASP3 rs1049253 rs2592394 (SNP7) 0.001 
CASP3 rs1049216 rs2592394 (SNP7) 0.008 
BID rs8919 
H
O
X
D
 
rs6758117 (SNP11) 0.007 
CASP3 rs2720378 rs6668 (SNP13) 0.004 
CASP3 rs1049216 rs1859164 (SNP18) 0.004 
CASP3 rs2720378 rs1859164 (SNP18) 0.004 
CASP10 rs3900115 rs3779456 (SNP17) 0.008 
BID rs181405 rs3779456 (SNP17) 0.001 
BID rs181405 
H
O
X
A 
rs1859164 (SNP18) 0.005 
 
B. Hispanic population 
Gene 1 SNP 1 Gene 2 SNP 2 p-value 
CASP3 rs4647602 rs1318778 (SNP3) 0.0005 
CASP3 rs4647602 rs2113563 (SNP6) 0.009 
CASP3 rs2696057
HOXD 
rs741610 (SNP9) 0.008 
BCL-2 rs1564483 rs3801776 (SNP16) 0.002 
CASP9 rs4233533 rs3779456 (SNP17) 0.001 
APAF-1 rs1866477
HOXA 
rs6968828 (SNP19) 0.009 
aonly p<0.01 shown 
bp-values uncorrected for multiple testing 
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interaction between SNPs in HOXA and HOXD and SNPs in both Casp3 and Bid in 
nonHispanic whites (Table 5.4), and in Hispanics, the strongest interactions were between 
SNPs in Casp3 and HOXD (Table 5.4).   
 
“Because the HOX clusters are controlled by many different regulatory factors, SNPs in 
the intergenic regions of the clusters may be in enhancer or suppressor regions”.  Therefore, 
each of the overtransmitted SNPs in these regions was evaluated using three transcription 
factor binding site prediction algorithms.  SNP14 was predicted to change ancestral binding 
sites by all three programs, but the binding factors differed (Table 5.5).  The ancestral allele 
of SNP16 was not identified as a potential binding site by any of the programs, while the 
alternative SNP generated a potential binding site by two of the programs (Table 5.5).  SNP1 
was not predicted to change any binding sites (data not shown). 
SNPs within promoter regions have been shown to alter gene expression by affecting 
transcription factor binding sites156.  SNP16 is located in the basal promoter region of 
HOXA9.  The sequence surrounding SNP16 was inputted into three different transcription 
factor binding site prediction programs, Alibaba2, Patch and Transcription Element Search 
Software (TESS)93-95.  The results show a loss of a transcription factor binding site, although 
Table 5.5. Predicted transcription factor binding sites for HoxA 
SNPs in discovery populationa 
  Alibaba2 Patch TESS 
  Anc. Alt. Anc. Alt. Anc. Alt. 
rs2428431 
(SNP14) 
MIG1, 
Sp1 None 
Sp1, 
AML1 NF-E 
TCF2α, 
MIG1, 
AML1 
NF-E, 
RAF 
rs3801776 
(SNP16) None 1-Oct None None None RAF 
aOnly SNPs with p<0.01 in regulatory regions shown 
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the predicted site varies between programs.  This suggests that the expression pattern of 
HOXA9 may be affected by the presence of alternative alleles at SNP16.   
Discussion 
This study assessed the role of HOX genes in clubfoot.  The T956A/M319K HOXD10 
mutation that has been shown to cause CVT in individuals with isolated clubfoot148 was 
tested in the discovery population.  This mutation was not found in cases or controls.  This 
result confirms the previous finding of Dobbs et al. and provides further evidence that this 
mutation does not cause isolated clubfoot157. 
Next, we assessed variants in the HOXA and HOXD gene clusters for an association with 
clubfoot.  SNP1, which is 3’ of the HOXD cluster, had altered transmission but is not 
expected to affect HOXD genes expressed in the limbs31,33.  SNP14 and SNP16, both in the 
HOXA gene cluster, were significantly overtransmitted.  “SNP14 is in intron 1 of HOXA2 and 
changes predicted DNA binding sites [Table 5.5].  HOXA2 is not expressed in the limb and is 
not likely to contribute to clubfoot, but we cannot exclude the possibility that these SNPs 
may regulate expression levels of other upstream 5’ HOXD genes”.  SNP16, is located in the 
HOXA9 basal promoter region, and showed altered transmission in nonHispanic whites in 
both the discovery and validation groups.  Pairwise haplotypes involving SNP16 were 
overtransmitted and this SNP had gene-gene interactions.  “HOXA9 is expressed in both the 
proximal and distal limb and the variant allele is predicted to introduce novel DNA binding 
sites [Table 5.5]”.  This change may alter HOXA9 expression levels and affect limb or 
muscle development.   
Perturbations in limb developmental processes may affect the final positioning of the 
foot, as would abnormal muscle or tendon development that is associated with clubfoot 
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1,7,11,14.  We found that genetic variants in HOXD and HOXA are associated with clubfoot, 
and these variants may perturb gene expression and contribute to clubfoot.  Additionally, we 
found variation in apoptotic genes interacts with variants in HOXD and HOXA genes, and 
these interactions are associated with clubfoot106.  These results are supported by work 
indicating that apoptosis is important for muscle morphogenesis22. 
Apoptosis is associated with interdigital removal of excess skin; however, 
it has more recently been shown to play a far more subtle role in later limb 
development shaping muscle and tendons. Specifically, Casp3 has been 
shown to modulate apoptosis in later muscle and tendon development.  While 
we did not find a strong association with Casp3 and clubfoot alone, we did 
find evidence for interactions between Casp3 and variants in HOX genes.  
This implies that individual variation in Casp3 may not be sufficient to cause 
clubfoot but that the interaction with genes in other limb and muscle 
developmental pathways, such as HOXA and HOXD, are necessary in order to 
disrupt the developmental process.  (Ester, 2009) 
The interactions seen between the mitochondrial mediated programmed cell death genes 
and HOXA and HOXD genes suggest that there may be a common pathway or regulatory 
element controlling these two pathways.  Perturbations of this common regulatory pathway 
may also lead to clubfoot.  Apoptosis in hind limb myocytes helps shape developing muscles 
and coordinates muscle-tendon connections28.  This process is regulated by retinoic acid, 
which has also been shown to control HOX genes22,158.   
The goal of these studies was to identify high-risk haplotypes that would 
contribute to clubfoot.  The first step in this process is to identify genetic 
variants that are associated with clubfoot and to determine whether they 
interact. In this study we found evidence for an association between a basal 
promoter SNP in HOXA9 and clubfoot, and provide further evidence that 
mitochondrial mediated apoptotic genes play a role in clubfoot.  (Ester, 2009) 
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Conclusions 
Clubfoot is a common birth defect occurring in more than 135,000 live births worldwide 
each year39,159,160.  Treatment modalities such as casting and surgery have improved the long 
term outcome but residual foot and leg abnormalities often persist42,82,83.  Little is known 
about how clubfoot develops, and knowledge gained by studying abnormalities of foot 
development, such as clubfoot, may help identify the genes that are involved with the final 
stages of limb development and rotation.  The information can be translated into improved 
genetic counseling.  The overall goal of this project was to define genes that contribute to 
clubfoot to provide a better understanding about how this disorder develops.   
These studies were undertaken to identify genetic variation that contributes to clubfoot.  
A previous study interrogated a clubfoot chromosomal deletion region and found that 
apoptotic genes, Casp8 and Casp10, were associated with clubfoot78.  These studies follow 
from this previous work and had three objectives: 1) to determine if genes which act 
downstream of Casp8 and Casp10 in the mitochondrial mediated pathway are associated with 
clubfoot, 2) to identify genes involved in the apoptotic pathway within clubfoot deletion 
regions and test for association with clubfoot, and 3) to interrogate other candidate genes in 
the clubfoot deletion regions such as those involved in patterning of the limbs. 
Candidate genes were selected from processes known to participate in limb development, 
particularly in muscle development, including apoptotic and HOX genes.  Many of these 
candidate genes were located in chromosomal deletion regions associated with clubfoot69.   
One SNP from each mitochondrial mediated apoptotic gene was moderately associated with 
clubfoot106.  This confirmed the previous study in which Casp8 and Casp10 were associated 
with clubfoot.   
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Because the role of a subset of apoptotic genes in clubfoot development was confirmed, 
genotyping was expanded to all genes in the clubfoot deletion regions known to be involved 
in the apoptotic pathway.  Apoptotic genes were excellent candidate genes because they were 
the only class of genes found in all six clubfoot deletion regions.  192 SNPs across 29 genes 
were assessed for association with clubfoot.  Of note, there was no overlap in significant 
SNPs in both NHW and Hispanic samples, although several gene family members were 
positive in each ethnicity.  For the NHW sample, TNIP2 was the most significant gene and 
NFAT2 was most significant in Hispanics.  Haplotype analysis confirmed these results.  
Gene-gene interactions were detected, and although the SNPs from the single SNP analysis 
weren’t involved in these interactions, some of the same genes were involved.  These results 
suggest that there is heterogeneity between individual clubfoot families, and when the same 
genes are involved in the disease process, there is also allelic heterogeneity between the 
genetic variants. 
There are other candidate genes within the clubfoot deletion regions in addition to the 
apoptotic genes that were interrogated, including the HOXD cluster, which is a family of 
transcription factors involved in patterning of the limbs.  HOXA and HOXD have redundant 
function in the limbs, and so variants in the HOXA and HOXD gene clusters were tested for 
an association with clubfoot.  SNP14 and SNP16, both in the HOXA gene cluster, were both 
significantly overtransmitted.  “SNP14 is in intron 1 of HOXA2 and changes predicted DNA 
binding sites.  SNP16, is located in the HOXA9 basal promoter region, and showed altered 
transmission in nonHispanic whites in both the discovery and validation groups”.  This 
change may alter HOXA9 expression levels and possibly could perturb limb or muscle 
development.   
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  Taken together, these results support our working model for clubfoot (Fig. 4.2).  
Individual variants in candidate genes may be necessary but not sufficient until combined 
with other clubfoot predisposing variants.  Clubfoot is a malformation of the foot, and 
although the variants in these genes are found ubiquitously in all cell type, perturbation of 
gene expression may be limited to particular regions of the body, such as the lower limb. For 
example, a slight perturbation of expression in an apoptotic gene may have no global 
phenotype but when combined with another variant that is only be expressed in the limb, 
such as a HOXD polymorphism, clubfoot may result. 
The information from these studies may be used to improve risk assessment and develop 
population-based genetic screening programs for clubfoot.  Additionally, this information 
may translate into improved genetic counseling for clubfoot families. Determination of the 
genetic variation that contributes to clubfoot may allow for advances in detection and 
treatment methods that will diminish the medical and psychosocial impact that clubfoot has 
on the child and their families. 
 
Future Studies 
The mitochondrial mediated apoptotic gene SNPs were genotyped on a smaller sample 
set than the HOX and clubfoot deletion region apoptotic genes because of the continuing 
collection of samples from new clubfoot families.  Currently these SNPs are being evaluated 
on the expanded sample set.  Once completed, gene-gene interactions will be run between the 
mitochondrial mediated and the clubfoot deletion region apoptotic genes. 
The SNPlex assay for the clubfoot deletion region apoptotic genes produced low call 
rates, and so another assay with higher fidelity, such as TaqMan, will need to be used to 
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validate the results presented in Chapter 4.  In addition, the most positive results will need to 
be assessed in our case-control validation population.   
Because maternal smoking has consistently been associated with clubfoot, smoking 
metabolism genes are currently being interrogated and significant findings will be submitted 
for gene-gene interaction analysis.  The outcome may provide information about the role of 
smoking metabolism and apoptosis genes together in clubfoot.  
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Table A1.  LD plot for CASP8 and CASP10 
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Significant LD values shown in yellow, NHW shown above the diagonal and Hispanics below the diagonal. 
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Table A2.  LD plot for CASP3 
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Significant LD values shown in yellow, NHW shown above the diagonal and Hispanics below the diagonal. 
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Table A3.  LD plot for APAF-1 
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Table A4.  LD plot for BCL-2 
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Table A5. LD plot for BID 
 
 
 
 
 
 
 
 
 
 
 
 
 
Significant LD values shown in yellow, NHW shown above the diagonal and Hispanics below the diagonal. 
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Appendix B:  Clubfoot Chromosomal Deletion Region 
Apoptotic Genes Supplemental Tables
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Table B1.  SNP locations, call rates and minor allele frequency (MAF) 
 
Gene Chr SNP BP Pos. Location 
Allele 
1 
Allele 
2 
Call 
Rate 
NHW 
MAF 
Hisp. 
CAF 
ZAK 2 rs989531 173641864 Upstream C T 68.4 0.34 0.34 
ZAK 2 rs6433395 173652126 Intron 1 C T 75.0 0.48 0.33 
ZAK 2 rs6759787 173668095 Intron 2 C T 72.2 0.40 0.44 
ZAK 2 rs17302977 173681546 Intron 2 C T 66.9 0.43 0.20 
ZAK 2 rs3769192 173700047 Intron 2 C T 69.1 0.44 0.28 
ZAK 2 rs4344898 173718318 Intron 2 G T 74.8 0.41 0.42 
ZAK 2 rs13032010 173741939 Intron 2 A G 70.6 0.38 0.22 
ZAK 2 rs1837470 173756617 Intron 4 C T 72.3 0.48 0.59 
ZAK 2 rs4972533 173779131 Intron 8 G T 68.8 0.39 0.24 
ZAK 2 rs2028382 173795993 
Intron 
10/3'UTR G T 70.6 0.49 0.33 
ZAK 2 rs11685001 173812993 Intron 14 A G 66.3 0.48 0.33 
ZAK 2 rs11686011 173826292 Intron 14 A G 66.4 0.43 0.23 
ZAK 2 rs12618933 173844602 Downstream C T 74.1 0.49 0.28 
CREB2 2 rs212352 175651527 Intron 12 C T 73.7 0.33 0.40 
CREB2 2 rs2698545 175697794 Intron 4 A G 73.3 0.16 0.20 
CREB2 2 rs10930693 175708457 Intron 3 C T 71.1 0.23 0.28 
CERKL 2 rs1047307 182109997 3' UTR A G 74.9 0.39 0.43 
CERKL 2 rs11680383 182127394 Intron 6 C T 66.5 0.35 0.24 
CERKL 2 rs895901 182145339 Intron 3 A T 74.8 0.28 0.33 
CERKL 2 rs10445770 182168959 Intron 2 A C 68.5 0.45 0.38 
CERKL 2 rs1992394 182186910 Intron 1 C T 70.3 0.45 0.43 
CERKL 2 rs935087 182212013 Intron 1 A G 64.5 0.37 0.34 
CERKL 2 rs1866888 182235205 Upstream C T 72.7 0.45 0.40 
GULP1 2 rs10931346 188862356 Upstream C T 71.1 0.44 0.60 
GULP1 2 rs7593546 188877480 Intron 1 A G 73.0 0.41 0.28 
GULP1 2 rs4396679 188898949 Intron 1 G T 73.1 0.40 0.28 
GULP1 2 rs7586390 188922938 Intron 1 A G 73.3 0.49 0.34 
GULP1 2 rs12624002 188969212 Intron 2 G T 69.9 0.46 0.50 
GULP1 2 rs12474692 188989874 Intron 2 A G 71.3 0.44 0.32 
GULP1 2 rs10931359 189016529 Intron 2 A G 66.4 0.39 0.52 
GULP1 2 rs6724428 189085754 Intron 4 A G 72.7 0.50 0.60 
GULP1 2 rs11685321 189105316 Intron 6 A G 72.2 0.43 0.34 
GULP1 2 rs13034731 189122609 Intron 7 C T 70.3 0.36 0.28 
GULP1 2 rs1354905 189154716 Intron 8 A G 73.6 0.49 0.46 
STAT1 2 rs12468579 191540509 Downstream A G 73.7 0.44 0.51 
STAT1 2 rs13395505 191546759 Intron 24 A G 67.7 0.46 0.37 
STAT1 2 rs2280233 191558811 Intron 14 A G 71.0 0.45 0.32 
STAT1 2 rs7562024 191563766 Intron 11 C T 70.3 0.34 0.48 
STAT1 2 rs6751855 191593016 Upstream A G 43.3 0.37 0.41 
STAT4 2 rs925847 191605785 Intron 21 C T 72.4 0.32 0.50 
STAT4 2 rs16833215 191622044 Intron 13 A G 51.2 0.37 0.59 
STAT4 2 rs1517352 191639709 Intron 6 A C 83.1 0.36 0.28 
STAT4 2 rs16833249 191656517 Intron 3 C T 74.0 0.37 0.41 
STAT4 2 rs11693480 191665940 Intron 3 A C 72.4 0.43 0.47 
STAT4 2 rs12463658 191673589 Intron 3 A C 71.3 0.34 0.26 
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Gene Chr SNP BP Pos. Location  
Allele 
1 
Allele 
2 
Call 
Rate 
NHW 
MAF 
Hisp. 
CAF 
STAT4 2 rs4853543 191684879 Intron 3 A G 71.6 0.50 0.72 
STAT4 2 rs4341967 191692531 Intron 3 A T 71.1 0.44 0.40 
STAT4 2 rs6738544 191697601 Intron 3 A C 68.9 0.37 0.39 
STAT4 2 rs7574909 191706191 Intron 3 C T 72.7 0.35 0.43 
STAT4 2 rs2356350 191710783 Intron 3 A G 67.1 0.39 0.36 
STAT4 2 rs11685878 191717700 Intron 3 C T 55.9 0.33 0.30 
STAT4 2 rs7572482 191723317 Intron 1 A G 70.7 0.46 0.35 
STAT4 2 rs897200 191726016 Upstream A G 88.0 0.38 0.32 
SUMO1 2 rs6717044 202778312 Downstream C T 78.5 0.40 0.25 
SUMO1 2 rs4675272 202794974 Intron 1 C G 83.5 0.40 0.22 
SUMO1 2 rs6755690 202798838 Intron 1 C G 81.8 0.48 0.35 
SUMO1 2 rs6709162 202806804 Intron 1 C T 83.7 0.50 0.61 
SUMO1 2 rs3754931 202811646 Upstream C T 79.4 0.46 0.57 
CREB1 2 rs2253206 208100223 Upstream A G 70.9 0.42 0.34 
CREB1 2 rs2551640 208116138 Intron 1 A G 72.4 0.45 0.46 
CREB1 2 rs10932201 208134502 Intron 4 A G 72.5 0.42 0.40 
CREB1 2 rs2254137 208152273 Intron 8 A C 71.5 0.40 0.44 
SPSB4 3 rs1108693 142351405 Upstream C T 73.4 0.43 0.45 
RNF7 3 rs1980191 142939365 Upstream A T 67.8 0.49 0.45 
RNF7 3 rs6769676 142944537 Intron 1 G T 69.9 0.33 0.22 
RNF7 3 rs6776205 142955345 Downstream C G 73.4 0.44 0.55 
TFDP2 3 rs2163294 143151143 Downstream A C 68.3 0.44 0.41 
TFDP2 3 rs7642874 143180562 Intron 3 C T 73.2 0.40 0.33 
TFDP2 3 rs9877536 143200426 Intron 1 C G 67.5 0.49 0.34 
TFDP2 3 rs13065446 143220532 Upstream C T 63.7 0.40 0.29 
ATR 3 rs9816736 143655470 Intron 43 C T 68.2 0.43 0.53 
ATR 3 rs3922730 143685547 Intron 34 A T 68.2 0.44 0.52 
ATR 3 rs4273389 143696620 Intron 31 A G 66.9 0.49 0.39 
ATR 3 rs6440085 143715433 Intron 24 A T 68.3 0.46 0.51 
ATR 3 rs7651071 143726540 Intron 21 A T 70.0 0.50 0.42 
ATR 3 rs13085998 143746502 Intron 16 C T 66.0 0.43 0.51 
ATR 3 rs2227928 143764302 Intron 4 C T 62.4 0.43 0.28 
ATR 3 rs6792259 143784129 Upstream A T 72.2 0.47 0.48 
MAEA 4 rs1680073 1270337 Upstream C T 70.0 0.47 0.33 
MAEA 4 rs11727167 1275521 Intron 1 A G 72.0 0.45 0.53 
MAEA 4 rs7673398 1290077 Intron 1 A G 64.9 0.40 0.32 
MAEA 4 rs12641735 1294434 Intron 1 C G 73.7 0.23 0.16 
MAEA 4 rs12642410 1298409 Intron 2 A G 72.8 0.47 0.45 
MAEA 4 rs1316393 1305619 Intron 3 A G 73.1 0.40 0.31 
MAEA 4 rs7664474 1319116 Intron 6 A T 75.2 0.37 0.42 
MAEA 4 rs12647145 1328618 Downstream A C 69.9 0.28 0.16 
TNIP2 4 rs9683949 2714278 Intron 5 C T 69.1 0.40 0.38 
TNIP2 4 rs4690055 2718461 Intron 2 A G 72.1 0.49 0.71 
TNIP2 4 rs4690060 2730020 Upstream A G 68.2 0.43 0.39 
HTT 4 rs762855 3044593 Upstream C T 65.4 0.37 0.39 
HTT 4 rs2285086 3059057 Intron 2 C T 60.8 0.49 0.42 
HTT 4 rs10015979 3079240 Intron 6 A G 71.6 0.44 0.36 
HTT 4 rs6446723 3096611 Intron 10 C T 68.3 0.42 0.48 
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HTT 4 rs6855981 3118074 Intron 19 A G 70.8 0.40 0.36 
HTT 4 rs4690074 3131854 Intron 23 C T 66.0 0.44 0.33 
HTT 4 rs363096 3149819 Intron 28 A G 61.2 0.27 0.35 
HTT 4 rs363092 3165827 Intron 34 G T 65.0 0.39 0.36 
HTT 4 rs362336 3183630 Intron 39 C T 65.1 0.33 0.30 
HTT 4 rs362331 3185633 Intron 41 C T 64.0 0.46 0.35 
HTT 4 rs2269478 3204626 Intron 51 A C 64.4 0.38 0.32 
TLR10 4 rs10776482 38451180 
Exon 4 
(synon) C T 69.8 0.40 0.25 
TLR10 4 rs11096955 38452502 
Exon 4 
(I369L) A C 67.5 0.40 0.22 
TLR10 4 rs11096957 38452886 
Exon 4 
(N241H) A C 70.2 0.48 0.35 
TLR10 4 rs7658893 38458815 Intron 1 A G 69.9 0.50 0.61 
TLR1 4 rs4833095 38476105 
Exon 4 
(N248S) C T 67.9 0.46 0.57 
TLR1 4 rs5743565 38482378 Intron 1 A G 71.7 0.42 0.34 
TLR6 4 rs5743818 38505558 
Exon 1 
(synon) G T 69.7 0.45 0.46 
TLR6 4 rs3821985 38506407 
Exon 1 
(synon) C G 63.0 0.34 0.34 
TLR6 4 rs5743810 38506745 
Exon 1 
(S249P) C T 70.7 0.42 0.40 
WDR19 4 rs1451821 38856812 Upstream A C 62.5 0.40 0.44 
WDR19 4 rs6815686 38876186 Intron 5 A T 68.9 0.43 0.45 
WDR19 4 rs9997015 38900692 Intron 12 A G 71.9 0.49 0.45 
WDR19 4 rs9998591 38918506 Inron 17 A C 67.9 0.33 0.22 
WDR19 4 rs11096987 38935585 Intron 22 A G 71.1 0.44 0.55 
WDR19 4 rs3733280 38947936 Intron 25 A G 65.2 0.44 0.41 
WDR19 4 rs12648082 38956119 Intron 29 C T 68.4 0.40 0.33 
WDR19 4 rs1057807 38965868 Downstream C T 58.5 0.49 0.34 
UBE2K 4 rs3912392 39375133 Upstream A G 75.1 0.40 0.29 
UBE2K 4 rs13122400 39390138 Intron 1 C T 55.7 0.43 0.53 
UBE2K 4 rs12644528 39398637 Intron 1 C T 74.9 0.44 0.52 
UBE2K 4 rs302947 39419957 Intron 2 C T 72.3 0.49 0.39 
UBE2K 4 rs305827 39436384 Intron 4 G T 73.3 0.46 0.51 
UBE2K 4 rs10440307 39442582 Intron 4 C T 41.3 0.50 0.42 
UBE2K 4 rs4263408 39461671 Downstream C T 75.9 0.43 0.51 
CARMA1 7 rs11982651 2908799 Downstream C T 70.3 0.43 0.28 
CARMA1 7 rs1713911 2928435 Intron 15 A C 66.9 0.47 0.48 
CARMA1 7 rs1476636 2950046 Intron 5 C T 64.4 0.47 0.33 
CARMA1 7 rs4722276 2985330 Intron 1 C G 64.1 0.45 0.53 
CARMA1 7 rs12538346 2997820 Intron 1 C T 66.9 0.40 0.32 
CARMA1 7 rs10236776 3015535 Intron 1 A G 70.5 0.23 0.16 
CARMA1 7 rs4722356 3044023 Intron 1 C G 71.3 0.47 0.45 
RBAK 7 rs7805748 5048563 Upstream C T 72.2 0.40 0.31 
RBAK 7 rs10238244 5062844 Intron 2 C T 70.4 0.37 0.42 
RBAK 7 rs7778444 5074398 3' UTR A G 70.6 0.28 0.16 
TRIAD3 7 rs852374 5642645 Downstream A G 72.2 0.40 0.38 
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TRIAD3 7 rs13246406 5647119 Intron 15 C T 72.7 0.49 0.71 
TRIAD3 7 rs852522 5660069 Intron 13 C T 68.5 0.43 0.39 
TRIAD3 7 rs13247447 5665490 Intron 13 A G 69.3 0.37 0.39 
TRIAD3 7 rs852417 5670195 Intron 13 C T 13.9 0.49 0.42 
TRIAD3 7 rs3823681 5675186 Intron 13 C T 72.3 0.44 0.36 
TRIAD3 7 rs3779092 5679126 Intron 13 C T 71.8 0.42 0.48 
TRIAD3 7 rs852394 5687974 Intron 13 C T 82.2 0.40 0.36 
TRIAD3 7 rs1468996 5700983 Intron 13 A G 78.5 0.44 0.33 
TRIAD3 7 rs2302907 5727386 Intron 8 C T 80.4 0.27 0.35 
TRIAD3 7 rs13239194 5736015 Intron 6 C T 69.4 0.39 0.36 
TRIAD3 7 rs13237614 5740628 Intron 5 G T 78.7 0.33 0.30 
TRIAD3 7 rs2112006 5752771 Intron 3 C T 77.9 0.46 0.35 
TRIAD3 7 rs11771172 5760746 Intron 2 C T 79.6 0.38 0.32 
TRIAD3 7 rs6971918 5768152 Intron 1 C T 83.9 0.40 0.25 
TRIAD3 7 rs10257204 5773667 Intron 1 A G 80.5 0.40 0.22 
TRIAD3 7 rs6967635 5780459 Intron 1 G T 87.2 0.48 0.35 
TRIAD3 7 rs2017620 5802244 Upstream C T 73.8 0.50 0.61 
TNFSF13B 13 rs9514828 107719374 Upstream C T 85.4 0.46 0.57 
TNFSF13B 13 rs8181791 107732046 Intron 1 A G 62.2 0.42 0.34 
TNFSF13B 13 rs10508198 107740789 Intron 2 C G 60.2 0.45 0.46 
TNFSF13B 13 rs9520835 107754318 Intron 3 A G 84.0 0.34 0.34 
TNFSF13B 13 rs1224163 107763060 Downstream G T 85.8 0.42 0.40 
ING1 13 rs4773240 110158586 Upstream A G 67.0 0.40 0.44 
ING1 13 rs1441043 110165651 Intron 1 A G 63.0 0.43 0.45 
ING1 13 rs6492308 110175830 Downstream C T 70.9 0.49 0.45 
TFDP1 13 rs7325214 113284925 Upstream C T 67.7 0.33 0.22 
TFDP1 13 rs4150703 113300578 Intron 2 A G 61.8 0.44 0.55 
TFDP1 13 rs9577595 113316202 Intron 3 C T 71.5 0.44 0.41 
TFDP1 13 rs12428926 113332373 Intron 4 C T 71.5 0.04 0.33 
TFDP1 13 rs4150832 113343955 Downstream C T 65.1 0.49 0.34 
TNFRSF11A 18 rs2981007 58133882 Upstream C T 79.2 0.40 0.29 
TNFRSF11A 18 rs4941125 58148664 Intron 1 A G 82.7 0.43 0.53 
TNFRSF11A 18 rs7239261 58156026 Intron 1 A C 85.4 0.44 0.52 
TNFRSF11A 18 rs4263037 58167213 Intron 2 A G 82.7 0.49 0.39 
TNFRSF11A 18 rs7236060 58174262 Intron 4 A G 85.1 0.46 0.51 
TNFRSF11A 18 rs8094884 58179108 Intron 6 A G 77.2 0.50 0.42 
TNFRSF11A 18 rs8089829 58182884 Intron 7 A G 74.0 0.43 0.51 
TNFRSF11A 18 rs12959396 58190289 Intron 9 G T 82.0 0.43 0.28 
TNFRSF11A 18 rs9646629 58202179 Intron 9 C G 26.6 0.47 0.48 
TNFRSF11A 18 rs2957125 58209322 Downstream A T 52.8 0.47 0.33 
SOCS6 18 rs7230661 66099091 Upstream A G 83.7 0.45 0.53 
SOCS6 18 rs713130 66111574 Intron 1 C T 74.5 0.40 0.32 
SOCS6 18 rs2053420 66118259 Intron 1 C T 83.6 0.23 0.16 
NFAT2 18 rs9962479 75256172 Upstream A G 64.3 0.47 0.45 
NFAT2 18 rs8090692 75264917 Intron 2 A G 82.5 0.40 0.31 
NFAT2 18 rs2036892 75269524 Intron 2 A T 84.9 0.37 0.42 
NFAT2 18 rs4799055 75282991 Intron 3 G T 79.6 0.28 0.16 
NFAT2 18 rs8097537 75294234 Intron 3 C T 82.8 0.40 0.38 
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NFAT2 18 rs12608349 75300626 Intron 4 C T 80.4 0.49 0.71 
NFAT2 18 rs2290154 75312163 Intron 6 C T 78.1 0.43 0.39 
NFAT2 18 rs7227107 75328464 
Exon 9 
(synon) A G 37.9 0.37 0.39 
NFAT2 18 rs370989 75348674 Intron 10 C G 85.5 0.49 0.42 
NFAT2 18 rs1667673 75353032 Intron 10 C G 79.0 0.44 0.36 
NFAT2 18 rs1660139 75371686 Intron 10 A G 83.3 0.42 0.48 
NFAT2 18 rs177820 75377952 Intron 10 C T 76.5 0.40 0.36 
NFAT2 18 rs3894049 75385918 Intron 10 C G 86.2 0.44 0.33 
NFAT2 18 rs183374 75392406 Downstream A G 83.5 0.27 0.35 
Chr=chromosome; BP Pos.=base pair position; NHW=nonHispanic white; MAF=minor 
allele frequency; Hisp.=Hispanic; CAF=corresponding allele frequency; synon=synonymous; 
blue squares denote SNPs out of Hardy-Weinberg Equilibrium. 
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Table B2.  Association of apoptotic genes with clubfoot in nonHispanic whites. 
 
   NHW NHW FHx NHW Trios 
Gene Chr SNP APL PDT GenPDT APL PDT GenPDT APL PDT GenPDT
ZAK 2 rs989531 0.794 0.383 0.482 0.273 0.674 0.185 0.300 0.276 0.461 
ZAK 2 rs6433395 0.039 0.591 0.064 0.241 0.842 0.647 0.068 0.109 0.011 
ZAK 2 rs6759787 0.107 0.125 0.288 0.061 0.098 0.181 0.813 0.782 0.911 
ZAK 2 rs17302977 0.616 0.712 0.947 0.843 0.652 0.929 0.785 1.000 0.924 
ZAK 2 rs3769192 0.012 0.272 0.548 0.281 0.933 0.988 0.011 0.071 0.212 
ZAK 2 rs4344898 0.393 0.867 0.879 0.751 0.409 0.666 0.428 0.387 0.629 
ZAK 2 rs13032010 0.034 0.187 0.401 0.318 0.334 0.666 0.035 0.317 0.361 
ZAK 2 rs1837470 N/A N/A N/A N/A N/A N/A N/A N/A N/A 
ZAK 2 rs4972533 0.557 0.657 0.919 0.866 0.610 0.865 0.567 1.000 0.918 
ZAK 2 rs2028382 0.519 0.649 0.707 0.799 0.466 0.565 0.247 0.668 0.903 
ZAK 2 rs11685001 0.198 0.098 0.180 0.595 0.265 0.467 0.144 0.166 0.308 
ZAK 2 rs11686011 0.314 0.543 0.663 0.104 0.363 0.138 0.668 0.655 0.447 
ZAK 2 rs12618933 0.485 0.281 0.622 0.339 0.317 0.586 0.990 0.647 0.632 
ATF2/CREB2 2 rs212352 0.043 0.154 0.212 0.263 0.490 0.378 0.089 0.061 0.134 
ATF2/CREB2 2 rs2698545 N/A N/A N/A N/A N/A N/A N/A N/A N/A 
ATF2/CREB2 2 rs10930693 N/A N/A N/A N/A N/A N/A N/A N/A N/A 
CERKL 2 rs1047307 0.931 1.000 0.968 0.654 0.785 0.910 0.459 0.639 0.893 
CERKL 2 rs11680383 0.345 N/A N/A 0.608 N/A N/A 0.430 N/A N/A 
CERKL 2 rs895901 0.303 0.312 0.548 0.405 0.224 0.188 0.568 0.893 0.334 
CERKL 2 rs10445770 0.330 0.350 0.332 0.791 0.590 0.355 0.073 0.345 0.670 
CERKL 2 rs1992394 0.050 0.147 0.279 0.354 0.248 0.293 0.071 0.376 0.318 
CERKL 2 rs935087 0.493 0.466 0.728 0.434 0.541 0.817 0.913 0.691 0.525 
CERKL 2 rs1866888 0.862 0.519 0.443 0.712 0.526 0.526 0.814 0.895 0.817 
GULP1 2 rs10931346 0.249 0.302 0.613 0.856 0.155 0.248 0.127 0.674 0.297 
GULP1 2 rs7593546 0.779 0.904 0.694 0.127 0.427 0.648 0.021 0.132 0.271 
GULP1 2 rs4396679 0.095 0.826 0.447 0.803 0.735 0.302 0.016 0.307 0.622 
GULP1 2 rs7586390 0.691 0.844 0.937 0.385 0.363 0.550 0.081 0.233 0.057 
GULP1 2 rs12624002 0.746 0.773 0.876 0.512 0.746 0.954 0.811 1.000 0.696 
GULP1 2 rs12474692 0.136 0.938 0.646 0.869 0.233 0.371 0.027 0.083 0.219 
GULP1 2 rs10931359 0.247 0.212 0.307 0.507 0.927 0.792 0.006 0.025 0.112 
GULP1 2 rs6724428 0.116 1.000 0.344 0.396 0.807 0.658 0.100 0.639 0.348 
GULP1 2 rs11685321 0.110 0.140 0.352 0.329 0.351 0.571 0.201 0.180 0.243 
GULP1 2 rs13034731 0.124 0.957 0.995 0.483 0.732 0.888 0.145 0.446 0.640 
GULP1 2 rs1354905 0.734 0.175 0.460 0.400 0.665 0.879 0.208 0.047 0.160 
STAT1 2 rs12468579 0.406 0.785 0.561 0.814 0.211 0.326 0.291 0.095 0.209 
STAT1 2 rs13395505 0.325 0.292 0.521 0.977 0.270 0.482 0.127 0.847 0.953 
STAT1 2 rs2280233 0.767 0.632 0.710 0.271 0.901 0.821 0.525 0.547 0.801 
STAT1 2 rs7562024 0.508 0.895 0.973 0.216 0.882 0.969 0.724 1.000 1.000 
STAT1 2 rs6751855 0.425 0.243 0.154 0.577 0.066 0.173 0.533 0.599 0.178 
STAT4 2 rs925847 0.701 0.558 0.401 0.526 0.895 0.982 0.875 0.317 0.032 
STAT4 2 rs16833215 0.580 0.635 0.851 0.913 0.782 0.241 0.514 0.647 0.098 
STAT4 2 rs1517352 0.830 0.541 0.826 0.207 0.307 0.562 0.345 0.612 0.860 
STAT4 2 rs16833249 0.465 0.567 0.216 0.079 0.836 0.092 0.329 0.052 0.180 
STAT4 2 rs11693480 0.817 0.484 0.328 0.610 0.541 0.522 0.377 0.695 0.400 
STAT4 2 rs12463658 0.894 0.498 0.692 0.482 0.363 0.696 0.292 0.763 0.574 
STAT4 2 rs4853543 0.863 0.394 0.052 0.930 0.330 0.020 0.622 1.000 1.000 
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STAT4 2 rs4341967 0.656 0.574 0.695 0.892 0.915 0.730 0.420 0.332 0.578 
STAT4 2 rs6738544 0.506 0.878 0.071 0.270 0.602 0.053 0.833 0.194 0.429 
STAT4 2 rs7574909 0.227 0.768 0.926 0.396 0.592 0.864 0.358 0.617 0.783 
STAT4 2 rs2356350 0.976 0.118 0.218 0.385 0.439 0.764 0.333 0.020 0.016 
STAT4 2 rs11685878 0.303 0.458 0.014 0.873 0.924 0.057 0.064 0.105 0.121 
STAT4 2 rs7572482 0.961 0.958 0.063 0.735 0.859 0.079 0.730 0.808 0.761 
STAT4 2 rs897200 0.219 0.830 0.808 0.313 0.717 0.316 0.484 0.413 0.459 
SUMO1 2 rs6717044 0.481 0.319 0.334 0.692 0.694 0.855 0.141 0.152 0.144 
SUMO1 2 rs4675272 0.099 0.820 0.947 0.387 0.950 0.994 0.157 0.701 0.770 
SUMO1 2 rs6755690 0.260 0.357 0.081 0.402 0.354 0.143 0.483 0.816 0.241 
SUMO1 2 rs6709162 N/A N/A N/A N/A N/A N/A N/A N/A N/A 
SUMO1 2 rs3754931 0.735 0.569 0.266 0.252 0.462 0.210 0.427 0.862 0.963 
CREB1 2 rs2253206 N/A N/A N/A N/A N/A N/A N/A N/A N/A 
CREB1 2 rs2551640 0.013 0.307 0.176 0.031 0.682 0.314 0.128 0.150 0.367 
CREB1 2 rs10932201 N/A N/A N/A N/A N/A N/A N/A N/A N/A 
CREB1 2 rs2254137 0.540 0.068 0.174 0.790 0.083 0.091 0.592 0.547 0.258 
SPSB4 3 rs1108693 0.861 0.806 0.416 0.155 0.747 0.721 0.132 0.842 0.193 
RNF7 3 rs1980191 0.589 0.380 0.330 0.906 0.729 0.204 0.398 0.273 0.555 
RNF7 3 rs6769676 0.672 0.836 0.884 0.439 0.496 0.759 0.862 0.304 0.399 
RNF7 3 rs6776205 0.290 0.796 0.630 0.899 0.756 0.524 0.055 1.000 1.000 
TFDP2 3 rs2163294 0.611 0.389 0.684 0.666 0.596 0.840 0.198 0.398 0.749 
TFDP2 3 rs7642874 0.896 0.868 0.767 0.215 0.843 0.561 0.173 0.537 0.809 
TFDP2 3 rs9877536 N/A N/A N/A N/A N/A N/A N/A N/A N/A 
TFDP2 3 rs13065446 0.757 0.939 0.663 0.991 0.722 0.530 0.632 0.466 0.781 
ATR 3 rs9816736 N/A N/A N/A N/A N/A N/A N/A N/A N/A 
ATR 3 rs3922730 0.135 0.429 0.702 0.376 0.451 0.519 0.178 0.786 0.657 
ATR 3 rs4273389 0.330 0.391 0.489 0.938 0.071 0.063 0.119 0.149 0.023 
ATR 3 rs6440085 0.245 0.759 0.303 0.201 0.914 0.306 0.871 0.537 0.781 
ATR 3 rs7651071 0.246 0.576 0.855 0.898 0.698 0.627 0.062 0.124 0.052 
ATR 3 rs13085998 0.258 0.383 0.669 0.952 0.925 0.483 0.112 0.140 0.175 
ATR 3 rs2227928 0.487 0.674 0.352 0.497 0.437 0.304 0.492 0.796 0.895 
ATR 3 rs6792259 0.711 0.473 0.811 0.605 0.122 0.380 0.910 0.413 0.700 
EMP 4 rs1680073 0.402 0.665 0.191 0.153 0.452 0.261 0.708 0.668 0.247 
EMP 4 rs11727167 0.486 0.417 0.629 0.474 0.916 0.390 0.107 0.170 0.249 
EMP 4 rs7673398 0.240 0.365 0.305 0.449 0.777 0.377 0.021 0.059 0.175 
EMP 4 rs12641735 0.794 0.519 0.619 0.885 0.579 0.682 0.836 0.724 0.895 
EMP 4 rs12642410 0.123 0.377 0.603 0.979 0.837 0.484 0.018 0.040 0.133 
EMP 4 rs1316393 0.074 0.190 0.135 0.949 0.683 0.081 0.010 0.063 0.114 
EMP 4 rs7664474 0.920 0.682 0.811 0.135 0.772 0.863 0.134 0.217 0.490 
EMP 4 rs12647145 0.756 0.755 0.818 0.527 0.649 0.911 0.802 0.879 0.479 
TNIP2 4 rs9683949 0.298 0.243 0.520 0.235 0.066 0.206 0.900 0.466 0.450 
TNIP2 4 rs4690055 0.015 0.191 0.448 0.662 0.584 0.803 0.004 0.001 0.007 
TNIP2 4 rs4690060 0.424 1.000 0.746 0.538 1.000 0.356 0.742 1.000 0.543 
HTT 4 rs762855 0.286 0.171 0.389 0.373 0.249 0.409 0.489 0.460 0.659 
HTT 4 rs2285086 0.816 0.131 0.193 0.146 0.031 0.022 0.132 0.297 0.508 
HTT 4 rs10015979 N/A N/A N/A N/A N/A N/A N/A N/A N/A 
HTT 4 rs6446723 N/A N/A N/A N/A N/A N/A N/A N/A N/A 
HTT 4 rs6855981 0.340 0.334 0.275 0.213 0.334 0.287 0.891 0.796 0.872 
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HTT 4 rs4690074 0.688 0.382 0.321 0.684 0.344 0.364 0.925 0.891 0.811 
HTT 4 rs363096 N/A N/A N/A N/A N/A N/A N/A N/A N/A 
HTT 4 rs363092 0.728 0.433 0.455 0.355 0.203 0.069 0.552 0.599 0.214 
HTT 4 rs362336 0.680 0.944 0.078 0.805 0.937 0.060 0.630 0.768 0.866 
HTT 4 rs362331 0.401 1.000 0.875 0.105 0.850 0.936 0.617 0.763 0.828 
HTT 4 rs2269478 0.986 0.514 0.831 0.880 0.569 0.537 0.944 0.746 0.433 
TLR10 4 rs10776482 0.627 0.317 0.153 0.696 0.933 0.247 0.146 0.080 0.154 
TLR10 4 rs11096955 0.850 0.701 0.186 0.850 0.521 0.612 0.614 0.777 0.115 
TLR10 4 rs11096957 0.004 0.041 0.148 0.191 0.180 0.462 0.003 0.090 0.203 
TLR10 4 rs7658893 N/A N/A N/A N/A N/A N/A N/A N/A N/A 
TLR1 4 rs4833095 0.664 0.662 0.856 0.371 1.000 0.742 0.713 0.355 0.682 
TLR1 4 rs5743565 0.690 0.513 0.366 0.677 1.000 0.488 0.811 0.180 0.357 
TLR6 4 rs5743818 0.043 0.185 0.504 0.161 0.377 0.703 0.128 0.258 0.135 
TLR6 4 rs3821985 0.356 0.246 0.445 0.979 0.936 0.266 0.102 0.014 0.017 
TLR6 4 rs5743810 0.194 0.253 0.363 0.313 0.246 0.314 0.433 0.786 0.967 
WDR19 4 rs1451821 0.017 0.237 0.412 0.367 0.918 0.983 0.012 0.053 0.135 
WDR19 4 rs6815686 0.540 0.867 0.289 0.611 0.463 0.505 0.687 0.484 0.303 
WDR19 4 rs9997015 0.152 0.262 0.494 0.104 0.544 0.703 0.864 0.238 0.533 
WDR19 4 rs9998591 0.492 0.667 0.499 0.961 0.742 0.686 0.336 0.140 0.364 
WDR19 4 rs11096987 0.666 0.368 0.579 0.912 0.480 0.711 0.350 0.572 0.809 
WDR19 4 rs3733280 0.017 0.293 0.117 0.307 0.833 0.376 0.015 0.059 0.112 
WDR19 4 rs12648082 0.044 0.686 0.631 0.155 0.924 0.759 0.127 0.355 0.646 
WDR19 4 rs1057807 N/A N/A N/A N/A N/A N/A N/A N/A N/A 
UBE2K 4 rs3912392 0.929 0.655 0.262 0.830 0.592 0.229 0.912 0.105 0.269 
UBE2K 4 rs13122400 N/A N/A N/A N/A N/A N/A N/A N/A N/A 
UBE2K 4 rs12644528 0.575 0.750 0.908 0.278 0.514 0.777 0.916 0.647 0.898 
UBE2K 4 rs302947 0.290 0.171 0.389 0.500 0.262 0.319 0.387 0.411 0.113 
UBE2K 4 rs305827 0.966 0.898 0.309 0.339 0.440 0.142 0.274 0.042 0.160 
UBE2K 4 rs10440307 0.466 0.761 0.434 0.359 0.513 0.697 0.977 0.405 0.277 
UBE2K 4 rs4263408 0.556 0.657 0.892 0.032 0.211 0.508 0.089 0.237 0.515 
CARMA1 7 rs11982651 0.607 0.570 0.829 0.346 0.123 0.222 0.753 0.140 0.114 
CARMA1 7 rs1713911 0.518 1.000 0.973 0.921 0.689 0.897 0.386 0.612 0.889 
CARMA1 7 rs1476636 0.521 0.109 0.311 0.196 0.022 0.090 0.583 0.411 0.625 
CARMA1 7 rs4722276 0.985 0.690 0.091 0.633 0.698 0.237 0.731 0.889 0.344 
CARMA1 7 rs12538346 0.598 0.357 0.650 0.584 0.190 0.290 0.881 0.789 0.484 
CARMA1 7 rs10236776 0.026 0.049 0.121 0.024 0.050 0.116 0.356 0.612 0.692 
CARMA1 7 rs4722356 0.911 0.945 0.812 0.364 0.622 0.438 0.217 0.529 0.565 
RBAK 7 rs7805748 0.381 0.758 0.820 0.278 0.454 0.719 0.847 0.586 0.241 
RBAK 7 rs10238244 0.175 0.080 0.169 0.136 0.048 0.093 0.875 1.000 0.333 
RBAK 7 rs7778444 0.767 0.241 0.444 0.988 0.284 0.345 0.587 0.631 0.805 
TRIAD3 7 rs852374 0.608 0.196 0.426 0.624 0.325 0.558 0.836 0.387 0.716 
TRIAD3 7 rs13246406 0.275 0.544 0.765 0.092 0.371 0.620 0.962 0.724 0.921 
TRIAD3 7 rs852522 0.916 0.689 0.356 0.905 0.385 0.550 0.781 0.612 0.404 
TRIAD3 7 rs13247447 0.130 0.645 0.690 0.214 0.365 0.594 0.327 0.564 0.717 
TRIAD3 7 rs852417 0.093 0.317 0.513 0.174 1.000 1.000 0.291 0.317 0.317 
TRIAD3 7 rs3823681 N/A N/A N/A N/A N/A N/A N/A N/A N/A 
TRIAD3 7 rs3779092 N/A N/A N/A N/A N/A N/A N/A N/A N/A 
TRIAD3 7 rs852394 0.362 0.159 0.265 0.460 0.330 0.306 0.564 0.258 0.540 
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TRIAD3 7 rs1468996 0.411 0.900 0.925 0.573 0.944 0.743 0.601 0.680 0.071 
TRIAD3 7 rs2302907 N/A N/A N/A N/A N/A N/A N/A N/A N/A 
TRIAD3 7 rs13239194 0.571 0.404 0.452 0.429 1.000 0.488 0.131 0.170 0.390 
TRIAD3 7 rs13237614 0.755 0.772 0.830 0.192 0.732 0.636 0.077 0.273 0.518 
TRIAD3 7 rs2112006 0.801 0.137 0.446 0.528 0.052 0.289 0.872 1.000 0.920 
TRIAD3 7 rs11771172 0.012 0.127 0.121 0.006 0.336 0.361 0.659 0.189 0.233 
TRIAD3 7 rs6971918 0.730 0.408 0.773 0.513 0.320 0.685 0.802 0.886 0.974 
TRIAD3 7 rs10257204 0.680 0.290 0.352 0.404 0.768 0.614 0.254 0.149 0.268 
TRIAD3 7 rs6967635 0.421 0.502 0.813 0.482 0.368 0.712 0.648 0.763 0.910 
TRIAD3 7 rs2017620 N/A N/A N/A N/A N/A N/A N/A N/A N/A 
TNFSF13B 13 rs9514828 0.619 0.536 0.760 0.969 0.216 0.345 0.523 0.453 0.137 
TNFSF13B 13 rs8181791 N/A N/A N/A N/A N/A N/A N/A N/A N/A 
TNFSF13B 13 rs10508198 0.329 0.644 0.777 0.628 0.912 0.753 0.421 0.317 0.214 
TNFSF13B 13 rs9520835 0.004 0.009 0.023 0.005 0.113 0.166 0.218 0.022 0.083 
TNFSF13B 13 rs1224163 N/A N/A N/A N/A N/A N/A N/A N/A N/A 
ING1 13 rs4773240 0.388 0.645 0.538 0.249 0.433 0.697 0.837 0.493 0.309 
ING1 13 rs1441043 0.038 0.788 0.118 0.551 0.739 0.407 0.020 0.366 0.184 
ING1 13 rs6492308 0.166 0.667 0.877 0.174 0.916 0.910 0.653 0.555 0.866 
TFDP1 13 rs7325214 0.428 0.902 0.367 0.846 0.826 0.786 0.283 0.569 0.141 
TFDP1 13 rs4150703 0.289 0.581 0.140 0.348 0.383 0.171 0.523 0.732 0.638 
TFDP1 13 rs9577595 0.805 0.504 0.098 0.480 0.269 0.162 0.789 0.706 0.475 
TFDP1 13 rs12428926 0.247 1.000 0.812 0.605 0.331 0.232 0.022 0.114 0.126 
TFDP1 13 rs4150832 N/A N/A N/A N/A N/A N/A N/A N/A N/A 
TNFRSF11A 18 rs2981007 0.362 0.854 0.209 0.086 0.947 0.297 0.575 0.758 0.419 
TNFRSF11A 18 rs4941125 N/A N/A N/A N/A N/A N/A N/A N/A N/A 
TNFRSF11A 18 rs7239261 0.302 0.419 0.335 0.211 0.461 0.319 0.784 0.732 0.932 
TNFRSF11A 18 rs4263037 0.484 0.887 0.972 0.520 0.933 0.682 0.737 0.895 0.207 
TNFRSF11A 18 rs7236060 N/A N/A N/A N/A N/A N/A N/A N/A N/A 
TNFRSF11A 18 rs8094884 0.292 1.000 0.786 0.607 0.865 0.275 0.362 0.768 0.452 
TNFRSF11A 18 rs8089829 0.041 0.660 0.178 0.048 0.558 0.623 0.422 0.879 0.100 
TNFRSF11A 18 rs12959396 0.565 0.687 0.335 0.204 0.871 0.708 0.736 0.500 0.229 
TNFRSF11A 18 rs9646629 0.240 0.059 0.070 0.090 0.103 0.135 0.754 0.317 0.317 
TNFRSF11A 18 rs2957125 0.238 0.088 0.197 0.542 0.116 0.510 0.307 0.423 0.081 
SOCS6 18 rs7230661 0.135 0.777 0.338 0.308 0.398 0.161 0.265 0.439 0.749 
SOCS6 18 rs713130 0.379 0.293 0.176 0.379 0.225 0.456 0.658 1.000 0.021 
SOCS6 18 rs2053420 0.037 0.041 0.062 0.016 0.030 0.080 0.806 0.691 0.695 
NFAT2 18 rs9962479 0.942 0.555 0.391 0.430 0.347 0.261 0.454 0.662 0.890 
NFAT2 18 rs8090692 0.892 0.172 0.308 0.649 0.365 0.648 0.714 0.267 0.290 
NFAT2 18 rs2036892 0.585 0.163 0.401 0.862 0.086 0.136 0.379 0.668 0.429 
NFAT2 18 rs4799055 0.957 0.475 0.484 0.523 0.686 0.280 0.445 0.332 0.484 
NFAT2 18 rs8097537 0.852 0.364 0.173 0.965 0.160 0.071 0.731 0.500 0.807 
NFAT2 18 rs12608349 0.848 0.710 0.761 0.913 0.480 0.758 0.688 0.606 0.171 
NFAT2 18 rs2290154 0.397 0.490 0.482 0.688 0.847 0.542 0.073 0.241 0.369 
NFAT2 18 rs7227107 0.412 0.493 0.040 0.683 1.000 0.189 0.126 0.206 0.169 
NFAT2 18 rs370989 0.458 0.020 0.062 0.495 0.013 0.036 0.700 0.896 0.979 
NFAT2 18 rs1667673 N/A N/A N/A N/A N/A N/A N/A N/A N/A 
NFAT2 18 rs1660139 N/A N/A N/A N/A N/A N/A N/A N/A N/A 
NFAT2 18 rs177820 0.684 0.620 0.833 0.561 0.871 0.976 0.230 0.385 0.445 
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NFAT2 18 rs3894049 0.788 0.041 0.166 0.560 0.042 0.163 0.827 0.593 0.527 
NFAT2 18 rs183374 N/A N/A N/A N/A N/A N/A N/A N/A N/A 
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Table B3.  Association of apoptotic genes with clubfoot in Hispanics. 
      Hisp. Hisp. FHx Hisp. Trios 
Gene Chr SNP APL PDT GenPDT APL PDT GenPDT APL PDT GenPDT 
ZAK 2 rs989531 0.552 0.316 0.448 0.359 0.262 0.329 0.938 0.866 0.511 
ZAK 2 rs6433395 N/A N/A N/A N/A N/A N/A N/A N/A N/A 
ZAK 2 rs6759787 N/A N/A N/A N/A N/A N/A N/A N/A N/A 
ZAK 2 rs17302977 0.273 0.328 0.502 0.288 0.562 0.393 0.588 0.178 0.226 
ZAK 2 rs3769192 N/A N/A N/A N/A N/A N/A N/A N/A N/A 
ZAK 2 rs4344898 0.156 0.079 0.152 0.385 0.340 0.564 0.310 0.103 0.215 
ZAK 2 rs13032010 0.390 0.063 0.231 0.933 0.237 0.143 0.351 0.152 0.183 
ZAK 2 rs1837470 0.981 0.371 0.537 0.386 0.380 0.596 0.518 0.786 0.897 
ZAK 2 rs4972533 0.328 0.702 0.672 0.486 0.277 0.493 0.085 0.317 0.461 
ZAK 2 rs2028382 N/A N/A N/A N/A N/A N/A N/A N/A N/A 
ZAK 2 rs11685001 N/A N/A N/A N/A N/A N/A N/A N/A N/A 
ZAK 2 rs11686011 0.797 0.406 0.720 0.278 0.144 0.250 0.657 0.876 0.723 
ZAK 2 rs12618933 0.988 0.496 0.690 0.391 0.463 0.579 0.624 1.000 1.000 
ATF2/CREB2 2 rs212352 0.046 0.069 0.063 0.500 0.254 0.236 0.070 0.083 0.175 
ATF2/CREB2 2 rs2698545 N/A N/A N/A N/A N/A N/A N/A N/A N/A 
ATF2/CREB2 2 rs10930693 0.525 0.423 0.768 0.815 0.632 0.915 0.290 0.466 0.774 
CERKL 2 rs1047307 0.825 0.424 0.549 0.809 0.340 0.445 0.763 0.858 0.441 
CERKL 2 rs11680383 0.325 0.448 0.702 0.281 0.456 0.668 0.664 0.873 0.796 
CERKL 2 rs895901 0.327 0.190 0.333 0.899 0.831 0.289 0.196 0.019 0.110 
CERKL 2 rs10445770 0.342 0.861 0.871 0.038 0.225 0.373 0.740 0.310 0.100 
CERKL 2 rs1992394 0.963 1.000 0.963 0.494 0.594 0.742 0.535 0.160 0.412 
CERKL 2 rs935087 N/A N/A N/A N/A N/A N/A N/A N/A N/A 
CERKL 2 rs1866888 0.751 0.562 0.830 0.937 0.547 0.808 0.749 0.893 0.958 
GULP1 2 rs10931346 0.345 0.353 0.262 0.788 0.406 0.382 0.285 0.655 0.627 
GULP1 2 rs7593546 0.726 0.603 0.850 0.367 0.480 0.709 0.827 0.891 0.799 
GULP1 2 rs4396679 0.698 1.000 0.302 0.535 0.697 0.235 0.932 0.446 0.738 
GULP1 2 rs7586390 N/A N/A N/A N/A N/A N/A N/A N/A N/A 
GULP1 2 rs12624002 N/A N/A N/A N/A N/A N/A N/A N/A N/A 
GULP1 2 rs12474692 0.987 0.424 0.099 0.921 0.935 0.128 0.964 0.114 0.285 
GULP1 2 rs10931359 N/A N/A N/A N/A N/A N/A N/A N/A N/A 
GULP1 2 rs6724428 0.622 0.592 0.777 0.946 0.413 0.680 0.601 0.777 0.413 
GULP1 2 rs11685321 0.786 0.301 0.573 0.110 0.460 0.656 0.534 0.013 0.030 
GULP1 2 rs13034731 0.418 0.281 0.589 0.332 0.876 0.943 0.761 0.180 0.364 
GULP1 2 rs1354905 0.204 0.043 0.243 0.161 0.025 0.246 0.692 0.492 0.431 
STAT1 2 rs12468579 0.872 0.286 0.452 0.286 0.077 0.212 0.379 0.873 0.975 
STAT1 2 rs13395505 0.155 0.007 0.040 0.835 0.251 0.646 0.089 0.013 0.050 
STAT1 2 rs2280233 0.770 0.604 0.616 0.742 0.748 0.454 0.973 0.662 0.913 
STAT1 2 rs7562024 0.144 0.491 0.010 0.986 0.758 0.182 0.105 0.170 0.025 
STAT1 2 rs6751855 0.959 0.292 0.381 0.369 0.519 0.763 0.461 0.317 0.155 
STAT4 2 rs925847 0.429 0.092 0.072 0.016 0.096 0.136 0.537 0.578 0.419 
STAT4 2 rs16833215 0.765 0.922 0.222 0.064 0.206 0.368 0.386 0.385 0.072 
STAT4 2 rs1517352 0.617 0.302 0.665 0.813 0.493 0.474 0.685 0.439 0.469 
STAT4 2 rs16833249 0.516 0.102 0.039 0.685 0.221 0.305 0.650 0.262 0.026 
STAT4 2 rs11693480 0.568 1.000 0.298 0.781 0.144 0.216 0.380 0.228 0.088 
STAT4 2 rs12463658 0.209 0.906 0.116 0.544 0.847 0.269 0.314 0.763 0.418 
STAT4 2 rs4853543 0.400 0.134 0.330 0.109 0.159 0.462 0.981 0.492 0.598 
STAT4 2 rs4341967 0.808 1.000 0.169 0.759 0.851 0.192 0.919 0.758 0.611 
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STAT4 2 rs6738544 0.300 0.093 0.330 0.106 0.044 0.212 0.916 0.746 0.260 
STAT4 2 rs7574909 0.168 0.095 0.283 0.383 0.083 0.153 0.280 0.547 0.595 
STAT4 2 rs2356350 0.760 0.914 0.670 0.806 0.901 0.472 0.873 1.000 1.000 
STAT4 2 rs11685878 0.751 0.117 0.087 0.724 0.128 0.149 0.444 0.537 0.038 
STAT4 2 rs7572482 0.141 0.325 0.053 0.381 0.900 0.478 0.202 0.128 0.049 
STAT4 2 rs897200 0.443 0.393 0.434 0.361 0.345 0.474 0.772 0.789 0.698 
SUMO1 2 rs6717044 0.714 0.927 0.614 0.539 0.816 0.170 0.973 0.882 0.835 
SUMO1 2 rs4675272 0.693 0.933 0.484 0.152 0.732 0.927 0.642 0.806 0.214 
SUMO1 2 rs6755690 0.179 0.755 0.292 0.921 0.051 0.040 0.113 0.071 0.051 
SUMO1 2 rs6709162 0.898 0.612 0.244 0.585 0.178 0.122 0.577 0.307 0.651 
SUMO1 2 rs3754931 0.237 0.510 0.735 0.032 0.106 0.205 0.920 0.257 0.492 
CREB1 2 rs2253206 N/A N/A N/A N/A N/A N/A N/A N/A N/A 
CREB1 2 rs2551640 0.758 0.845 0.922 0.607 0.722 0.716 0.334 0.384 0.315 
CREB1 2 rs10932201 0.193 0.922 0.891 0.658 0.086 0.283 0.061 0.286 0.356 
CREB1 2 rs2254137 N/A N/A N/A N/A N/A N/A N/A N/A N/A 
SPSB4 3 rs1108693 0.159 0.022 0.098 0.256 0.050 0.090 0.349 0.237 0.121 
RNF7 3 rs1980191 0.383 0.052 0.187 0.351 0.128 0.421 0.681 0.228 0.156 
RNF7 3 rs6769676 0.225 0.484 0.526 0.796 0.670 0.477 0.168 0.578 0.829 
RNF7 3 rs6776205 0.962 0.925 0.986 0.746 0.696 0.776 0.763 0.586 0.809 
TFDP2 3 rs2163294 0.603 0.603 0.840 0.258 0.325 0.561 1.000 0.593 0.092 
TFDP2 3 rs7642874 N/A N/A N/A N/A N/A N/A N/A N/A N/A 
TFDP2 3 rs9877536 N/A N/A N/A N/A N/A N/A N/A N/A N/A 
TFDP2 3 rs13065446 N/A N/A N/A N/A N/A N/A N/A N/A N/A 
ATR 3 rs9816736 0.196 0.178 0.112 0.883 0.469 0.146 0.179 0.139 0.072 
ATR 3 rs3922730 0.425 0.773 0.235 0.681 0.414 0.254 0.498 0.221 0.354 
ATR 3 rs4273389 0.133 0.399 0.135 0.022 0.433 0.728 0.653 0.647 0.098 
ATR 3 rs6440085 N/A N/A N/A N/A N/A N/A N/A N/A N/A 
ATR 3 rs7651071 0.906 0.192 0.141 0.077 0.280 0.281 0.230 0.456 0.468 
ATR 3 rs13085998 0.617 0.325 0.459 0.240 0.387 0.588 0.730 0.602 0.308 
ATR 3 rs2227928 0.733 0.356 0.531 0.883 0.174 0.289 0.615 0.131 0.231 
ATR 3 rs6792259 N/A N/A N/A N/A N/A N/A N/A N/A N/A 
EMP 4 rs1680073 0.633 0.651 0.874 0.282 0.612 0.843 0.816 0.879 0.773 
EMP 4 rs11727167 0.809 0.235 0.584 0.503 0.132 0.426 0.824 0.793 0.624 
EMP 4 rs7673398 0.862 0.916 0.448 0.611 0.586 0.418 0.847 0.612 0.801 
EMP 4 rs12641735 0.077 0.048 0.051 0.726 0.201 0.399 0.045 0.131 0.080 
EMP 4 rs12642410 0.328 0.035 0.218 0.125 0.040 0.325 0.868 0.264 0.309 
EMP 4 rs1316393 N/A N/A N/A N/A N/A N/A N/A N/A N/A 
EMP 4 rs7664474 0.577 0.166 0.478 0.091 0.027 0.302 0.741 1.000 0.486 
EMP 4 rs12647145 N/A N/A N/A N/A N/A N/A N/A N/A N/A 
TNIP2 4 rs9683949 0.603 0.652 0.278 0.645 0.827 0.360 0.756 0.631 0.629 
TNIP2 4 rs4690055 0.783 0.216 0.420 0.942 1.000 0.683 0.726 0.103 0.252 
TNIP2 4 rs4690060 0.329 1.000 0.681 0.707 0.505 0.678 0.198 0.606 0.749 
HTT 4 rs762855 0.010 0.211 0.469 0.053 0.078 0.211 0.105 0.842 0.921 
HTT 4 rs2285086 0.682 0.547 0.602 0.573 0.397 0.642 0.961 0.670 0.418 
HTT 4 rs10015979 0.484 0.838 0.980 0.956 0.889 0.588 0.503 0.655 0.548 
HTT 4 rs6446723 0.042 0.365 0.172 <0.001 0.330 0.587 0.654 0.752 0.107 
HTT 4 rs6855981 0.265 0.710 0.758 0.240 0.633 0.217 0.656 1.000 0.657 
HTT 4 rs4690074 0.799 0.169 0.246 0.590 0.513 0.528 0.518 0.128 0.018 
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HTT 4 rs363096 0.567 0.806 0.223 0.913 0.862 0.754 0.561 0.602 0.247 
HTT 4 rs363092 0.370 0.228 0.165 0.819 0.268 0.322 0.340 0.622 0.408 
HTT 4 rs362336 0.994 0.199 0.355 0.406 0.096 0.147 0.515 0.622 0.703 
HTT 4 rs362331 0.936 0.686 0.356 0.564 0.907 0.432 0.583 0.549 0.757 
HTT 4 rs2269478 0.144 0.384 0.462 0.363 0.637 0.665 0.239 0.398 0.512 
TLR10 4 rs10776482 0.153 0.480 0.552 0.133 0.399 0.464 0.535 1.000 0.878 
TLR10 4 rs11096955 0.118 0.547 0.696 0.022 0.683 0.879 0.648 0.297 0.445 
TLR10 4 rs11096957 0.932 0.942 0.537 0.763 0.859 0.690 0.867 0.710 0.761 
TLR10 4 rs7658893 0.481 0.251 0.183 0.750 0.245 0.327 0.529 0.900 0.376 
TLR1 4 rs4833095 0.670 0.180 0.129 0.296 0.458 0.735 0.268 0.182 0.013 
TLR1 4 rs5743565 N/A N/A N/A N/A N/A N/A N/A N/A N/A 
TLR6 4 rs5743818 0.444 0.289 0.543 0.610 0.772 0.902 0.548 0.038 0.095 
TLR6 4 rs3821985 0.665 0.458 0.722 0.490 0.742 0.318 0.301 0.384 0.448 
TLR6 4 rs5743810 0.379 0.015 0.088 0.192 0.179 0.243 0.053 0.033 0.112 
WDR19 4 rs1451821 N/A N/A N/A N/A N/A N/A N/A N/A N/A 
WDR19 4 rs6815686 0.186 0.140 0.248 0.054 0.586 0.818 0.707 0.096 0.131 
WDR19 4 rs9997015 0.248 0.029 0.045 0.271 0.067 0.142 0.414 0.216 0.230 
WDR19 4 rs9998591 0.622 0.701 0.769 0.139 0.933 0.664 0.629 0.433 0.796 
WDR19 4 rs11096987 0.664 0.207 0.379 0.701 0.302 0.576 0.455 0.446 0.236 
WDR19 4 rs3733280 0.437 0.820 0.850 0.502 0.281 0.463 0.150 0.199 0.385 
WDR19 4 rs12648082 N/A N/A N/A N/A N/A N/A N/A N/A N/A 
WDR19 4 rs1057807 N/A N/A N/A N/A N/A N/A N/A N/A N/A 
UBE2K 4 rs3912392 N/A N/A N/A N/A N/A N/A N/A N/A N/A 
UBE2K 4 rs13122400 0.131 0.187 0.134 0.651 0.535 0.512 0.113 0.157 0.169 
UBE2K 4 rs12644528 0.203 0.383 0.288 0.771 0.706 0.744 0.205 0.307 0.235 
UBE2K 4 rs302947 0.160 0.150 0.332 0.200 0.375 0.530 0.424 0.216 0.453 
UBE2K 4 rs305827 N/A N/A N/A N/A N/A N/A N/A N/A N/A 
UBE2K 4 rs10440307 0.925 0.330 0.112 0.175 0.317 0.178 0.338 0.670 0.507 
UBE2K 4 rs4263408 0.657 0.678 0.888 0.244 0.756 0.882 0.209 0.267 0.351 
CARMA1 7 rs11982651 0.158 0.302 0.573 0.923 0.746 0.893 0.091 0.285 0.582 
CARMA1 7 rs1713911 N/A N/A N/A N/A N/A N/A N/A N/A N/A 
CARMA1 7 rs1476636 0.815 0.052 0.177 0.232 0.052 0.193 0.626 0.516 0.601 
CARMA1 7 rs4722276 0.814 0.537 0.521 0.260 0.371 0.570 0.563 1.000 0.654 
CARMA1 7 rs12538346 0.603 0.082 0.322 0.275 0.100 0.323 0.873 0.522 0.484 
CARMA1 7 rs10236776 0.265 0.211 0.444 0.407 0.216 0.336 0.506 0.758 0.258 
CARMA1 7 rs4722356 0.109 0.243 0.031 0.090 0.924 0.391 0.483 0.028 0.048 
RBAK 7 rs7805748 0.189 0.884 0.724 0.602 0.601 0.816 0.242 0.354 0.134 
RBAK 7 rs10238244 0.640 0.258 0.494 0.447 0.144 0.284 0.941 0.686 0.905 
RBAK 7 rs7778444 N/A N/A N/A N/A N/A N/A N/A N/A N/A 
TRIAD3 7 rs852374 0.005 0.003 0.020 0.013 0.020 0.087 0.058 0.063 0.223 
TRIAD3 7 rs13246406 0.747 1.000 1.000 0.240 0.619 0.691 0.266 0.446 0.755 
TRIAD3 7 rs852522 0.066 0.012 0.042 0.006 0.017 0.116 0.759 0.297 0.195 
TRIAD3 7 rs13247447 0.359 0.384 0.383 0.275 0.446 0.800 0.655 0.655 0.181 
TRIAD3 7 rs852417 0.612 0.317 0.513 0.440 1.000 1.000 0.272 0.317 0.317 
TRIAD3 7 rs3823681 0.429 0.928 0.991 0.848 0.895 0.853 0.317 1.000 0.739 
TRIAD3 7 rs3779092 0.594 0.912 0.572 0.996 0.516 0.453 0.543 0.446 0.681 
TRIAD3 7 rs852394 0.515 0.878 0.646 0.136 0.626 0.378 0.775 0.710 0.850 
TRIAD3 7 rs1468996 0.599 1.000 0.831 0.211 1.000 0.616 0.913 1.000 1.000 
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      Hisp. Hisp. FHx Hisp. Trios 
Gene Chr SNP APL PDT GenPDT APL PDT GenPDT APL PDT GenPDT 
TRIAD3 7 rs2302907 0.158 0.384 0.713 0.072 0.505 0.820 0.487 0.553 0.805 
TRIAD3 7 rs13239194 0.578 0.535 0.670 0.891 0.425 0.487 0.445 1.000 0.203 
TRIAD3 7 rs13237614 0.391 0.155 0.248 0.682 0.361 0.550 0.180 0.257 0.402 
TRIAD3 7 rs2112006 0.933 0.508 0.185 0.910 0.796 0.379 0.889 0.392 0.279 
TRIAD3 7 rs11771172 0.558 0.722 0.090 0.209 0.310 0.584 0.111 0.134 0.050 
TRIAD3 7 rs6971918 0.732 0.652 0.445 0.817 0.612 0.283 0.785 0.898 0.980 
TRIAD3 7 rs10257204 0.773 0.909 0.544 0.804 0.862 0.754 0.789 0.763 0.683 
TRIAD3 7 rs6967635 0.882 0.459 0.507 0.455 0.183 0.279 0.488 0.500 0.725 
TRIAD3 7 rs2017620 0.612 0.157 0.363 0.311 0.170 0.385 0.859 0.578 0.860 
TNFSF13B 13 rs9514828 0.218 0.684 0.593 0.159 0.763 0.866 0.646 0.782 0.622 
TNFSF13B 13 rs8181791 N/A N/A N/A N/A N/A N/A N/A N/A N/A 
TNFSF13B 13 rs10508198 0.353 0.579 0.690 0.904 0.267 0.252 0.246 0.578 0.177 
TNFSF13B 13 rs9520835 0.849 0.395 0.075 0.423 0.066 0.120 0.808 0.655 0.425 
TNFSF13B 13 rs1224163 0.911 0.243 0.462 0.371 0.269 0.416 0.403 0.623 0.879 
ING1 13 rs4773240 N/A N/A N/A N/A N/A N/A N/A N/A N/A 
ING1 13 rs1441043 0.117 0.056 0.157 0.722 0.157 0.337 0.056 0.189 0.380 
ING1 13 rs6492308 0.236 0.164 0.227 0.337 0.311 0.416 0.448 0.217 0.357 
TFDP1 13 rs7325214 0.688 0.579 0.414 0.252 0.274 0.175 0.178 0.752 0.899 
TFDP1 13 rs4150703 0.139 0.070 0.016 0.929 0.819 0.269 0.053 0.028 0.041 
TFDP1 13 rs9577595 0.610 0.630 0.513 0.315 0.352 0.228 0.870 0.456 0.695 
TFDP1 13 rs12428926 N/A N/A N/A N/A N/A N/A N/A N/A N/A 
TFDP1 13 rs4150832 N/A N/A N/A N/A N/A N/A N/A N/A N/A 
TNFRSF11A 18 rs2981007 N/A N/A N/A N/A N/A N/A N/A N/A N/A 
TNFRSF11A 18 rs4941125 0.025 0.475 0.635 <0.001 0.608 0.810 0.598 0.617 0.777 
TNFRSF11A 18 rs7239261 0.007 0.075 0.179 0.103 0.353 0.636 0.033 0.128 0.276 
TNFRSF11A 18 rs4263037 0.337 0.454 0.765 0.307 0.354 0.612 0.597 0.895 0.979 
TNFRSF11A 18 rs7236060 0.654 0.296 0.513 0.752 0.592 0.391 0.816 0.332 0.096 
TNFRSF11A 18 rs8094884 0.071 0.010 0.111 0.042 0.059 0.435 0.448 0.066 0.185 
TNFRSF11A 18 rs8089829 0.789 0.840 0.922 0.875 0.686 0.859 0.836 0.879 0.976 
TNFRSF11A 18 rs12959396 0.765 0.796 0.584 0.111 0.793 0.309 0.557 0.569 0.774 
TNFRSF11A 18 rs9646629 N/A N/A N/A N/A N/A N/A N/A N/A N/A 
TNFRSF11A 18 rs2957125 0.463 0.842 0.533 0.635 0.486 0.320 0.284 0.117 0.286 
SOCS6 18 rs7230661 0.600 0.629 0.496 0.843 1.000 0.226 0.412 0.453 0.701 
SOCS6 18 rs713130 0.727 0.689 0.625 0.730 0.276 0.202 0.821 0.555 0.866 
SOCS6 18 rs2053420 0.125 0.191 0.387 0.152 0.739 0.782 0.424 0.118 0.153 
NFATC1/NFAT2 18 rs9962479 0.924 0.297 0.204 0.275 0.083 0.083 0.242 0.763 0.695 
NFATC1/NFAT2 18 rs8090692 N/A N/A N/A N/A N/A N/A N/A N/A N/A 
NFATC1/NFAT2 18 rs2036892 0.996 0.706 0.273 0.856 0.564 0.624 0.944 0.317 0.271 
NFATC1/NFAT2 18 rs4799055 N/A N/A N/A N/A N/A N/A N/A N/A N/A 
NFATC1/NFAT2 18 rs8097537 0.025 <0.001 0.002 0.183 0.433 0.752 0.053 <0.001 0.001 
NFATC1/NFAT2 18 rs12608349 0.102 0.061 0.001 0.552 0.884 0.027 0.021 0.016 0.005 
NFATC1/NFAT2 18 rs2290154 0.877 0.928 0.922 0.540 0.366 0.680 0.766 0.574 0.840 
NFATC1/NFAT2 18 rs7227107 0.958 0.884 0.423 0.808 0.414 0.574 0.817 0.876 0.635 
NFATC1/NFAT2 18 rs370989 0.003 0.003 0.003 0.001 0.274 0.164 0.077 0.003 0.009 
NFATC1/NFAT2 18 rs1667673 0.123 0.206 0.347 0.291 0.297 0.366 0.249 0.456 0.761 
NFATC1/NFAT2 18 rs1660139 0.690 0.302 0.537 0.657 0.144 0.073 0.499 0.803 0.613 
NFATC1/NFAT2 18 rs177820 0.399 0.317 0.550 0.062 0.132 0.186 0.709 0.655 0.761 
NFATC1/NFAT2 18 rs3894049 <0.001 0.001 0.004 0.016 0.670 0.935 0.007 0.000 0.000 
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NFATC1/NFAT2 18 rs183374 0.588 0.212 0.430 0.199 0.615 0.868 0.133 0.172 0.422 
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Table B4.   Gene-gene interactions of clubfoot deletion region apoptotic genes p<0.01 in 
NHW. 
 
Gene 1 SNP 1 Gene 2 SNP 2 p-value 
ATF2/CREB2 rs10930693 CERKL rs11680383 0.0024 
ATF2/CREB2 rs10930693 HTT rs2269478 0.0091 
ATF2/CREB2 rs2698545 TNFSF13B rs8181791 0.0082 
ATR rs13085998 NFATC1/NFAT2 rs4799055 0.0029 
ATR rs13085998 NFATC1/NFAT2 rs8097537 0.0073 
ATR rs13085998 TNIP2 rs4690060 0.0046 
ATR rs13085998 TRIAD3 rs13246406 0.0088 
ATR rs2227928 TRIAD3 rs852394 0.0098 
ATR rs6440085 TRIAD3 rs852417 0.0079 
ATR rs13085998 UBE2K rs302947 0.0044 
ATR rs6792259 UBE2K rs302947 0.0094 
ATR rs7651071 UBE2K rs302947 0.0042 
CARD11/CARMA1 rs12538346 ING1 rs4773240 0.0074 
CARD11/CARMA1 rs11982651 NFATC1/NFAT2 rs2290154 0.0054 
CARD11/CARMA1 rs1713911 TNFSF13B rs8181791 0.002 
CERKL rs1866888 HTT rs6855981 0.0035 
CERKL rs1866888 EMP rs12641735 0.0011 
CERKL rs11680383 NFATC1/NFAT2 rs1660139 0.0091 
CERKL rs1866888 TFDP1 rs4150832 0.0015 
CERKL rs1047307 TLR1 rs5743565 0.009 
CERKL rs895901 TLR6 rs3821985 0.007 
CERKL rs11680383 TNFRSF11A rs9646629 0.0068 
CREB1 rs2253206 ATR rs6440085 0.0037 
CREB1 rs2551640 HTT rs2285086 0.0002 
CREB1 rs10932201 NFATC1/NFAT2 rs2290154 0.0057 
CREB1 rs2254137 NFATC1/NFAT2 rs3894049 0.0068 
CREB1 rs2551640 NFATC1/NFAT2 rs3894049 0.0044 
CREB1 rs2254137 TLR10 rs11096955 0.0058 
GULP1 rs10931359 ING1 rs4773240 0.01 
GULP1 rs13034731 STAT4 rs1517352 0.0076 
GULP1 rs10931346 TFDP2 rs13065446 0.0082 
GULP1 rs12624002 TFDP2 rs13065446 0.0092 
GULP1 rs13034731 TFDP2 rs13065446 0.0031 
GULP1 rs13034731 TFDP2 rs7642874 0.0019 
GULP1 rs7586390 TNFRSF11A rs7239261 0.0078 
GULP1 rs1354905 TNFSF13B rs10508198 0.0004 
GULP1 rs13034731 TRIAD3 rs10257204 0.0063 
GULP1 rs1354905 UBE2K rs4263408 0.0067 
GULP1 rs13034731 WDR19 rs12648082 0.0048 
GULP1 rs12624002 WDR19 rs9998591 0.0015 
GULP1 rs7586390 WDR19 rs9998591 0.0063 
HTT rs2285086 TLR1 rs4833095 0.0096 
HTT rs2269478 TRIAD3 rs6967635 0.0044 
HTT rs762855 TRIAD3 rs6967635 0.0043 
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HTT rs2269478 TRIAD3 rs6971918 0.0045 
HTT rs363092 TRIAD3 rs852394 0.01 
HTT rs6855981 TRIAD3 rs852394 0.01 
HTT rs10015979 TRIAD3 rs852417 0.0021 
HTT rs362331 TRIAD3 rs852417 0.003 
HTT rs362336 UBE2K rs302947 0.001 
HTT rs2285086 WDR19 rs3733280 0.0043 
ING1 rs1441043 NFATC1/NFAT2 rs8090692 0.0073 
EMP rs12647145 HTT rs362336 0.0043 
EMP rs1316393 HTT rs6855981 0.0081 
EMP rs1680073 EMP rs11727167 0.0091 
EMP rs1680073 EMP rs7664474 0.0067 
EMP rs7664474 NFATC1/NFAT2 rs183374 0.0032 
EMP rs1316393 NFATC1/NFAT2 rs2036892 0.0049 
EMP rs12641735 NFATC1/NFAT2 rs3894049 0.0015 
EMP rs7673398 TLR10 rs11096955 0.0032 
EMP rs11727167 TLR10 rs11096957 0.0063 
EMP rs12642410 TLR10 rs11096957 0.0022 
EMP rs1316393 TLR10 rs11096957 0.0026 
EMP rs7664474 TLR10 rs11096957 0.007 
EMP rs7673398 TLR10 rs11096957 0.005 
EMP rs12641735 TNFRSF11A rs8089829 0.0043 
EMP rs12642410 TRIAD3 rs13246406 0.0042 
EMP rs7664474 TRIAD3 rs852417 0.0054 
EMP rs1680073 UBE2K rs10440307 0.0013 
EMP rs12641735 WDR19 rs11096987 0.0037 
EMP rs12641735 WDR19 rs9998591 0.0031 
NFATC1/NFAT2 rs8090692 NFATC1/NFAT2 rs177820 0.0062 
NFATC1/NFAT2 rs2036892 NFATC1/NFAT2 rs7227107 0.0095 
RBAK rs7805748 TNFSF13B rs9520835 0.0099 
RNF7 rs6769676 ATR rs13085998 0.0004 
RNF7 rs6769676 ATR rs4273389 0.0001 
RNF7 rs6769676 ATR rs7651071 <.0001 
RNF7 rs6769676 TLR10 rs11096955 0.0068 
RNF7 rs1980191 TLR10 rs11096957 0.0008 
RNF7 rs6769676 TNIP2 rs4690055 0.0042 
RNF7 rs6769676 WDR19 rs3733280 0.0049 
SOCS6 rs713130 NFATC1/NFAT2 rs7227107 0.0066 
SPSB4 rs1108693 HTT rs2285086 0.0098 
SPSB4 rs1108693 TNFSF13B rs10508198 0.0079 
STAT1 rs6751855 NFATC1/NFAT2 rs370989 0.0093 
STAT1 rs6751855 NFATC1/NFAT2 rs3894049 0.0018 
STAT1 rs2280233 TFDP1 rs4150703 0.0045 
STAT1 rs12468579 TLR10 rs11096957 0.0049 
STAT1 rs7562024 TNFRSF11A rs4941125 0.0094 
STAT1 rs12468579 TRIAD3 rs13246406 0.0027 
STAT4 rs1517352 CARD11/CARMA1 rs1713911 0.003 
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STAT4 rs4341967 NFATC1/NFAT2 rs177820 0.0082 
STAT4 rs897200 NFATC1/NFAT2 rs4799055 0.0028 
STAT4 rs1517352 TLR10 rs11096955 0.0022 
STAT4 rs1517352 TLR10 rs11096957 0.0001 
STAT4 rs4341967 TLR10 rs7658893 0.006 
STAT4 rs11693480 TNFRSF11A rs7236060 0.0064 
STAT4 rs12463658 UBE2K rs302947 0.001 
SUMO1 rs3754931 EMP rs1680073 0.0018 
SUMO1 rs6755690 NFATC1/NFAT2 rs177820 0.0057 
SUMO1 rs6755690 TLR1 rs5743565 0.0086 
TFDP1 rs12428926 TNFRSF11A rs4263037 0.0076 
TFDP2 rs2163294 HTT rs6855981 0.0046 
TFDP2 rs2163294 ING1 rs4773240 0.0099 
TFDP2 rs7642874 EMP rs12641735 0.0026 
TFDP2 rs7642874 NFATC1/NFAT2 rs1667673 0.0036 
TFDP2 rs9877536 NFATC1/NFAT2 rs4799055 0.0043 
TFDP2 rs7642874 TNFSF13B rs9514828 0.0077 
TFDP2 rs2163294 TNFSF13B rs9520835 0.0035 
TFDP2 rs9877536 TRIAD3 rs2302907 0.0075 
TLR1 rs4833095 CARD11/CARMA1 rs10236776 0.0081 
TLR1 rs5743565 NFATC1/NFAT2 rs4799055 0.0016 
TLR1 rs5743565 SOCS6 rs713130 0.0016 
TLR1 rs4833095 TNFRSF11A rs7239261 0.0044 
TLR1 rs4833095 TRIAD3 rs10257204 0.0043 
TLR1 rs4833095 TRIAD3 rs2302907 0.0027 
TLR1 rs5743565 TRIAD3 rs2302907 0.0028 
TLR10 rs10776482 CARD11/CARMA1 rs12538346 0.0037 
TLR10 rs10776482 NFATC1/NFAT2 rs12608349 0.0036 
TLR10 rs11096955 SOCS6 rs713130 0.0084 
TLR10 rs7658893 SOCS6 rs713130 0.003 
TLR10 rs11096957 TLR6 rs5743818 0.0027 
TLR10 rs11096957 TNFRSF11A rs12959396 0.0039 
TLR10 rs11096957 TNFRSF11A rs8094884 0.0062 
TLR10 rs11096957 TRIAD3 rs2112006 0.0099 
TLR10 rs7658893 UBE2K rs4263408 0.0043 
TLR6 rs5743818 CARD11/CARMA1 rs7805748 0.0087 
TLR6 rs3821985 NFATC1/NFAT2 rs9962479 0.0019 
TLR6 rs5743818 TFDP1 rs12428926 0.0049 
TLR6 rs5743810 TRIAD3 rs852417 0.0049 
TLR6 rs3821985 UBE2K rs13122400 0.0081 
TNFRSF11A rs2981007 NFATC1/NFAT2 rs183374 0.0082 
TNFSF13B rs1224163 TNFRSF11A rs2981007 0.0083 
TRIAD3 rs852394 ING1 rs4773240 0.0016 
TRIAD3 rs852374 NFATC1/NFAT2 rs177820 0.01 
TRIAD3 rs13239194 TNFRSF11A rs2957125 0.0081 
TRIAD3 rs13239194 TNFSF13B rs10508198 0.0082 
TRIAD3 rs13239194 TRIAD3 rs10257204 0.0052 
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TRIAD3 rs852417 TRIAD3 rs2302907 0.001 
TRIAD3 rs852417 TRIAD3 rs852394 0.0036 
UBE2K rs4263408 TFDP1 rs4150703 0.0049 
UBE2K rs302947 UBE2K rs4263408 0.0091 
WDR19 rs9997015 NFATC1/NFAT2 rs1667673 0.0083 
WDR19 rs1057807 NFATC1/NFAT2 rs7227107 0.0069 
WDR19 rs9997015 RBAK rs7805748 0.0092 
WDR19 rs9997015 TNFRSF11A rs4263037 0.0074 
WDR19 rs12648082 TNFSF13B rs1224163 0.0085 
WDR19 rs9997015 TNFSF13B rs9514828 0.0021 
WDR19 rs12648082 TRIAD3 rs2112006 0.0061 
WDR19 rs1057807 UBE2K rs302947 0.0008 
ZAK rs12618933 ATF2/CREB2 rs10930693 0.0019 
ZAK rs1837470 CERKL rs1047307 0.0064 
ZAK rs13032010 CREB1 rs10932201 0.0007 
ZAK rs3769192 GULP1 rs10931359 0.0014 
ZAK rs17302977 GULP1 rs1354905 0.009 
ZAK rs12618933 HTT rs362336 0.0093 
ZAK rs4972533 NFATC1/NFAT2 rs12608349 0.0012 
ZAK rs13032010 NFATC1/NFAT2 rs177820 0.0065 
ZAK rs12618933 NFATC1/NFAT2 rs7227107 0.0098 
ZAK rs989531 RBAK rs7805748 0.0069 
ZAK rs11686011 RNF7 rs6769676 0.0075 
ZAK rs12618933 STAT4 rs11685878 0.0071 
ZAK rs4972533 STAT4 rs2356350 0.0035 
ZAK rs6759787 SUMO1 rs6717044 0.0025 
ZAK rs13032010 TLR10 rs7658893 0.0098 
ZAK rs12618933 TLR6 rs5743818 0.0065 
ZAK rs6759787 TNFRSF11A rs7239261 0.0042 
ZAK rs12618933 UBE2K rs4263408 0.0031 
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Table B5.  Gene-gene interactions of clubfoot deletion region apoptotic genes p<0.01 in 
Hispanics. 
 
Gene 1 SNP 1 Gene 2 SNP 2 p-value 
ATF2/CREB2 rs212352 HTT rs6446723 0.0089 
ATF2/CREB2 rs2698545 NFATC1/NFAT2 rs8097537 0.0072 
ATR rs13085998 CARD11/CARMA1 rs1713911 0.0011 
ATR rs13085998 ING1 rs6492308 0.0095 
ATR rs13085998 TNFRSF11A rs7236060 0.0053 
ATR rs3922730 TNIP2 rs4690055 0.0028 
ATR rs4273389 NFATC1/NFAT2 rs1660139 0.0079 
ATR rs6440085 NFATC1/NFAT2 rs4799055 0.0077 
ATR rs7651071 CARD11/CARMA1 rs1713911 0.0065 
ATR rs7651071 WDR19 rs11096987 0.0013 
ATR rs9816736 WDR19 rs11096987 0.0033 
CARD11/CARMA1 rs10236776 TNFRSF11A rs2981007 0.009 
CARD11/CARMA1 rs10236776 TRIAD3 rs2302907 0.0097 
CARD11/CARMA1 rs11982651 ING1 rs1441043 0.0057 
CARD11/CARMA1 rs1713911 ING1 rs1441043 <.0001 
CARD11/CARMA1 rs1713911 TNFRSF11A rs8089829 0.0021 
CARD11/CARMA1 rs4722276 TNFRSF11A rs8094884 0.0047 
CARD11/CARMA1 rs4722276 TRIAD3 rs3779092 0.0071 
CARD11/CARMA1 rs4722356 TNFSF13B rs10508198 0.0076 
CERKL rs10445770 TNIP2 rs4690060 0.002 
CERKL rs10445770 TRIAD3 rs3823681 0.0043 
CERKL rs10445770 UBE2K rs12644528 0.0099 
CERKL rs1047307 CARD11/CARMA1 rs11982651 0.0018 
CERKL rs1047307 GULP1 rs7593546 0.0087 
CERKL rs1047307 NFATC1/NFAT2 rs177820 0.0009 
CERKL rs11680383 TRIAD3 rs13247447 0.0088 
CERKL rs1866888 HTT rs362331 0.0007 
CERKL rs1992394 NFATC1/NFAT2 rs177820 0.0062 
CERKL rs1992394 SUMO1 rs3754931 0.0044 
CERKL rs1992394 TLR10 rs10776482 0.0073 
CERKL rs1992394 TNFRSF11A rs2981007 0.0044 
CERKL rs1992394 TNFSF13B rs9520835 0.01 
CERKL rs895901 HTT rs6446723 0.0066 
CERKL rs895901 TLR10 rs11096957 0.0025 
CERKL rs895901 TRIAD3 rs13247447 0.0065 
CERKL rs935087 GULP1 rs12474692 0.0021 
CERKL rs935087 TLR1 rs4833095 0.0034 
CERKL rs935087 TRIAD3 rs6971918 0.0075 
CREB1 rs10932201 HTT rs10015979 0.01 
CREB1 rs2253206 TRIAD3 rs10257204 0.0098 
GULP1 rs10931346 NFATC1/NFAT2 rs7227107 0.0059 
GULP1 rs10931346 RBAK rs10238244 0.0014 
GULP1 rs10931359 ATR rs9816736 0.0076 
GULP1 rs11685321 STAT1 rs13395505 0.0042 
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GULP1 rs12474692 ATR rs13085998 0.007 
GULP1 rs12474692 RBAK rs7778444 0.0003 
GULP1 rs12474692 SOCS6 rs7230661 0.0015 
GULP1 rs13034731 ATR rs6440085 0.0058 
GULP1 rs13034731 WDR19 rs12648082 0.0066 
GULP1 rs13034731 WDR19 rs1451821 0.0054 
GULP1 rs13034731 WDR19 rs3733280 0.0025 
GULP1 rs4396679 CREB1 rs10932201 0.0042 
GULP1 rs4396679 RBAK rs10238244 0.0051 
GULP1 rs6724428 RBAK rs7778444 0.0066 
GULP1 rs7586390 ATR rs13085998 0.01 
GULP1 rs7586390 RBAK rs7778444 0.0006 
HTT rs10015979 HTT rs2269478 0.0069 
HTT rs10015979 NFATC1/NFAT2 rs2036892 0.0083 
HTT rs10015979 WDR19 rs12648082 0.0045 
HTT rs362331 CARD11/CARMA1 rs4722356 0.0056 
HTT rs362336 NFATC1/NFAT2 rs1667673 0.007 
HTT rs362336 NFATC1/NFAT2 rs4799055 0.0014 
HTT rs362336 TNFRSF11A rs2981007 0.0045 
HTT rs362336 TNFRSF11A rs8089829 0.005 
HTT rs362336 TNFSF13B rs8181791 0.005 
HTT rs362336 TNFSF13B rs9514828 0.0057 
HTT rs363092 NFATC1/NFAT2 rs7227107 0.0065 
HTT rs363092 TRIAD3 rs13247447 0.007 
HTT rs4690074 TLR10 rs11096957 0.0054 
HTT rs762855 NFATC1/NFAT2 rs177820 0.0011 
ING1 rs4773240 NFATC1/NFAT2 rs7227107 0.0056 
EMP rs11727167 HTT rs363092 0.008 
EMP rs12641735 SOCS6 rs713130 0.0095 
EMP rs12647145 NFATC1/NFAT2 rs3894049 0.0056 
EMP rs1680073 TLR10 rs7658893 0.0054 
RBAK rs7778444 TFDP1 rs4150703 0.0065 
RBAK rs7778444 TNFRSF11A rs4263037 0.0028 
RBAK rs7778444 TNFRSF11A rs7236060 0.0018 
RBAK rs7778444 TNFRSF11A rs8089829 0.0009 
RBAK rs7778444 TNFSF13B rs9514828 0.0008 
RBAK rs7805748 NFATC1/NFAT2 rs177820 0.0082 
RBAK rs7805748 TFDP1 rs7325214 0.002 
RBAK rs7805748 TFDP1 rs9577595 0.003 
RNF7 rs1980191 HTT rs363092 0.0011 
RNF7 rs6769676 UBE2K rs305827 0.0036 
RNF7 rs6776205 CARD11/CARMA1 rs11982651 0.0028 
RNF7 rs6776205 EMP rs7664474 0.0029 
RNF7 rs6776205 TNFRSF11A rs12959396 0.0018 
RNF7 rs6776205 TRIAD3 rs13247447 0.0005 
RNF7 rs6776205 TRIAD3 rs852374 0.0043 
SOC6 rs2053420 NFATC1/NFAT2 rs1667673 0.0016 
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Gene 1 SNP 1 Gene 2 SNP 2 p-value 
STAT1 rs12468579 STAT4 rs925847 0.0008 
STAT1 rs13395505 CARD11/CARMA1 rs4722276 0.0031 
STAT1 rs13395505 TNFRSF11A rs8089829 0.0087 
STAT1 rs2280233 EMP rs12641735 0.0017 
STAT1 rs2280233 EMP rs12647145 0.0095 
STAT1 rs2280233 UBE2K rs302947 0.0081 
STAT1 rs6751855 TRIAD3 rs1468996 0.0062 
STAT1 rs7562024 HTT rs363092 0.0096 
STAT1 rs7562024 TNFRSF11A rs2981007 0.0055 
STAT4 rs11685878 CARD11/CARMA1 rs4722356 0.01 
STAT4 rs1517352 SOCS6 rs7230661 0.0056 
STAT4 rs16833215 HTT rs363096 0.0031 
STAT4 rs16833215 SUMO1 rs3754931 0.0049 
STAT4 rs16833215 TNIP2 rs9683949 0.0095 
STAT4 rs16833215 TRIAD3 rs11771172 0.0018 
STAT4 rs16833215 TRIAD3 rs13246406 0.001 
STAT4 rs16833249 RNF7 rs6776205 0.0095 
STAT4 rs4853543 NFATC1/NFAT2 rs12608349 0.0024 
STAT4 rs4853543 STAT4 rs6738544 0.0089 
STAT4 rs6738544 ATR rs13085998 0.0066 
STAT4 rs6738544 TRIAD3 rs13246406 0.005 
STAT4 rs7572482 CARD11/CARMA1 rs10236776 0.0039 
STAT4 rs7572482 UBE2K rs3912392 0.002 
STAT4 rs7574909 NFATC1/NFAT2 rs8090692 0.0033 
STAT4 rs7574909 RNF7 rs6769676 0.0035 
STAT4 rs925847 EMP rs11727167 0.0052 
STAT4 rs925847 EMP rs12642410 0.0012 
STAT4 rs925847 EMP rs1316393 0.0057 
STAT4 rs925847 EMP rs7673398 0.0035 
STAT4 rs925847 RNF7 rs1980191 0.0014 
STAT4 rs925847 STAT4 rs1517352 0.0032 
STAT4 rs925847 STAT4 rs4853543 0.0034 
STAT4 rs925847 TNFRSF11A rs12959396 0.0091 
STAT4 rs925847 TNFRSF11A rs8094884 0.0003 
STAT4 rs925847 UBE2K rs13122400 0.0035 
SUMO1 rs4675272 SUMO1 rs3754931 0.0012 
SUMO1 rs4675272 TNFSF13B rs9520835 0.0002 
SUMO1 rs4675272 TRIAD3 rs11771172 0.0012 
SUMO1 rs6717044 HTT rs2285086 0.0055 
SUMO1 rs6717044 RBAK rs7778444 0.0012 
TFDP1 rs7325214 NFATC1/NFAT2 rs7227107 0.0007 
TFDP1 rs7325214 TNFRSF11A rs4263037 0.0051 
TFDP1 rs7325214 TNFRSF11A rs8089829 0.0028 
TFDP1 rs9577595 NFATC1/NFAT2 rs4799055 0.0097 
TFDP1 rs9577595 NFATC1/NFAT2 rs7227107 0.0027 
TFDP1 rs9577595 TNFRSF11A rs8089829 0.0077 
TLR1 rs4833095 TNFSF13B rs1224163 0.0052 
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Gene 1 SNP 1 Gene 2 SNP 2 p-value 
TLR1 rs4833095 TRIAD3 rs10257204 0.005 
TLR10 rs10776482 CARD11/CARMA1 rs10236776 0.0049 
TLR10 rs11096955 CARD11/CARMA1 rs10236776 0.0055 
TLR6 rs5743818 UBE2K rs10440307 0.0078 
TNFRSF11A rs4263037 TNFRSF11A rs8089829 0.002 
TNFRSF11A rs7236060 NFATC1/NFAT2 rs177820 0.0051 
TNFRSF11A rs9646629 NFATC1/NFAT2 rs4799055 0.0086 
TNFSF13B rs9514828 NFATC1/NFAT2 rs2290154 0.009 
TNFSF13B rs9520835 TNFRSF11A rs4941125 0.0069 
TNIP2 rs4690060 NFATC1/NFAT2 rs8090692 0.0058 
TNIP2 rs4690060 TRIAD3 rs2017620 0.0019 
TNIP2 rs4690060 TRIAD3 rs6971918 0.0063 
TNIP2 rs9683949 TRIAD3 rs13246406 0.0053 
TRIAD3 rs2017620 TNFRSF11A rs7239261 0.0061 
TRIAD3 rs3779092 NFATC1/NFAT2 rs8090692 0.0029 
TRIAD3 rs3823681 TNFRSF11A rs7239261 0.0057 
TRIAD3 rs6967635 TNFRSF11A rs7239261 0.0062 
TRIAD3 rs6971918 TNFRSF11A rs7239261 0.0018 
TRL6 rs3821985 UBE2K rs305827 0.0005 
UBE2K rs12644528 TRIAD3 rs2017620 0.0046 
UBE2K rs305827 NFATC1/NFAT2 rs8090692 0.0047 
UBE2K rs305827 TRIAD3 rs6967635 0.0066 
UBE2K rs305827 TRIAD3 rs6971918 0.0055 
UBE2K rs3912392 CARD11/CARMA1 rs11982651 0.0069 
UBE2K rs3912392 NFATC1/NFAT2 rs8090692 0.0052 
WDR19 rs12648082 CARD11/CARMA1 rs1713911 0.0033 
WDR19 rs1451821 CARD11/CARMA1 rs1713911 0.0065 
WDR19 rs3733280 RBAK rs7805748 0.0082 
WDR19 rs3733280 TNFRSF11A rs2981007 0.0032 
WDR19 rs6815686 WDR19 rs3733280 0.0072 
ZAK rs11685001 CERKL rs10445770 0.0029 
ZAK rs11685001 CREB1 rs2254137 0.0098 
ZAK rs11685001 TRIAD3 rs3779092 0.0057 
ZAK rs11686011 CERKL rs10445770 0.006 
ZAK rs11686011 STAT4 rs4341967 0.0006 
ZAK rs13032010 CARD11/CARMA1 rs10236776 0.0063 
ZAK rs13032010 CERKL rs10445770 0.0061 
ZAK rs13032010 SOCS6 rs7230661 0.0052 
ZAK rs1837470 RNF7 rs6769676 0.005 
ZAK rs2028382 CERKL rs10445770 0.0023 
ZAK rs2028382 TFDP1 rs9577595 0.0019 
ZAK rs3769192 CERKL rs10445770 0.0088 
ZAK rs4972533 CERKL rs10445770 0.0013 
ZAK rs4972533 TRIAD3 rs3779092 0.0003 
ZAK rs4972533 TRL6 rs3821985 0.0096 
ZAK rs6433395 STAT4 rs16833249 0.0078 
ZAK rs6433395 TNFRSF11A rs7239261 0.0097 
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Gene 1 SNP 1 Gene 2 SNP 2 p-value 
ZAK rs6759787 NFATC1/NFAT2 rs177820 0.0098 
ZAK rs989531 HTT rs362336 0.0024 
ZAK rs989531 UBE2K rs3912392 0.0097 
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Supplemental Table I. Linkage disequilibrium (D’) for HOXD (A) and HOXA (B) for nonHispanic white populationa,b 
A. 
  rs6749771 rs1446575 rs1318778 rs1542180 rs1867863 rs2113563 rs2592394 rs847146 rs741610 rs711812 rs6758117 
  SNP1 SNP2 SNP3 SNP4 SNP5 SNP6 SNP7 SNP8 SNP9 SNP10 SNP11 
rs6749771 SNP1   0.789 0.613 0.795 0.715 0.39 0.401 0.094 0.273 0.193 0.2 
rs1446575 SNP2 0.712   0.973 0.99 0.899 0.483 0.484 0.163 0.32 0.286 0.332 
rs1318778 SNP3 0.384 0.935   1 0.845 0.514 0.45 0.236 0.582 0.492 0.013 
rs1542180 SNP4 0.708 0.986 1   0.902 0.513 0.52 0.169 0.334 0.255 0.35 
rs1867863 SNP5 0.632 0.926 0.824 0.928   0.759 0.471 0.158 0.32 0.244 0.413 
rs2113563 SNP6 0.13 0.39 0.479 0.418 0.814   0.825 0.387 0.108 0.042 0.335 
rs2592394 SNP7 0.22 0.522 0.499 0.572 0.679 0.856   0.008 0.488 0.305 0.295 
rs847146 SNP8 0.153 0.242 0.33 0.254 0.235 0.387 0.182   0.762 0.72 0.267 
rs741610 SNP9 0.226 0.316 0.608 0.324 0.242 0.02 0.314 0.74   0.988 0.425 
rs711812 SNP10 0.196 0.288 0.514 0.282 0.218 0.011 0.289 0.695 0.985   0.362 
rs6758117 SNP11 0.234 0.438 0.397 0.422 0.417 0.406 0.461 0.331 0.31 0.322   
aD’ of affecteds above diagnonal; D’ of normals below diagonal. 
bD’>0.8 shown in dark orange; 0.6<D’<0.8 shown in medium orange; 0.3<D’<0.6 shown in pale yellow 
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B. 
    rs2462907  rs6668 rs2428431 rs3757640 rs3801776 rs3779456 rs1859164 rs6968828 rs3807598 
    SNP12 SNP13 SNP14 SNP15 SNP16 SNP17 SNP18 SNP19 SNP20 
rs2462907  SNP12   0.773 0.749 0.156 0.016 0.257 0.207 0.068 0.126 
rs6668 SNP13 0.767   0.948 0.638 0.601 0.195 0.232 0.04 0.151 
rs2428431 SNP14 0.747 0.966   0.698 0.601 0.181 0.226 0.018 0.119 
rs3757640 SNP15 0.07 0.697 0.701   0.56 0.055 0.545 0.318 0.324 
rs3801776 SNP16 0.06 0.57 0.555 0.557   0.027 0.451 0.313 0.265 
rs3779456 SNP17 0.245 0.198 0.178 0.063 0.211   0.975 0.498 0.701 
rs1859164 SNP18 0.226 0.143 0.134 0.559 0.651 0.992   0.779 0.728 
rs6968828 SNP19 0.155 0.074 0.045 0.353 0.476 0.515 0.733   0.941 
rs3807598 SNP20 0.164 0.163 0.117 0.363 0.477 0.721 0.77 0.966   
aD’ of affecteds above diagnonal; D’ of normals below diagonal. 
bD’>0.8 shown in dark orange; 0.6<D’<0.8 shown in medium orange; 0.3<D’<0.6 shown in pale yellow 
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Supplemental Table III. Linkage disequilibrium (D’) for HOXD (A) and HOXA (B) for Hispanic populationa,b 
A. 
  rs6749771 rs1446575 rs1318778 rs1542180 rs1867863 rs2113563 rs2592394 rs847146 rs741610 rs711812 rs6758117 
  SNP1 SNP2 SNP3 SNP4 SNP5 SNP6 SNP7 SNP8 SNP9 SNP10 SNP11 
rs6749771 SNP1  0.778 0.671 0.775 0.786 0.303 0.478 0.231 0.403 0.422 0.343 
rs1446575 SNP2 0.772  1 1 0.951 0.351 0.726 0.231 0.472 0.414 0.477 
rs1318778 SNP3 0.615 0.964  1 0.97 0.631 0.612 0.366 0.586 0.503 0.324 
rs1542180 SNP4 0.762 0.978 1  0.951 0.348 0.725 0.228 0.469 0.41 0.484 
rs1867863 SNP5 0.791 0.955 0.956 0.939  0.819 0.707 0.13 0.24 0.241 0.403 
rs2113563 SNP6 0.216 0.302 0.674 0.322 0.766  0.93 0.144 0.111 0.106 0.34 
rs2592394 SNP7 0.37 0.588 0.676 0.655 0.596 0.928  0.235 0.412 0.249 0.361 
rs847146 SNP8 0.214 0.356 0.466 0.353 0.241 0.107 0.159  0.739 0.685 0.29 
rs741610 SNP9 0.312 0.401 0.519 0.436 0.271 0.036 0.447 0.713  0.974 0.046 
rs711812 SNP10 0.352 0.415 0.556 0.433 0.28 0.053 0.388 0.642 0.969  0.059 
rs6758117 SNP11 0.408 0.499 0.571 0.528 0.425 0.365 0.378 0.546 0.089 0.08  
aD’ of affecteds above diagnonal; D’ of normals below diagonal. 
bD’>0.8 shown in dark orange; 0.6<D’<0.8 shown in medium orange; 0.3<D’<0.6 shown in pale yellow 
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B. 
    rs2462907  rs6668 rs2428431 rs3757640 rs3801776 rs3779456 rs1859164 rs6968828 rs3807598 
    SNP12 SNP13 SNP14 SNP15 SNP16 SNP17 SNP18 SNP19 SNP20 
rs2462907  SNP12  0.696 0.706 0.217 0.254 0.172 0.254 0.086 0.082 
rs6668 SNP13 0.707  0.982 0.611 0.453 0.276 0.257 0.052 0.044 
rs2428431 SNP14 0.724 0.975  0.626 0.439 0.294 0.282 0.089 0.022 
rs3757640 SNP15 0.203 0.415 0.448  0.605 0.158 0.403 0.189 0.14 
rs3801776 SNP16 0.406 0.574 0.6 0.672  0.506 0.715 0.187 0.676 
rs3779456 SNP17 0.031 0.088 0.14 0.181 0.56  0.967 0.072 0.779 
rs1859164 SNP18 0.095 0.012 0.068 0.405 0.766 0.969  0.26 0.755 
rs6968828 SNP19 0.209 0.126 0.126 0.302 0.173 0.317 0.493  0.934 
rs3807598 SNP20 0.032 0.158 0.137 0.148 0.632 0.812 0.731 0.971  
aD’ of affecteds above diagonal; D’ of normals below diagonal. 
bD’>0.8 shown in dark orange; 0.6<D’<0.8 shown in medium orange; 0.3<D’<0.6 shown in pale yellow 
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Supplemental Table V. Results of APL analysis of HOXA haplotypes in discovery populationa,b,c 
 
  rs2462907  rs6668 rs2428431 rs3757640 rs3801776 rs3779456 rs1859164 rs6968828 rs3807598 
SNP Pos. SNP12 SNP13 SNP14 SNP15 SNP16 SNP17 SNP18 SNP19 SNP20 
rs2462907  SNP12   0.878 0.527 0.493 0.035 0.507 0.362 0.604 0.148 
rs6668 SNP13 0.119   0.206 0.351 0.022 0.416 0.529 0.803 0.165 
rs2428431 SNP14 0.051 0.065   0.350 0.020 0.672 0.510 0.597 0.264 
rs3757640 SNP15 0.016 0.037 0.009   0.028 0.191 0.380 0.466 0.151 
rs3801776 SNP16 0.006 0.050 0.019 0.105   0.018 0.004 0.017 0.015 
rs3779456 SNP17 0.049 0.066 0.058 0.804 0.426   0.451 0.509 0.235 
rs1859164 SNP18 0.029 0.017 0.035 0.675 0.255 0.405   0.848 0.364 
rs6968828 SNP19 0.218 0.031 0.006 0.629 0.383 0.422 0.730   0.495 
rs3807598 SNP20 0.165 0.156 0.103 0.830 0.348 0.749 0.696 0.580   
aHispanic p values shown below diagonal, nonHispanic white above the diagonal. 
bp<0.01 shown in red and p<0.05 shown in blue, respectively. 
cp-values uncorrected for multiple testing 
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Supplemental Table VI.  Results of APL analysis of HOXD haplotypes in discovery populationa,b,c 
 
  rs6749771 rs1446575 rs1318778 rs1542180 rs1867863 rs2113563 rs2592394 rs847146 rs741610 rs711812 rs6758117 
SNP Pos. SNP1 SNP2 SNP3 SNP4 SNP5 SNP6 SNP7 SNP8 SNP9 SNP10 SNP11 
rs6749771 SNP1  0.007 0.037 0.019 0.018 0.007 0.006 0.010 0.100 0.076 0.101 
rs1446575 SNP2 0.761  0.090 0.136 0.224 0.111 0.071 0.101 0.147 0.104 0.086 
rs1318778 SNP3 0.416 0.543  0.138 0.483 0.426 0.606 0.660 0.259 0.790 0.197 
rs1542180 SNP4 0.699 0.068 0.643  0.256 0.214 0.182 0.151 0.375 0.201 0.267 
rs1867863  SNP5 0.903 0.829 0.621 0.527  0.366 0.374 0.407 0.712 0.572 0.438 
rs2113563 SNP6 0.862 0.662 0.196 0.604 0.314  0.804 0.107 0.347 0.113 0.646 
rs2592394 SNP7 0.312 0.188 0.038 0.204 0.213 0.671  0.491 0.909 0.331 0.643 
rs847146 SNP8 0.992 0.710 0.300 0.544 0.653 0.883 0.626  0.520 0.594 0.560 
rs741610 SNP9 0.888 0.766 0.557 0.849 0.724 0.931 0.586 0.709  0.282 0.792 
rs711812  SNP10 0.915 0.752 0.198 0.838 0.811 0.806 0.499 0.653 0.508  0.831 
rs6758117 SNP11 0.872 0.875 0.753 0.795 0.731 0.853 0.341 0.015 0.564 0.606  
aHispanic shown below diagonal, nonHispanic white above the diagonal. 
bp<0.01 shown in red and p<0.05 shown in blue, respectively. 
cp-values uncorrected for multiple testing 
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Supplemental Table IX. Results of GEE Analysis for gene-gene interactions between HOXA 
and HOXD and IGFBP3 in nonHispanic whitesa,b 
 
Gene1 SNP1 Gene2 SNP2 p-value 
rs1446575 (SNP2) rs2453839 (SNP30) 0.022 
rs1318778 (SNP3) rs3793345 (SNP26) 0.034 
rs1318778 (SNP3) rs2471551 (SNP27) 0.019 
rs1542180 (SNP4) rs2453839 (SNP30) 0.018 
rs1867863 (SNP5) rs2453839 (SNP30) 0.013 
rs2113563 (SNP6) rs3793345 (SNP26) 0.008 
rs2113563 (SNP6) rs2471551 (SNP27) 0.007 
rs2592394 (SNP7) rs2132571 (SNP21) 0.024 
rs2592394 (SNP7) rs2854744 (SNP23) 0.047 
rs2592394 (SNP7) rs2854746 (SNP24) 0.012 
rs2592394 (SNP7) rs3793345 (SNP26) 0.003 
rs2592394 (SNP7) rs2471551 (SNP27) 0.001 
H
O
XD
 
rs2592394 (SNP7) rs3110697 (SNP28) 0.044 
rs3757640 (SNP15) rs13223993 (SNP32) 0.010 
rs3801776 (SNP16) rs2132572 (SNP22) 0.025 
rs3801776 (SNP16) rs13223993 (SNP32) <0.001 
rs1859164 (SNP18) rs2854744 (SNP23) 0.027 
rs6968828 (SNP19) rs2854744 (SNP23) 0.019 
rs6968828 (SNP19) rs2854747 (SNP25) 0.003 
rs6968828 (SNP19) rs3110697 (SNP28) 0.001 
rs3807598 (SNP20) rs2854747 (SNP25) 0.033 
H
O
XA
 
rs3807598 (SNP20) 
IG
FB
P3
 
rs3110697 (SNP28) 0.011 
ap<0.05 shown and p<0.01 in bold 
bp-values uncorrected for multiple testing 
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Supplemental Table X. Results of GEE Analysis for gene-gene interactions between HOXA 
and HOXD and IGFBP3 in Hispanic populationa,b 
 
Gene1 SNP1 Gene2 SNP2 p-value 
rs1318778 (SNP3) rs13223993 (SNP32) 0.015 
rs847146 (SNP8) rs13223993 (SNP32) 0.022 
rs741610 (SNP9) rs13223993 (SNP32) 0.002 
rs711812 (SNP10) rs13223993 (SNP32) 0.003 H
O
XD
 
rs6758117 (SNP11) rs6670 (SNP31) 0.025 
rs3801776 (SNP16) rs2132571 (SNP21) 0.018 
rs3779456 (SNP17) rs2132571 (SNP21) 0.032 
H
O
XA
 
rs1859164 (SNP18) 
IG
FB
P3
 
rs2132571 (SNP21) 0.033 
ap<0.05 shown, p<0.01 in bold 
bp-values uncorrected for multiple testing 
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Supplemental Table XI.  Results of GEE analysis for gene-gene interactions between HOXA 
and HOXD and IGFBP3 in validation populationa,b 
 
Gene 1 SNP1 Gene2 SNP2 p-value 
rs6749771 (SNP1) rs3110697 (SNP28) 0.016 
rs1542180 (SNP4) rs2132572 (SNP22) 0.035 
rs1542180 (SNP4) rs2854747 (SNP25) 0.002 
rs1542180 (SNP4) rs3793345 (SNP26) 0.035 
rs1542180 (SNP4) rs2471551 (SNP27) 0.044 
rs1542180 (SNP4) rs3110697 (SNP28) 0.0003 
rs1542180 (SNP4) rs2453839 (SNP30) 0.002 
rs1867863 (SNP5) rs2854747 (SNP25) 0.031 
rs1867863 (SNP5) rs2453839 (SNP30) 0.011 
rs2592394 (SNP7) rs2132572 (SNP22) 0.033 
rs2592394 (SNP7) rs2854744 (SNP23) 0.037 
rs2592394 (SNP7) rs2854747 (SNP25) 0.0006 
rs2592394 (SNP7) rs3793345 (SNP26) 0.021 
rs2592394 (SNP7) rs2471551 (SNP27) 0.026 
rs2592394 (SNP7) rs3110697 (SNP28) <0.0001 
rs2592394 (SNP7) rs2453839 (SNP30) 0.004 
rs847146 (SNP8) rs2132572 (SNP22) 0.034 
rs847146 (SNP8) rs2854747 (SNP25) 0.004 
rs847146 (SNP8) rs3793345 (SNP26) 0.038 
rs847146 (SNP8) rs2471551 (SNP27) 0.044 
rs847146 (SNP8) rs3110697 (SNP28) 0.001 
HOXD 
rs2462907 (SNP12) rs3793345 (SNP26) 0.016 
rs2462907 (SNP12) rs2471551 (SNP27) 0.007 HOXA 
rs6968828 (SNP19) 
IGFBP3
rs6670 (SNP31) 0.016 
ap<0.05 shown and p<0.01 in bold 
bp-values uncorrected for multiple testing 
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Supplemental Table XII. Results of GEE Analysis for gene-gene interactions for HOX, 
IGFBP3 and mitochondrial mediated apoptotic variants in nonHispanic white populationa,b 
Gene1 SNP1 Gene2 SNP2 p-value 
Apaf1 rs2288729 rs711812 (SNP10) 0.047 
Bid rs3788284 rs2113563 (SNP6) 0.045 
Bid rs181405 rs847146 (SNP8) 0.026 
Bid rs8919 rs6758117 (SNP11) 0.007 
Bcl2 rs1801018 rs6749771 (SNP1) 0.049 
Bcl2 rs1809319 rs1867863 (SNP5) 0.025 
Bcl2 rs1801018 rs1867863 (SNP5) 0.029 
Casp3 rs1049216 rs6749771 (SNP1) 0.002 
Casp3 rs1405937 rs6749771 (SNP1) 0.005 
Casp3 rs1405944 rs6749771 (SNP1) 0.011 
Casp3 rs2720378 rs6749771 (SNP1) 0.014 
Casp3 rs4647602 rs6749771 (SNP1) 0.016 
Casp3 rs2696057 rs6749771 (SNP1) 0.037 
Casp3 rs1049253 rs1446575 (SNP2) 0.031 
Casp3 rs1049253 rs1542180 (SNP4) 0.049 
Casp3 rs1049216 rs1867863 (SNP5) 0.023 
Casp3 rs1049216 rs2113563 (SNP6) 0.018 
Casp3 rs1049253 rs2592394 (SNP7) 0.001 
Casp3 rs1049216 rs2592394 (SNP7) 0.008 
Casp3 rs1405944 rs741610 (SNP9) 0.043 
Casp3 rs1049253 rs6758117 (SNP11) 0.035 
Casp3 rs2720378 rs6758117 (SNP11) 0.040 
Casp9 rs4233533 rs741610 (SNP9) 0.017 
Casp9 rs2042370 rs741610 (SNP9) 0.044 
Casp10 rs3900115 
H
O
XD
 
rs6749771 (SNP1) 0.044 
Apaf1 rs7310804 rs3779456 (SNP17) 0.042 
Apaf1 rs7310804 rs1859164 (SNP18) 0.043 
Bid rs3788284 rs2462907 (SNP12) 0.029 
Bid rs5747351 rs2428431 (SNP14) 0.029 
Bid rs8190315 rs3757640 (SNP15) 0.023 
Bid rs8919 rs3801776 (SNP16) 0.016 
Bid rs8919 rs1859164 (SNP18) 0.036 
Bid rs181405 rs3779456 (SNP17) 0.001 
Bid rs181405 rs1859164 (SNP18) 0.005 
Casp3 rs1049216 
H
O
XA
 
rs6668 (SNP13) 0.014 
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Casp3 rs1405944 rs6668 (SNP13) 0.010 
Casp3 rs2720378 rs6668 (SNP13) 0.004 
Casp3 rs2720378 rs2428431 (SNP14) 0.039 
Casp3 rs1405937 rs3801776 (SNP16) 0.048 
Casp3 rs2720378 rs3779456 (SNP17) 0.033 
Casp3 rs1049216 rs1859164 (SNP18) 0.004 
Casp3 rs2720378 rs1859164 (SNP18) 0.004 
Casp3 rs1405944 rs1859164 (SNP18) 0.022 
Casp3 rs2696057 rs1859164 (SNP18) 0.014 
Casp3 rs4647602 rs1859164 (SNP18) 0.017 
Casp3 rs1405937 rs1859164 (SNP18) 0.029 
Casp3 rs1049216 rs6968828 (SNP19) 0.026 
Casp3 rs2696057 rs6968828 (SNP19) 0.041 
Casp3 rs1049216 rs3807598 (SNP20) 0.010 
Casp3 rs1405944 rs3807598 (SNP20) 0.025 
Casp3 rs2696057 rs3807598 (SNP20) 0.026 
Casp9 rs1052571 rs3757640 (SNP15) 0.024 
Casp9 rs2308941 rs6968828 (SNP19) 0.042 
Casp10 rs3900115 rs3779456 (SNP17) 0.008 
ap<0.05 shown and p<0.01 in bold 
bp-values uncorrected for multiple testing 
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Supplemental Table XIII. Results of GEE Analysis for gene-gene interactions of HOX, 
IGFBP3 and mitochondrial mediated apoptotic variants in Hispanic populationa,b 
 
Gene 1 SNP 1 Gene 2 SNP 2 p-value 
Bcl2 rs2551402 rs6749771 (SNP1) 0.045 
Bcl2 rs1809319 rs1446575 (SNP2) 0.038 
Bcl2 rs1809319 rs847146 (SNP8) 0.015 
Bcl2 rs1809319 rs711812 (SNP10) 0.016 
Bcl2 rs1809319 rs6758117 (SNP11) 0.012 
Bcl2 rs1801018 rs6758117 (SNP11) 0.037 
Bid rs5747351 rs6749771 (SNP1) 0.015 
Bid rs3788284 rs6749771 (SNP1) 0.010 
Bid rs181410 rs1318778 (SNP3) 0.034 
Bid rs181399 rs1318778 (SNP3) 0.030 
Bid rs5747351 rs1867863 (SNP5) 0.027 
Bid rs181410 rs2113563 (SNP6) 0.045 
Bid rs3788284 rs2113563 (SNP6) 0.032 
Bid rs181399 rs2592394 (SNP7) 0.024 
Bid rs3788284 rs2592394 (SNP7) 0.018 
Casp3 rs4647602 rs1318778 (SNP3) <0.001 
Casp3 rs4647602 rs2113563 (SNP6) 0.009 
Casp3 rs2696057 rs2592394 (SNP7) 0.041 
Casp3 rs4647602 rs2592394 (SNP7) 0.015 
Casp3 rs2696057 rs741610 (SNP9) 0.008 
Casp3 rs2696057 rs711812 (SNP10) 0.040 
Casp9 rs4233533 
H
O
XD
 
rs2428431 (SNP14) 0.043 
Apaf1 rs1866477 rs3757640 (SNP15) 0.047 
Apaf1 rs2278361 rs1859164 (SNP18) 0.043 
Apaf1 rs7310804 rs6968828 (SNP19) 0.038 
Apaf1 rs3782558 rs6968828 (SNP19) 0.010 
Apaf1 rs1866477 rs6968828 (SNP19) 0.009 
Apaf1 rs7968661 
H
O
XA
 
rs3807598 (SNP20) 0.023 
ap<0.05 shown and p<0.01 in bold 
bp-values uncorrected for multiple testing
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